---
document_datetime: 2023-09-21 21:25:09
document_pages: 80
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0011-epar-assessment-report-variation_en.pdf
document_name: retsevmo-h-c-005375-ii-0011-epar-assessment-report-variation_en.pdf
version: success
processing_time: 144.6202158
conversion_datetime: 2025-12-19 05:50:06.612728
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
22 April 2022 EMA/583379/2022

Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Retsevmo

International non-proprietary name: selpercatinib

Procedure No. EMEA/H/C/005375/II/0011

Marketing authorisation holder (MAH) Eli Lilly Nederland B.V.

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................9                       |
| 2.1. Introduction.........................................................................................................9 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................9           |
| 2.1.2. About the product............................................................................................10      |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......11                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................11                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................12          |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12    |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................13      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................18         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................18      |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................18             |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology                                                                                 | .................................................................18                                     |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................18    |
| 2.4.1. Dose response study........................................................................................18        |                                                                                                         |
| 2.4.2. Main study......................................................................................................19   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy                                                                                      | ............................................................................56                          |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................59          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................60  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................71                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................72                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................72 |
| 2.6. Risk management plan........................................................................................72         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................74                              |
| 2.7.1. User consultation.............................................................................................74     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................75                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................75           |
| 3.1.1. Disease or condition.........................................................................................75      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical                                                                                | need.......................................................75                                           |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................75             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................75        |
| 3.3. Uncertainties and limitations about favourable effects                                                                 | .............................................76                                                         |
| 3.4. Unfavourable effects...........................................................................................76      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................77                                                             |
| 3.6. Effects Table......................................................................................................77  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................78              |                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects                                                                    | ..............................................78                                                        |
| 3.7.2. Balance of benefits and risks.............................................................................78         |                                                                                                         |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ...........................................79                                                           |

<div style=\"page-break-after: always\"></div>

3.8. Conclusions .......................................................................................................  79

4. Recommendations .................................................................................  79

5. EPAR changes  ........................................................................................  80

CHMP extension of indication variation assessment report

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADR adverse drug reaction                                                                     |
|-----------------------------------------------------------------------------------------------|
| AE adverse event                                                                              |
| AESI adverse event of special interest                                                        |
| ALK anaplastic lymphoma kinase                                                                |
| ALT alanine aminotransferase                                                                  |
| AST aspartate aminotransferase                                                                |
| AUC area under the curve                                                                      |
| AUC(0- ∞ ) area under the plasma concentration-versus time curve from time zero to infinity   |
| AUC0-12 area under the plasma concentration-versus time curve from time zero through 12 hours |
| AUC0-24 area under the concentration versus time curve, from time 0 to 24 hours               |
| BID twice daily                                                                               |
| CHMP Committee for Medicinal Products for Human Use                                           |
| CI confidence interval                                                                        |
| Cmax maximum observed drug concentration                                                      |
| CNS central nervous system                                                                    |
| CR complete response                                                                          |
| CSR clinical study report                                                                     |
| CTCAE common terminology criteria for adverse events                                          |
| DDI drug-drug interaction                                                                     |
| DOR duration of response                                                                      |
| ECG electrocardiogram                                                                         |
| ECOG Eastern Cooperative Oncology Group                                                       |
| eGFR estimated glomerular filtration rate                                                     |
| ESMO European Society for Medical Oncology                                                    |
| EU European Union                                                                             |
| GFR GDNF family receptor- α                                                                   |
| IAS Integrated Analysis Set                                                                   |
| INV Investigator                                                                              |
| IRC Independent Review Committee                                                              |
| KRAS Kirsten rat sarcoma viral oncogene homolog                                               |
| MA marketing authorisation                                                                    |
| MAA marketing authorisation application                                                       |

MedDRA Medical Dictionary for Regulatory Activities: a standard coding terminology for adverse events used globally in compliance with International Conference for Harmonisation (ICH) guidelines

MEN multiple endocrine neoplasia

MKI multikinase inhibitors

mOS median overall survival

mPFS median progression-free survival

ms millisecond

MTC medullary thyroid cancer

NA analysis not performed

NDA New Drug Application

NE not estimable

NGS next generation sequencing

NSCLC

non-small cell lung cancer

NTRK

Neurotrophic tropomyosin receptor kinase

ORR objective response rate

OS overall survival

PAS Primary Analysis Set

PD pharmacodynamic

PD-1 programmed cell death 1 receptor

PD-L1

programmed cell death ligand 1

PFS progression-free survival

P-gp P-glycoprotein

PK pharmacokinetic

PR partial response

PT preferred term

QTc corrected QT interval

QTcF QT interval corrected using Fridericia's Formula

RAI radioactive iodine

RECIST Response Evaluation Criteria in Solid Tumours

Response

therapeutic-area-specific terms

RET rearranged during transfection

ROS1

reactive oxygen species 1

RT radiotherapy

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| SAE serious adverse event                      |
|------------------------------------------------|
| SCE Summary of Clinical Efficacy               |
| SmPC Summary of Product Characteristics        |
| TEAE treatment-emergent adverse event          |
| TESAE treatment-emergent serious adverse event |
| Tmax time to maximum plasma concentration      |
| TTR time to response                           |
| US United States                               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Eli Lilly Nederland B.V. submitted to the European Medicines Agency on 10 November 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the first-line treatment of RET fusion-positive NSCLC for Retsevmo based on results from study LIBRETTO-001, an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours; as a consequence, sections 4.1, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0399/2021  on  the  acceptance  of  a  modification  of  an  agreed  Paediatric  Investigation  Plan  for selpercatinib (restevmo) (P/0369/2019). Some timelines of the PIP have been modified.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. However, the MAH withdrew the request during the procedure.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 10 November 2021 |
| Start of procedure:                                  | 27 November 2021 |
| CHMP Rapporteur Assessment Report                    | 21 January 2022  |
| PRAC Rapporteur Assessment Report                    | 31 January 2022  |
| PRAC members comments                                | 2 February 2022  |
| PRAC Outcome                                         | 10 February 2022 |
| CHMP members comments                                | 14 February 2022 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 17 February 2022 |
| Request for supplementary information (RSI)          | 24 February 2022 |
| CHMP Rapporteur Assessment Report                    | 06 April 2022    |
| CHMP members comments                                | 11 April 2022    |
| Updated CHMP Rapporteur Assessment Report            | 13 April 2022    |
| Opinion                                              | 22 April 2022    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The sought extension of indication is: 'Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive nonsmall cell lung cancer (NSCLC)' .

## Epidemiology

Lung cancer is the second most diagnosed cancer and the most common cause of death due to cancer with  approximately  2.2  million  new  cases  and  1.8  million  deaths  in  2020  (Sung  H  et  al,  2021). Approximately 80% to 90% of lung cancers are NSCLC (Perez-Moreno et al. 2012; ESMO 2019).

Approximately 75% of lung adenocarcinomas harbour genetic alterations that promote the RTK/RAS/RAF signalling pathway including drivers such as KRAS, EGFR, ALK, ROS1, BRAF, MET, NTRK, and RET, among others (Inamura, 2017; Rosell and Karachaliou, 2016).

RET fusions are present in 1% to 2% of NSCLC patients of both Asian and European descent (Kohno et al.  2013; Ferrara et al. 2018) and the RET fusions are typically found in adenocarcinoma histology, though occasionally also in squamous cell carcinoma (Lin et al, 2015; Takeuchi et al, 2019).

## Biologic features

RET is a receptor tyrosine kinase that normally requires ligand and co-receptor binding for activation. Genetic alterations in the RET gene have been implicated in the pathogenesis of several human cancers. RET  can become  oncogenically activated  through  two  primary  mechanisms:  1)  chromosomal rearrangements that fuse  the  RET  kinase  domain with  a  partner  protein  dimerization  domain  (e.g., Coiled-coil  domain-containing  protein  6  (CCDC6)/papillary  thyroid  cancer-1  (PTC1),  Kinesin  Family Member  5B  (KIF5B),  NCOA4/PTC3),  producing  hybrid  proteins  that  endow  the  kinase  with  ligandindependent, constitutive activity; and 2) point mutations that directly or indirectly activate the kinase (Drilon et al. 2018). Both mechanisms of oncogenic activation result in constitutively active, ligandindependent RET kinase activity and activation of downstream signalling pathways (Drilon et al, 2018).

## Clinical presentation, diagnosis and stage/prognosis

Most patients with NSCLC present with metastatic or advanced stage, unresectable disease, and poor prognosis, with a 5-year survival rate of 6% for patients diagnosed with distant disease (ESMO 2019; ACS 2020). In addition, the symptoms associated with advanced and metastatic NSCLC represent a significant burden to patients and include dyspnea, cough, fatigue, anxiety, depression, insomnia, and pain.

Patients with RET fusion-positive lung cancer commonly have brain metastases at rates similar to the overall NSCLC population, in approximately 20% to 50% of patients (Fenske et al. 2017; Drilon et al.

<div style=\"page-break-after: always\"></div>

2018). RET fusion-positive lung cancer is associated with identifiable clinicopathologic characteristics including younger age, never-smoker status, with relatively equal sex distribution, early lymph node metastases, and a solid predominant subtype. RET rearrangement seems to be mutually exclusive with other driver alterations (e.g., EGFR, ROS1, KRAS) (Wang et al. 2012).

For NSCLCs, including lung adenocarcinomas, no significant difference has been reported in progression - free survival (PFS) or overall survival (OS) between untreated patients with RET-positive and RETnegative tumours (Wang et al, 2012).

## Management

RET fusion-positive NSCLC patients are treated with non-targeted first-line treatment options, which consist of platinum-based doublet chemotherapy, alone or in combination with an immune checkpoint inhibitor. Currently recommended subsequent therapies after progression on platinum doublet-based therapy consist generally of immune checkpoint inhibitor monotherapy, single agent chemotherapy, or docetaxel in combination with ramucirumab (Planchard et al, 2018).

Vandetanib and cabozantinib are included in the NCCN guidelines as a possible treatment option in certain circumstances (NCCN 2021) but have not received regulatory approval for the indication of RET fusion-positive NSCLC.

In 18 Nov 2021, Gavreto (Pralsetinib) a selective RET inhibitor targeting aberrant signaling resulting from oncogenic RET alterations, was approved in Europe for the treatment of advanced RET fusionpositive NSCLC based on data from a Phase I/II study (ARROW study).

## 2.1.2. About the product

Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase.

RETSEVMO (Selpercatinib) was granted  a CMA on 11 Feb 2021 for 1) the treatment of metastatic RET fusion-positive NSCLC in adult patients who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy, 2) RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib and 3) RET-mutant MTC in adult and pediatric patients 12 years of age and older who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

The conditional MA was approved based on ORR and DOR observed in the ongoing Phase 1/2 study, LIBRETTO-001.

The presence of a RET gene fusion (NSCLC and non-medullary thyroid cancer) or mutation (MTC) should be confirmed by a validated test prior to initiation of treatment with Retsevmo.

The recommended dose of Retsevmo based on body weight is:

-Less than 50 kg: 120 mg twice daily.

-50 kg or greater: 160 mg twice daily.

If  a  patient  vomits  or  misses  a  dose,  the  patient  should  be  instructed  to  take  the  next  dose  at  its scheduled time; an additional dose should not be taken.

Treatment should be continued until disease progression or unacceptable toxicity.

The MAH is seeking an extension of indication of selpercatinib for the first line treatment of advanced RET fusion-positive NSCLC.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Selpercatinib is currently being investigated in the Phase 1/2 study, LIBRETTO-001 (LOXO-RET-17001). It is a multicenter, single-arm, multicohort, open-label, dose-escalation study in patients 12 years or older with advanced solid tumours, including RET fusion-positive solid tumours, RET-mutant MTC, and other tumours with RET activation.

LIBRETTO-001 was initiated in May 2017. The Phase 1 portion of the study has been completed, and the Phase 2 portion is ongoing.

Data at the DCO date of 15 June 2021 are submitted to support the use of selpercatinib for the treatment of RET fusion positive advanced NSCLC in the first line. The exploratory objectives are not presented at the DCO.

The  table  below  summarises  relevant  CHMP  interactions  for  Retsevmo  for  the  first-line  RET  fusionpositive NSCLC indication.

Table 1: Selpercatinib - Key Regulatory Interactions in the EU

| Date             | Submission /Activity                   | Additional Information                                                                                                                                                                                                                                                                                                                                          |
|------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 25 July 2019     | Scientific Advice                      | Climical advice on a number of development aspects including the potential for an indication including patients with RET fusion-positive NSCLC who are previously umtreated.                                                                                                                                                                                    |
| 20 December 2019 | Initial MAA                            | Applied indication: for the treatment of adults with advanced RET fusion-positive NSCLC who require systemic therapy.                                                                                                                                                                                                                                           |
| 16 0ctober 2020  | MAA Day 180 List of Outstanding Issues | Major Objection (MO): CHMP concem that completion of Phase 3 study could be hampered if a broad indication is given to selpercatinib for the treatment of patients with advamced RET fiusion-positive NSCLC. Also required fiurther justification that selpercatinib provided therapeutic advantage over existing available therapies in the sought indication. |
| 30 0ctober 2020  | MAA Post-Day 180 Clarification Meeting | To clarify the Day 180 MO. Aligument to restrict the indication to previously treated advanced RET fusion- positive NSCLC.                                                                                                                                                                                                                                      |
| 29 Jume 2021     | Meeting with (co)Rapporteurs and EMA   | To discuss the applicant's proposal for a Type II variation to expand the indication to enable use of selpercatinib in patients with umtreated RET fiusion- positive NSCLC.                                                                                                                                                                                     |

Abbreviations: CHMP =Committee for Medicinal Products for Human Use; EU =Euuropean Union; EMA = European Medicines Agency: MAA = marketing authorisation application; MO = major objection; NSCLC = non-small cell lumg cancer; RET = reairanged duuing transfection.

## 2.1.4. General comments on compliance with GCP

The  MAH  stated  that  the  clinical  trial  LOXO-RET-17001  that  support  the  proposed  indication  of selpercatinib was conducted in accordance with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS), International Ethical Guidelines for Biomedical Research Involving Human Subjects,  and  the  International  Conference  on  Harmonisation  (ICH)  Good  Clinical  Practices  (GCP) Guideline (E6).

The clinical trial LOXO-RET-17001 (LIBRETTO-001) conducted outside the European Union meets the ethical requirements of Directive 2001/20/EC.

Study  LOXO-RET-17001  was  subject  to  independent  audit  by  regulatory  authorities.  The  audits

<div style=\"page-break-after: always\"></div>

performed as of 15 June 2021 were:

Table 2. Audits performed for Study LOXO-RET-17001 as of 15 June 2021

| AgencyName                  | Audit Dates                | Audit Site                                    |
|-----------------------------|----------------------------|-----------------------------------------------|
| US FDA                      | 8 Jam 2020 to 14 Jam2020   | University of Texas MD Anderson Cancer Center |
| US FDA                      | 27 Jam 2020 to 7Feb2020    | The Ohio State University                     |
| US FDA                      | 30Jam2020to10Feb2020       | Massachusetts General Hospital                |
| Phanmaceuticals and Medical | 17 May 2021 to 17 May 2021 | JapanAffiliate                                |

Abbreviations: US FDA = United States Food and Drug Administration

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## Environmental risk assessment

The Phase I ERA provided by the MAH contained no new data compared to the one submitted with the initial MAA. The justification from the MAH for not providing a new ERA was the following: ' The calculated prevalence in the variation is the same as that calculated in the original Phase I ERA, therefore, the concentration of selpercatinib in surface water is the same as in the original MAA and the conclusion of lack of risk to the environment is the same '.

The PEC calculated from prevalence data in Italy (showing the highest prevalence in Europe) is less than 10 ng/L. The Kow is less than 4.5. No phase II studies have been conducted. The product is considered to have a low risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Abbreviations: AUC(o-o) = area umder the concentation versus time cuve, from the time of dosing to infinity: Cmx = maximum observed plasma concentration: CBR = clinical benefit rnte: CNS = cental nervous sy stem; CSR = clinical study report; DoR = duration of response; IA = investigator assessment; IR.C = Independent Review Committee: LOXO-292 = selpercatinib: MTC =medullary thyroid cancer: MTD = maximum tolerated dose: NSCLC =non-small cell lung cancer; ORR = objective response rate: OS = overall survival; PFS = progression-free survival; P-gp = P-glycoprotein; PK = pharmacokinetics: RET = reamanged duing transfecion: RP2D = recommended Phase 2 dose: tmmx = time to maximum observed concentation: TTBR = time-to-best response.

<!-- image -->

| Study ID                                 | Study Title and Description                                                                                                                                                                                           | Study Objectives or Outcomes                                                                                                                                                                                                                                                                                                                | Patient, Study Participant, or Tumor Population   | Number of Treated Participants   |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------|
| Registration Study                       | Registration Study                                                                                                                                                                                                    | Registration Study                                                                                                                                                                                                                                                                                                                          | Registration Study                                | Registration Study               |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | A Phase 1/2 Study of Oml L0X0-292 in Patients with Advanced Solid Tumors. Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Key design features: Multicenter | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | RET fusion-positive JIOSN                         | 356                              |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | A Phase 1/2 Study of Oml L0X0-292 in Patients with Advanced Solid Tumors. Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Key design features: Multicenter | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | RET-mutant MTC                                    | 319                              |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | A Phase 1/2 Study of Oml L0X0-292 in Patients with Advanced Solid Tumors. Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Key design features: Multicenter | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | RET fiusion-positive thyroid cancer               | 54                               |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | A Phase 1/2 Study of Oml L0X0-292 in Patients with Advanced Solid Tumors. Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Key design features: Multicenter | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | RET fusion-positive other cancers                 | 43                               |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | A Phase 1/2 Study of Oml L0X0-292 in Patients with Advanced Solid Tumors. Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Key design features: Multicenter | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | Other cancers                                     |                                  |
| LOX0-RET-7001 (2G-OX-JZIA: LIBRETTO-001) | Multi-cohort Open-label                                                                                                                                                                                               | Phase 1 Primary objectie: To detemine MTD and/or RP2D Secondary objeeriver: To assess safety and tolerability PK, and ORR. Phase 2 Primary objective: To assess ORR. by IRC. Seeondary objectives: To assess ORR by IA DOR, TTBR.PFS.CBR best change in tumor size by IRC and IA CNS ORR and DOR by R.C 0S safety and tolerability. and PK. | Totala                                            | 796                              |
| ING-MC-JZIV                              | An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers. Key design featwres: Open-label, and Single center.                                       | Primoryobjectives:Evaluate the effect of selpercatinib on P-gp activity. assessed by Cmax and AUC(0-o). Secondar objecthves:Evaluate the effect of dabigatran in combination with selpercatinib on safety and tolerability. and PK parameters: Cmw (m. and AUC(0-x)                                                                         | Healthy participants                              | 36                               |

Patients treated in LIBRETTO-001 as of 15 June 2021 data cutoff

Sources: LIBRETTO-001 Interim CSR Addendum (15 Jume 2021 data cutoff) and J2G-MC-JZJV CSR.

## 2.3.2. Pharmacokinetics

Selpercatinib  is  an  orally  available,  highly  selective,  adenosine  triphosphate  (ATP)-competitive  small molecule inhibitor of the RET receptor tyrosine kinase.

In  Europe,  selpercatinib  is  approved  under  the  brand  name  of  Retsevmo®.  Two  strengths  of  hard capsules, 40 and 80 mg are available. Selpercatinib is actually used as monotherapy for the treatment of adults with:

- advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy
- advanced  RET  fusion-positive  thyroid  cancer  who  require  systemic  therapy  following  prior treatment with sorafenib and/or lenvatinib

Selpercatinib is also indicated as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

Selpercatinib is orally given and the recommended dose is based on body weight:

- Less than 50 kg: 120 mg twice daily.

<div style=\"page-break-after: always\"></div>

- 50 kg or greater: 160 mg twice daily.

The pharmacokinetic (PK) properties of selpercatinib were sufficiently characterized in the initial MAA and are summarized below as described in the actual adopted SmpC.

In the current submission, the applicant seeks a modification of the indication of selpercatinib to include the treatment of RET fusion-positive NSCLC in the first-line setting (treatment of RET fusion-positive advanced NSCLC regardless of line of therapy).

There are neither new PK data that would change the main PK features of selpercatinib nor special populations . Also, no revision of section 5.2 PK properties of the SmpC is claimed.

The PK data provided in support of this submission includes:

- Descriptive, noncompartmental methods of analysis of selpercatinib PK data from all patients enrolled in the pivotal study LOXO-RET-17001 (LIBRETTO-001) as of the submission data cutoff date (15 June 2021) for whom PK data were not previously reported in the initial MAA.

The additional PK data from the pivotal study LOXO-RET-17001 are presented in the para graph 'PK in target population'.

## Absorption

After an oral dose of 160 mg, Retsevmo was rapidly absorbed, with Tmax of approximately 2 hours. Geometric mean absolute oral bioavailability was 73.2% (range: 60.2-81.5%).

## Effect of food

Compared to selpercatinib AUC and Cmax in the fasted state, selpercatinib AUC was increased by 9% and Cmax was reduced by 14% after oral administration of a single 160 mg dose to healthy subjects taken with a high-fat meal. These changes were not considered to be clinically relevant. Therefore, selpercatinib can be taken with or without food.

## Distribution

Selpercatinib mean (CV%) volume of distribution (Vss/F), estimated by Population PK analysis, is 191 (69%) L following oral administration of selpercatinib in adult patients. Selpercatinib is 96% bound to human  plasma  proteins  in  vitro  and  binding  is  independent  of  concentration.  The  blood-to-plasma concentration ratio is 0.7.

## Elimination

The mean (CV%) clearance (CL/F) of selpercatinib is 6.0 (49%) L/h and the half-life is 22 hours following oral  administration of  selpercatinib  in  adult  patients.  Following  oral  administration  of  a  single  [14C] radiolabeled  160  mg  dose  of  selpercatinib  to  healthy  subjects,  69%  (14%  unchanged)  of  the administered radioactivity was recovered in faeces and 24% (11.5% unchanged) was recovered in urine.

## Dose proportionality and time dependencies

The pharmacokinetics of selpercatinib were evaluated in patients with locally advanced or metastatic solid tumors administered 160 mg twice daily unless otherwise specified. Steady-state selpercatinib AUC

<div style=\"page-break-after: always\"></div>

and Cmax increased in a linear to supra-dose proportional manner over the dose range of 20 mg once daily to 240 mg twice daily.

Steady-state  was  reached  by  approximately  7  days  and  the  median  accumulation  ratio  after administration  of  160  mg  twice  daily  was  3.4-fold.  Mean  steady-state  selpercatinib  [coefficient  of variation (CV%)] Cmax was 2,980 (53%) ng/mL and AUC0-24h was 51,600 (58%) ng*h/mL.

## Special populations

## Age, gender and body weight

Age (range: 15 years to 90 years) or gender had no clinically meaningful effect on the pharmacokinetics of Retsevmo. Patients with a body weight ≤50 kg should start Retsevmo treatment with a d ose of 120 mg twice daily, while patients &gt;50 kg should start Retsevmo treatment with a dose of 160 mg twice daily.

## Hepatic impairment

Selpercatinib AUC0∞ increased by 7% in subjects with mild, 32% in subjects with moderate Child -Pugh classification. Thus, selpercatinib exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A and B) is comparable to exposure in healthy subjects when a dose of 160 mg is administered.

Selpercatinib AUC0∞ increased by 77% in subjects with s evere hepatic impairment (Child-Pugh class C). There is limited clinical data on the safety of selpercatinib in patients with severe hepatic impairment. Therefore, dose modification is recommended for patients with severe hepatic impairment (section 4.2).

## Renal impairment

In a clinical pharmacology study using single dose selpercatinib 160 mg, exposure (AUC) was unchanged in subjects with mild, moderate, or severe renal impairment. End stage renal disease (eGFR &lt;15 ml/min) and dialysis patients have not been studied.

## Paediatric population

Based on limited pharmacokinetic data, the Cmax and AUC was similar in adolescent patients, 12-18 years of age, and in adults.

## Pharmacokinetics in target population

Table  3  summarizes  the  steady-state  PK  parameters  (Cycle  1  Day  8)  for  plasma  selpercatinib concentrations in patients receiving 160 mg BID dose in the pivotal study LIBRETTO-001 collected from 09 May 2017 to 30 March 2020 (previous data submitted in the initial MAA) and from 01 April 2020 to 10 June 2021 (new data), respectively. A comparsion of steady-state AUCtau between the two periods is shown in Figure 1.

<div style=\"page-break-after: always\"></div>

Table 3 .Steady-State (Cycle 1 Day 8) Pharmacokinetic Parameters of Selpercatinib in Patients with Cancer

| Actual Dose   | Data Period      |      | Tmarad (h)   |   Cmar (ng/mL) |   AUCo-last (h*ng/mL) |   AUCtau (h*ng/mL) |   AUC014 (h*ng/mL) |   CL/F (L/h) |
|---------------|------------------|------|--------------|----------------|-----------------------|--------------------|--------------------|--------------|
| 160 mg BD     | 09 May 2017 to   | N    | 614          |          614   |                 614   |              601   |              601   |       601    |
| 160 mg BD     | 30 March 2020    | GM   | 2.00         |         3050   |               26100   |            26300   |            52600   |         6.08 |
| 160 mg BD     |                  | GCV% | 0.00-8.10    |           51.4 |                  55.7 |               55.5 |               55.5 |        55.5  |
| 160 mg BD     | 01 April 2020 to | N    | 32           |           32   |                  32   |               30   |               30   |        30    |
| 160 mg BD     | 10 Jume 2021     | GM   | 2.15         |         3310   |               29700   |            30200   |            60300   |         5.31 |
| 160 mg BD     |                  | GCV% | 0.00-8.08    |           44.5 |                  47.4 |               47.7 |               47.7 |        47.7  |

AUC0-24 = area under the plasma concentration-time curve from time 0 to 24 hours; AUC0-last = area under the plasma concentration-time curve up from time zero to the last observable concentration; AUC0-tau (AUC0-12) = area under the plasma concentration-time curve from time 0 to 12 hours; BID = twice daily; CLss/F = apparent total clearance of drug after oral administration at steady state; Cmax = maximum plasma concentration; CV% = percent coefficient of variation; GCV% = geometric CV%; GM = geometric mean; max = maximum; min = minimum; N = number of samples; Tmax = time to reach maximum plasma concentration.

Figure 1: Boxplots of plasma selpercatinib Cmax and AUC0-tau following selpercatinib 160 mg BID administrations of capsule formulation (Cycle 1 Day 8)

<!-- image -->

The dashed line is the median; the solid line is the arithmetic mean. The ends of the 'box' are the 25th and 75th percentiles. The whiskers show the lowest data value still within 1.5 IQR of the lower quartile and the highest value still within 1.5 IQR of the upper quartile, where IQR is the interquartile range (the difference between the third and first quartiles, the middle 50%).

The steady-state PK parameters (Tmax, Cmax, and AUC0-24) for patients with evaluable data at Cycle 1 Day 8 were previously calculated by non-compartmental analyses. The NCA PK parameters for patients with NSCLC from data cuts of 09 May 2017 to 30 March 2020 (LOXONCA- LOXO292-1229) and 01 April 2020 to 10 June 2021(LOXO-NCA-LOXO292-2829) were combined with tumour type data and treatment status for the analysis:

- geometric means and coefficient of variation summary statistics are provided in Table 4, and

<div style=\"page-break-after: always\"></div>

- bar charts showing the mean and 90% percentile intervals are provided in Figure 2.

Table 4. Steady-State (Cycle 1 Day 8) Pharmacokinetic Parameters of Selpercatinib in Patients with NSCLC

|      | Treatinent-Naive Patients   | Treatinent-Naive Patients   | Treatinent-Naive Patients   | Patients Previously-Treated with Platnum-Based Chemotherapy   | Patients Previously-Treated with Platnum-Based Chemotherapy   | Patients Previously-Treated with Platnum-Based Chemotherapy   | Patients Previously-Treated with Other Therapies   | Patients Previously-Treated with Other Therapies   | Patients Previously-Treated with Other Therapies   |
|------|-----------------------------|-----------------------------|-----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|      | Tmara (h)                   | Cmax (ng/mL)                | AUC0-24 (hr·ng/mL)          | Tmara (lh)                                                    | Cmax (ng/mL)                                                  | AUC0-24 (h·ng/mL)                                             | Tmara (h)                                          | Cmax (ng/mL)                                       | AUC0-24 (h·ng/mL)                                  |
| N    | 59                          | 59                          | 55                          | 197                                                           | 197                                                           | 193                                                           | 35                                                 | 35                                                 | 35                                                 |
| GM   | 2.0                         | 2930                        | 46700                       | 2.0                                                           | 3570                                                          | 64800                                                         | 2.0                                                | 3380                                               | 60100                                              |
| GCV% | 0.8-4.3                     | 58                          | 67                          | 0 - 8.1                                                       | 42                                                            | 45                                                            | 0 - 4.0                                            | 54                                                 | 53                                                 |

Abbreviations: AUCo-24 = area under the plasma concentration-time curve from time 0 to 24 hours; Cmax= maximum plasma concentration; GCV% = geometric coefficient of variation; GM = geometric mean; N = number of samples; NSCLC = non-small cell lung cancer; Tmax = time of maximum concentration.

- Median and range (minimum -- maximum).

Data available from 09 May 2017 to 10 June 2021.

Figure 2.  Bar charts of plasma selpercatinib Tmax, Cmax, and AUC0-24 following selpercatinib 160 mg BID administrations (Cycle 1 Day 8) in treatment-naïve patients, patients previously-treated with platinum-based chemotherapy, and patients previouslytreated with other therapies.

<!-- image -->

Abbreviations: AUCo-24 = area under the plasma concentration-time curve from time 0 to 24 hours; BID = twice daily; C1D8 = Cycle 1 Day 8; Cmax = maximum plasma concentration; n = mumber of

\"Previously treated refers to patients previously treated with platinum-based chemotherapy.

\"Other\" refers to patients previously treated with other therapies (see Table 3.1).

The bar height is the mean. The whiskers show the 5th and 95th percentiles of the data. The numbers below each box plots refer to the number of patients.

Data cut-off date 10 June 2021.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Certain point mutations in RET or chromosomal rearrangements involving in frame fusions of RET with various partners can result in constitutively activated chimeric RET fusion proteins that can act as oncogenic drivers  by  promoting  cell  proliferation  of  tumour  cell  lines.  In  in  vitro  and  in  vivo  tumour  models, selpercatinib demonstrated anti-tumour activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6 RET, KIF5B RET, RET V804M, and RET M918T. In addition, selpercatinib showed anti-tumour activity in mice intracranially implanted with a patient-derived RET fusion-positive tumour.

## Primary and secondary pharmacology

No new data have been submitted as part of this application.

## 2.3.4. PK/PD modelling

No new data have been submitted as part of this application.

## 2.3.5. Discussion on clinical pharmacology

No complementary formal PK investigations have been carried out in the context of the variation under review. Additional new PK data from the pivotal study LOXO-RET-17001 (n=32, collected from 01 April 2020 to 10 June 2021) have been provided and compared to the previous data already submitted in the initial  MAA (n= 614, collected from 09 May 2017 to 30 March 2020). Furthermore, a comparison of steady-state  selpercatinib  PK  parameters  in  the  target  NSCLC  patients  treatment-naïve  using  the recommended 160 mg BID dose with the reference NSCLC patients who had prior therapy is provided.

Overall, the PKs of selpercatinib in the target patients was assessed and the updated data identified no significant difference compared to other /current NSCLC cancer patients.

## 2.3.6. Conclusions on clinical pharmacology

The applicant applied for an extension of the indication to include adult patients with RET fusion-positive NSCLC in the first-line setting (treatment-naïve) in addition to patients with RET fusion-positive nonsmall  cell  lung  cancer  NSCLC  who  had  prior  therapy  (currently  approved).  Overall,  no  significant difference in PKs characteristics of selpercatinib is observed in the target patients by comparison to other cancer patients already assessed in the already authorised indication. No revision of section 5.2 of the SmpC is required.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Study LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours that was initiated in May 2017. The Phase 1 portion of the

<div style=\"page-break-after: always\"></div>

study allowed to determine the maximum tolerated dose and recommended Phase 2 dose of selpercatinib. A dose of 160 mg BID was selected for Phase 2.

The approved dose as recommended in the SmPC is 160 mg taken orally twice daily (body weight 50 mg or greater).

## 2.4.2. Main study

Study LOXO-RET-17001 (LIBRETTO-001): A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET 0Fusion-Positive Solid Tumours, RET-mutant Medullary Thyroid Cancer (MTC), and Other Tumours with RET Activation

## Methods

Figure 3: depicts the study design for the protocol version 9.0.

<!-- image -->

## Study participants

Eligibility criteria remained mostly the same as specified in the previous CSR (17 June 2019 data cutoff), except for the following listed below, which were updated in version 8.0 or 9.0 of the protocol.

Phase2

<div style=\"page-break-after: always\"></div>

## Inclusion Criteria for Phase 1

- Inclusion Criterion [2] -amended to remove the prohibition of prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]).
- Inclusion Criterion [5] - amended to note the exclusion of minor patients in Canada and Germany.
- Criterion  [11]:  -  allowed  enrolment  of  patients  with  adequate  renal  function,  with  estimated glomerular  filtration  rate  ≥  30  mL/minute  (up  to  6  participants  with  an  eGFR  ≥  15  and  &lt;  30 mL/minute were allowed to enroll with Sponsor approval).
- Criterion [13]: - amended to include additional details on observing conventional and effective birth control for the duration of treatment and for 3 months

## Inclusion Criteria for Phase 2

- Inclusion Criterion [1] -updated standard of care therapy criteria for Cohorts 2 and 4.
- Inclusion Criterion [5] - added to describe the inclusion criteria for Cohort 6: Participants who were otherwise eligible for Cohorts 1 to 5 who discontinued another RET inhibitor due to intolerance could be eligible with prior Sponsor approval.

## Exclusion Criteria for Phase 1 and Phase 2:

- Exclusion Criterion [2] - amended to further describe the inclusion criteria for Cohorts 1 through 6.
- Exclusion Criterion [3] - modified to further describe exclusion criteria for investigational agents or anticancer therapies.
- Exclusion Criterion [8] - modified to revise the criterion for QTcF.
- Exclusion Criterion [9] - amended to exclude patients with serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment.
- Exclusion Criterion [13] -amended to further clarify prohibited concomitant medications.
- Exclusion Criterion [17] - added to exclude patients with a history of hypersensitivity to any of the study intervention capsule components.

## Treatments

The RP2D of selpercatinib (160 mg BID) was selected in Phase 1 and has been used as the starting dose for patients in the Phase 2 dose expansion phase of the study.

Patients continued selpercatinib dosing in 28-day cycles until PD, unacceptable toxicity, or other reason for  treatment discontinuation.  Patients  with  PD  could  continue  selpercatinib if,  in  the  opinion  of  the Investigator, the patient was deriving clinical benefit from continuing study treatment, and continuation of treatment was approved by the Sponsor.

<div style=\"page-break-after: always\"></div>

## Objectives/Endpoints

Table 5. Objectives and endpoints of LIBRETTO-001 (Phase 2)

<!-- image -->

| Objectives (Phase 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Endpoints (Phase 2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| To assess, for each Phase 2 expansion cohort, the anti-humor activity of selpercatinib by detemmining ORR using RECIST 1.1 or RLANo, as appropriate to tumor type, as assessed by IRIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ORR based on RECIST 1.1 or RANO, as appropriate to humor type, as assessed by IR.c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| To assess, for each expansion cohort, the anti- ORR based on RECIST 1.1 or RANO, as appropriate to tuumor type, as assessed by Imvestigator Best change in humor size from baseline, as assessed by IRtC and Investigator DOR as assessed by IRC and Investigator CNS ORR based on RECIST 1.1 or RLANo, as appropriate to tumor type, as assessed by IRiC (for participants with brain metastases) CNS DOR. as assessed by IR.C (for participants with brain metastases) Time to amy and best response based on RECIST 1.1 or RANO, as appropriate to tumor type, as assessed by IRC and Imvestigator CBR. based on the proportion of participants with best overall response of CR, PR, or SD lasting 16 or more Weeks following initiation of selpercatinib, as assessed by IRiC and Investigator | Parameters of anti-humor activity/clinical benefit, including. ORR (by Iuvestigator) Best change in tumor size fiom baselline (by IRC and Investigator) DOR (by IRC and Investigator) CNS ORR (by IRC) CNS DOR (by IRC) Time to any and best response (by IRC and Investigator) CBR. (by IRC and Investigator) PFS (by IRC and Investigator)                                                                                                                                                                                                                                                                                                                                                             |
| To detenmine the safety profile and tolerability of selpercatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Frequency, severity, and relatedness of TEAEs audSAEs Changes in hematology and blood chemisby values Assessments ofphysical examinations Vital sigus ECGs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| To characterize the PK properties of selpercatimib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Plasma concenhationsof selpercatimib and PK parameters, inchuding, but not limited to, AUCo, C.ax, and T...a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Abbreviations: AuCo-4 = area tmder the concentation versus time cwve from time 0 to 24 houus; CBR. = clinical benefit rate; Cma = maximum dnug coucentration; CNS = ceniral nervous system; CR = complete response; DoR. = duration of response; ECG = electocardiogram; IRC =Independent Review Comumittee; ORR = objective response rate; OS = overall swvival; PFS = progression-free survival; PK = phammacokinetic(s): PR. = partial response; RANO = Response Assessment in Newo-Oncology Criteria; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; SD = stable disease; TEAE = treatment-emergent adverse event; Tm.x = time to maximum plasma concentration.                                                                                            | Abbreviations: AuCo-4 = area tmder the concentation versus time cwve from time 0 to 24 houus; CBR. = clinical benefit rate; Cma = maximum dnug coucentration; CNS = ceniral nervous system; CR = complete response; DoR. = duration of response; ECG = electocardiogram; IRC =Independent Review Comumittee; ORR = objective response rate; OS = overall swvival; PFS = progression-free survival; PK = phammacokinetic(s): PR. = partial response; RANO = Response Assessment in Newo-Oncology Criteria; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; SD = stable disease; TEAE = treatment-emergent adverse event; Tm.x = time to maximum plasma concentration. |

previously reported.

<div style=\"page-break-after: always\"></div>

## Sample size

## Phase 2

For Cohort 1 (patients with RET fusion-positive solid tumours who have progressed on or are intolerant to standard first-line therapy for their cancers), a sample size of 55 patients is estimated to provide 85% power to achieve a lower boundary of a two-sided 95% exact binomial confidence interval (CI) about the estimated ORR that exceeds 30%.

For Cohort 2 (patients with RET fusion-positive solid tumours without prior standard first-line therapy), a sample size of 59 patients is estimated to provide 85% power to achieve a lower boundary of a twosided 95% exact binomial CI about the estimated ORR that exceeds 35%. For Cohort 3 (patients with RET-mutant MTC who have progressed on or are intolerant to vandetanib and/or cabozantinib), a sample size of 83 patients is estimated to provide 85% power to achieve a lower boundary of a two-sided 95% exact binomial CI about the estimated ORR that exceeds 20%.

For  Cohort  4  (patients  with  RET-mutant  MTC  who  are  MKI-naïve),  a  sample  size  of  55  patients  is estimated to provide 85% power to achieve a lower boundary of a two-sided 95% exact binomial CI about the estimated ORR that exceeds 30%.

Enrolment  beyond  the  above  sample  sizes  in  each  of  Cohorts  1-5,  will  be  allowed,  in  order  to accommodate enrollment demand and allow for the characterization of AEs that may occur with low frequency. With a sample size of 150 patients, the probability of observing one or more instances of a specific AE within a cohort with a true incidence rate of 1% and 2% is 77.9% and 95.2%, respectively. The sample size for Cohort 1 was increased to ~250 to accommodate enrollment demand. Additional enrollment will also allow for the characterization of AEs that may occur with low frequency which would enhance knowledge of the safety profile of selpercatinib. Further, this cohort allows for the enrollment of patients with RET fusion-positive solid tumours other than NSCLC. While the enrollment demand for patients  with  RET  fusion-positive  NSCLC  has  been  adequate  for  statistical  analysis,  additional  solid tumour  types  remain  underrepresented  and  enrollment  expansion  allows  for  data  capture  in  this population.

Up to ~50 patients will be enrolled into Cohort 6 based on clinical consideration. Exploring efficacy in patients with a history of prior exposure to RET specific inhibitors may enhance understanding of the risk:benefit of additional RET specific therapy in these patients and aid in the consideration of resistance mechanisms in response to this type of therapy.

## Randomisation and blinding (masking)

The study is non-randomized and non-blinded single arm study.

## Statistical methods

There were no changes in the planned analyses for the study except some with minimal impact which are described in the SAP addendum dated 14 June 2021.

The overall rationale for the RET fusion-positive NSCLC SAP Addendum 1 is to outline the FDA RET fusionpositive  NSCLC  Accelerated  Approval  Requirement  (AAR)  and  detail  considerations  for  the  sNDA submission cutoff date.

In addition, subgroup analyses are planned for patients with vs without prior immune checkpoint inhibitor (ICI) therapy.

<div style=\"page-break-after: always\"></div>

## Intracranial Analysis

Time  to  CNS  progression  will  be  explored.  Time  to  CNS  progression  is  defined  as  the  time  from randomization until the occurrence of documented CNS progression by the IRC.

CNS progression, non-CNS progression, and death are competing risk events; CNS progression is the event of interest defined as progression due to newly developed intracranial lesions and/or progression of pre-existing intracranial lesions per RECIST version 1.1.

To account for the competing risks, the probability of the first event of CNS progression, non- CNS progression, or death without any progression will be estimated using a cumulative incidence function  (sub-distribution  function).  A  plot  of  the  estimated  cumulative-incidence  functions  will  be displayed.

## Intra-patient Analysis

Prior therapy data will be used to perform an exploratory analysis comparing benefit achieved on the last  therapy  patients  received  prior  to  the  study  enrollment  to  benefit  achieved  on  selpercatinib treatment  using  each  study  patient  as  their  own  control.  A  known  limitation  of  this  analysis  is retrospective prior therapy data collection based on patients' medical records without central review and confirmation based on RECIST criteria.

There is no change to efficacy analysis sets defined in the original version of the NSCLC SCE SAP.

Patients enrolled into the Phase 1 dose escalation as well as the Phase 1 and Phase 2 dose expansion cohorts were grouped to derive the analysis sets. The goal of the arrangement of these various data sets was to:

-maximize  information  through  the  consolidation  of  data  from  both  Phase  1  and  Phase  2  parts  of LIBRETTO-001, and.

-define groupings based on clinically meaningful distinctions, resulting in similarity of patients within a group, thus, facilitating the interpretation of results.

Patients with RET fusion-positive NSCLC who had received at least 1 dose of selpercatinib and achieved at least 6 months of potential follow-up time from the first dose of selpercatinib (or disease progression or death, whichever occurred first), as of 15 June 2021, were considered eligible for efficacy analyses.

The evaluation of efficacy consists of RET fusion-positive NSCLC analysis sets as defined in Table 3.2 (the basis for the initial regulatory submissions) and includes patients enrolled into Cohorts 1, 2, and 5. Cohort 6 includes patients who have received prior treatment with a selective RET inhibitor and are therefore  not  included  in  the  efficacy  analysis;  these  patients  were  excluded  in  LIBRETTO-001  until Cohort 6 was introduced in Protocol version 8.

The efficacy analysis for RET fusion-positive NSCLC primarily focused on 1) previously treated patients and 2) treatment-naïve patients. Efficacy was further assessed using the supportive efficacy analysis sets described in Table 3.2, including a CNS Response Analysis Set consisting of all patients with RET fusion-positive NSCLC who have investigator-identified CNS metastases at baseline (reported as target or nontarget lesion per RECIST v1.1).

<div style=\"page-break-after: always\"></div>

Table 6: Description of Efficacy Analysis Sets

| Efficacy Analysis                 | Analysis Set                                                                                                                | Analysis Set Description                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary efficacy analysis set     | Trealment-Naive Patients (N=69) (previously named SAS1)                                                                     | Includes treatment-naive patients with RET fiusion-positive NSCLC who met Criteria 1, 2, and 4 in foohote \"a\" These data support the proposed indication in the first-line setting.                                                                                                                                                                                                                     |
| Supportive efficacy analysis sets | Pafients Previously Treated WithPlatinum-Based Chemotherapy (N=247) (previously named LAS)                                  | Includes all patients with RET fiusion-positive NSCLC previously teated with platinuum-based chemotherapy who met the criteria in foomote \"a”\".                                                                                                                                                                                                                                                         |
|                                   | Patients Previously Treated With Other Systemic Therapy (N=19) (previously named SAS2)                                      | Includes patients with RET fusion-positive NSCLC previously treated with systemic therapies other than platimumm-baved chemotherapy who met Criteria 1, 2, and 4 in foomote “a”                                                                                                                                                                                                                         |
|                                   | Patients with Nou- Measurable Disease (N=20) (previously named SAS3)                                                        | Includes previously treated and treahment naivepatients with RET fiusion-positive NSCLC without measuable disease by RECIST 1.1 and met Criteria 1 and 4 in foomote \"a\".                                                                                                                                                                                                                                |
|                                   | The First l05 Patients Emrolled who were Previously Treated with Platinum-Based Chemotherapy (N=105) (previously named PAS) | Includes the first 105 consecutively emrolled patients with RET fision-positive NSCLC previously treated with platinum- based chemotherapy who met the criteria in footmote “a” This analysis setis a subset of the “Patients Previously Treated with Platinuum-Based Chemotherapy\"analysis set and was presented in the SmPC but is being superseded by the data presented in this submission dossier. |
|                                   | CNS Response Analysis Setb (N=106)                                                                                          | Includes patients with RET fiusion-positive NSCLC who had investigator-identified CNS metastases at baseline (reported as target or nontarget lesion per RECIST 1.1). This analysis set contains patients fiom across the primary and supportive eficacy analysis sets.                                                                                                                                 |

Abbreviations: CLIA = Clinical Laboratory Improvement Amendment; CNS = central nervous system; LAS = Integrated Analysis Set; NSCLC = non-small cell lmg cancer, PAS = Primary Analysis Set; RECIST =Response Evaluation Criteria in Solid Thumors; SAP = statistical analysis plan; SAS = Safety Analysis Set; SCE = summary of clinical efficacy.

- Criteria for inclusion:
1. Evidence of a protocol-defined qualifying and definitive RET-fiusion, prospectively identified on the basis of a documented CLIA-certified (or equivalent ex-US) Molecular Pathology Report. Patients with a RET fusion co-occuuming with anotber putative oncogemic driver, as detemmined at the time of shudy emrolment by local testing, were inchuded.
2. Measiuable disease by RECIST 1.1 by investigator assessment. Patients without measuwable disease who Were emrolled in Phase 1 dose escalation were included in the \"Patients Previously Treated with PlatinuumBased Chemotherapy\" and \"The First 105 Patients Emrolled who were Previously Treated with PlatinumBased Chemotherapy\" Analysis Sets. Refer to the NSCLC SCE SAP for details.
3. Received l or more lines of prior platinum-based chemotherapy.
- 4.Received 1 or more doses of selpercatinib.
- This analysis set provides evidence for selpercatinib's activity in patients with RET fision-positive NSCLC and CNS metastases (N=106). Of these 106 patients, 26 had measuwable disease and 80 had nou-measuwable disease at baseline as assessed by the investigator.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 4: RET fusion-positive NSCLC efficacy analysis and overall safety populations based on a data cutoff date of 15 June 2021 LIBRETTO-001.

<!-- image -->

Table 7. Screen Failures -Overall Safety Population (Data Cut-off: 15 June 2021)

<!-- image -->

| Ghnracteriatis                               | Total       |
|----------------------------------------------|-------------|
| Subjocta Screennd (n)                        | 921         |
| Subiocta Treuted (n, oj                      | 796(06.4]   |
| Subjoeto Sereenud and Mot Teonted(a,O)       | 12 12*0     |
| Subiocta with Seruun Failuco (o,oj.          | 123 ( 13.4) |
| Reuon for Scren Failurs lo, qjee             |             |
| DTDMOTSATTSPYAILTMGTUSTOHOREXCLUSTONCRIPNRTA | 70.71       |
| HTIDRAWALOTCOHSLNT                           | 11 0.91     |
|                                              | 10 0.11     |
| DNATII                                       | 2 1.61      |
| TNWTSTTGATOR.DNCTSTON                        | 2 1.61      |
| OTIER.                                       | 11 0.91     |

eePorcentages are baued on tha nucber ot subiocta (n) thnt hnd acreen tailuro.

<div style=\"page-break-after: always\"></div>

Table 8: Summary of Disposition RET Fusion-Positive NSCLC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

|                                                                            | Primary Analysis Sets       | Primary Analysis Sets   | Supportive Analysis Setsa     | Supportive Analysis Setsa   |              |
|----------------------------------------------------------------------------|-----------------------------|-------------------------|-------------------------------|-----------------------------|--------------|
| Analysis Set                                                               | Prior Platinum Chemotherapy | Treatment- Naive        | Prior Other Systeimic Therapy | Non- Measurable Disease     | Total NSCLCb |
| Treated                                                                    | 247                         | 69                      | 19                            | 20                          | 355          |
| Treatment continuing, n (%)                                                | 117 (47.4)                  | 32 (46.4)               | 6 (31.6)                      | 10 (50.0)                   | 165 (46.5)   |
| Continuing post progressionc                                               | 26 (10.5)                   | 5 (7.2)                 | 2 (10.5)                      | 3 (15.0)                    | 36 (10.1)    |
| Treatment discontinued, n (%6)                                             | 130 (52.6)                  | 37 (53.6)               | 13 (68.4)                     | 10 (50.0)                   | 190 (53.5)   |
| Disease progression                                                        | 73 (29.6)                   | 26 (37.7)               | 10 (52.6)                     | 6 (30.0)                    | 115 (32.4)   |
| Adverse event                                                              | 23 (9.3)                    | 6 (8.7)                 | 0 (0.0)                       | 3 (15.0)                    | 32 (9.0)     |
| Intercurrent illness compromising ability to fulfill protocol requirements | 1 (0.4)                     | 0 (0.0)                 | 0 (0.0)                       | 0 (0.0)                     | 1 (0.3)      |
| Requirementfor altermative treatment per investigator                      | 2 (0.8)                     | 0 (0.0)                 | 0 (0.0)                       | 0 (0.0)                     | 2 (0.6)      |
| Withdrawal of consent                                                      | 14 (5.7)                    | 3 (4.3)                 | 0 (0.0)                       | 0 (0.0)                     | 17 (4.8)     |
| Death                                                                      | 8 (3.2)                     | 2 (2.9)                 | 3 (15.8)                      | 1 (5.0)                     | 14 (3.9)     |
| Other                                                                      | 9 (3.6)                     | 0 (0.0)                 | 0 (0.0)                       | 0 (0.0)                     | 9 (2.5)      |
| Treatment continued post- progression, n (%6)                              | 86 (34.8)                   | 22 (31.9)               | 7 (36.8)                      | 5 (25.0)                    | 120 (33.8)   |
| Study status continuing.n (96)                                             | 143 (57.9)                  | 44 (63.8)               | 10 (52.6)                     | 11 (55.0)                   | 208 (58.6)   |
| Study status discontinued, n (9o)                                          | 104 (42.1)                  | 25 (36.2)               | 9 (47.4)                      | 9 (45.0)                    | 147 (41.4)   |
| Withdrawal of consent                                                      | 25 (10.1)                   | 5 (7.2)                 | 1 (5.3)                       | 3 (15.0)                    | 34 (9.6)     |
| Lost to follow-up                                                          | 1 (0.4)                     | 0 (0.0)                 | 1 (5.3)                       | 0 (0.0)                     | 2 (0.6)      |
| Death                                                                      | 78 (31.6)                   | 20 (29.0)               | 7 (36.8)                      | 6 (30.0)                    | 111 (31.3)   |

Abbreviations: n = number of patients in specific category: NSCLC = non-small cell lung cancer; RET = REarranged during Transfection.

a Patient disposition for The First 105 Patients with Prior Platinum Chemotherapy Analysis Set is presented in Table 8.4.

b The total columm is calculated from the Prior Platinum Chemotherapy, Treatment-Naive, Prior Other Systemic Therapy, and Non-Measurable Disease Analysis Sets.

Status as of the data cutoff date.

## Recruitment

This study was conducted at 80 centres that enrolled patients in North America, Asia Pacific, European Union, and the Middle East. The study is ongoing.

Study initiation date: 09 May 2017

Data cutoff date for interim analysis: 15 June 2021

Participants screened: 921

Participants treated: 796

Participants continuing study intervention: 462

## Conduct of the study

This interim report provides information on study conduct from Protocol version 8.0 up to Protocol version 9.0 (03 June 2020).

<div style=\"page-break-after: always\"></div>

Table 9: Summary of major changes, subsequent amendments, and the approval dates of the protocol.

| Version Number and   | Major Changes to the Protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8.0 10 June 2019     | New sections were added to define length of shudy and end of study aq tym sqnom g /ana Aeleupwondde mooo ot paiepdm sem meld net T aqi participant has withdrawn consent, is lost to follow-up, has died, or the sponsor makes a decision to close the shudy. Phase 2 descriptions were updated to increase participant mumbers following the selection of 160 mg BD as the RP2D and to account for addition of a new cohort (Cohort 6). Eligibility criteria were added, removed, or modified (as detailed in protocol Section 3.3.1). Additional details were provided regarding the shudy intervention (protocol Section 3.4.1). Additional Investigator guidance regarding possible AEs and re-escalations Were provided. Testsandevaluations Wereupdated to add testsat additional timepoints and increase ftequency of tests (as described in Section 7 of the protocol [appendix Protocol and addendaJ). Sample size was updated to reflect updated size for Cohort 1 and Cohort 6. Statistical portions were up dated to aligu with other protocol sections. Clarification that efficacy analyses will be conducted on the Safety Analysis Set Imless otherwise specified (as described in protocol Section 3.7). Defimition of life-threatening AEs was updated. Examples of multiple kinase imhibitors and RET activating mutations were updated |

<div style=\"page-break-after: always\"></div>

| 8.1 (Denmark) 10 Jume 2019                                                                                | Major changes from protocol version 7.3 (Demmark) to version 8.1 were: Rationale for ewrolling participants youmger thsn 18 years was provided to indicate teool qpanonddeg pallouma aq pmoo sreaf st meq raammof simedpgred jeg instinutional and coumtry regulatory authorities. All other revisions were made to aligu with version S.0.                                                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8.2 (Japan) 14 June 2019                                                                                  | Major changes fiom protocol version 7.2 (Japan) to version 8.2 were: Study design was updated to add clarification of enrollment in Japan. All other revisions were made to aligu with version 8.0.                                                                                                                                                                                                                                                                                                                                                    |
| 8.3 (Germany) 08 October 2019                                                                             | Major changes from protocol version 7.4 (Genmany) to version 8.3 were: Clinical safety and data updates Were made to aligu with IB version 5.0. Size of Cohort 1 was increased to up to approximately 200 participants. Cohort 6 was added for participants who discontinued another RE T imhibitor due to The 40 mg capsule and liquid suspension were added; the 10 mg capsule was removed. The ECG schedule was updated.                                                                                                                            |
| Addendum l to '8-0'81 02 April 2020                                                                       | The pwrpose of this addendum was to allow temporary flexibility in study visits, assessments, and shudy dnug dispensation because of the Cotm-l9 pandemic. The infonmation in this addendum supplements Protocol Section 7 and Table 7-1 in Protocol version 8.0, version 8.1, version 8.2,and version 8.3.                                                                                                                                                                                                                                            |
| 9.0 (Global) 03 Jmme 2020                                                                                 | Major changes from protocol version 8.3 (Genmany) to version 9.0 were: Aligued chamges added in response to EC/RA. queries in PA8.1 (Dewmark), PA8.3 (Gemmany), and PA8 addendhm (C anadla). Clinical safety and data updates were made to align with the IB T7.0. Size of Cohort 1 was increased to approximately 250 participants and Cohort 5 up to approximately 200. Reduced the requirement for in-climic visits beyoud C7 and provided the options of telemedicine and visits to local healthcare providers dwing nondisease assessment cycles. |
| Abbreviations: AE = adverse event; Bm = twice daily: C = cycle; CoViD-19 = coronavinus disease 2019; EC = | Abbreviations: AE = adverse event; Bm = twice daily: C = cycle; CoViD-19 = coronavinus disease 2019; EC =                                                                                                                                                                                                                                                                                                                                                                                                                                              |

## Protocol Deviations

Table 10: Summary of Important Protocol Deviations (Data Cutoff: 15 June 2021)

| Category                                 | NSCLC SafetyPopulation (N=356) n (%)   | Overall SafetyPopulation (N=796) n (%)   |
|------------------------------------------|----------------------------------------|------------------------------------------|
| Patients with Major Protocol Deviations  | 92 (25.8)                              | 161 (20.2)                               |
| Investigational Product                  | 33 (9.3)                               | 61 (7.7)                                 |
| Stuidy Proceduues                        | 21 (5.9)                               | 43 (5.4)                                 |
| SAE Reporting                            | 18 (5.1)                               | 35 (4.4)                                 |
| Restricted Concomitant Medication Change | 19 (5.3)                               | 23 (2.9)                                 |
| Inclusion Criteria                       | 12 (3.4)                               | 16 (2.0)                                 |
| Withdrawal Critenia                      | 7 (2.0)                                | 11 (1.4)                                 |
| Exclusion Critenia                       | 3 (0.8)                                | 5 (0.6)                                  |
| Infonmed Consent                         | 2 (0.6)                                | 4(0.5)                                   |

Abbreviations: N = mmber of patients; n = mumber of patients in specific category; NSCLC = non-small cell lumg camcer; SAE =serious adverse events.

## Baseline data

Demographics

<div style=\"page-break-after: always\"></div>

Table 11: Summary of Demographics RET Fusion-Positive NSCLC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

|                                         |                                     |                        | Supportive Analysis Sets            | Supportive Analysis Sets      |                |
|-----------------------------------------|-------------------------------------|------------------------|-------------------------------------|-------------------------------|----------------|
| Analysis Set                            | Prior Platinum Chemotherapy (N=247) | Treatment-Naive (N=69) | Prior Other Systemic Therapy (N=19) | Non-Measurable Disease (N=20) | Totalb (N=355) |
| Age (vears), n                          |                                     |                        |                                     |                               |                |
| Median (Range)                          | 61.0 (23-81)                        | 63.0 (23-92)           | 58.0 (47-71)                        | 56.0 (26-80)                  | 61.0 (23-92)   |
| Overall age gioup, n (%)                |                                     |                        |                                     |                               |                |
| 18-44 years                             | 33 (13.4)                           | 7 (10.1)               | 0 (0.0)                             | 4 (20.0)                      | 44 (12.4)      |
| 45-64 years                             | 127 (51.4)                          | 31 (44.9)              | 14 (73.7)                           | 10 (50.0)                     | 182 (51.3)     |
| 65-74 years                             | 70 (28.3)                           | 24 (34.8)              | 5 (26.3)                            | 5 (25.0)                      | 104 (29.3)     |
| 75-84 years                             | 17 (6.9)                            | 4 (5.8)                | 0 (0.0)                             | 1 (5.0)                       | 22 (6.2)       |
| >85 years                               | 0 (0.0)                             | 3 (4.3)                | 0 (0.0)                             | 0 (0.0)                       | 3 (0.8)        |
| Sex, n (%)                              |                                     |                        |                                     |                               |                |
| Male                                    | 107 (43.3)                          | 26 (37.7)              | 8 (42.1)                            | 11 (55.0)                     | 152 (42.8)     |
| Female                                  | 140 (56.7)                          | 43 (62.3)              | 11 (57.9)                           | 9 (45.0)                      | 203 (57.2)     |
| Race, n (%)                             |                                     |                        |                                     |                               |                |
| White                                   | 108 (43.7)                          | 48 (69.6)              | 12 (63.2)                           | 6 (30.0)                      | 174 (49.0)     |
| Black or Afican Amenican                | 12 (4.9)                            | 4 (5.8)                | 0 (0.0)                             | 0 (0.0)                       | 16 (4.5)       |
| American Indian or Alaska Native        | 1 (0.4)                             | 0 (0.0)                | 0 (0.0)                             | 0 (0.0)                       | 1 (0.3)        |
| Native Hawaiian or OtherPacificIslander | 0 (0.0)                             | 0 (0.0)                | 0 (0.0)                             | 0 (0.0)                       | 0 (0.0)        |
| Asian                                   | 118 (47.8)                          | 13 (18.8)              | 7 (36.8)                            | 14 (70.0)                     | 152 (42.8)     |
| Other/Missing                           | 8 (3.2)                             | 4 (5.8)                | 0 (0.0)                             | 0 (0.0)                       | 12 (3.4)       |
| Ethmicity, n (%)                        |                                     |                        |                                     |                               |                |
| Hispanic or Latino                      | 7 (2.8)                             | 1 (1.4)                | 1 (5.3)                             | 1 (5.0)                       | 10 (2.8)       |
| Not Hispanic or Latino                  | 235 (95.1)                          | 67 (97.1)              | 18 (94.7)                           | 19 (95.0)                     | 339 (95.5)     |
| Missing                                 | 5 (2.0)                             | 1 (1.4)                | 0 (0.0)                             | 0 (0.0)                       | 6 (1.7)        |
| Body weight (kg)                        |                                     |                        |                                     |                               |                |
| n                                       | 246                                 | 69                     | 19                                  | 20                            | 354            |
| Median                                  | 64.950                              | 71.200                 | 59.500                              | 62.550                        | 64.950         |
| Range                                   | 38.85-148.00                        | 44.00-130.50           | 48.60-109.50                        | 46.10-106.80                  | 38.85-148.00   |
| Baseline ECOG, n (%)                    |                                     |                        |                                     |                               |                |
| 0                                       | 90 (36.4)                           | 25 (36.2)              | 5 (26.3)                            | 11 (55.0)                     | 131 (36.9)     |
| 1                                       | 150 (60.7)                          | 40 (58.0)              | 13 (68.4)                           | 9 (45.0)                      | 212 (59.7)     |
| 2                                       | 7 (2.8)                             | 4 (5.8)                | 1 (5.3)                             | 0                             | 12 (3.4)       |
| Smoking history, n (%6)                 |                                     |                        |                                     |                               |                |
| Never smoked                            | 165 (66.8)                          | 48 (69.6)              | 13 (68.4)                           | 15 (75.0)                     | 241 (67.9)     |
| Fommer smoker                           | 78 (31.6)                           | 19 (27.5)              | 6 (31.6)                            | 5 (25.0)                      | 108 (30.4)     |
| Curent smoker                           | 4 (1.6)                             | 2 (2.9)                | 0                                   | 0                             | 6 (1.7)        |

Abbreviations: ECOG = Eastem Cooperative Oncology Group; N = mumber of patients; n = mumber of patients in specific category, NSCLC = non-small cell lumg cancer; RET =REarranged dhuing Transfection.

Patient demographics for The First 105 Patients with Prior Platimum Chemotherapy Analysis Set is provided in Table 8.7.

The total columm is calculated from the Prior Platimm Chemotherapy, Treatment-Naive, Prior Other Systemic Therapy, and Non-Measuuable Disease Analysis Sets.

<div style=\"page-break-after: always\"></div>

## Baseline Disease Characteristics

Table 12: Baseline Disease Characteristics - RET Fusion Positive NSCLC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

|                                                            |                                                            |                                                            | Supportive Analysis Sets\"                                  | Supportive Analysis Sets\"                                  |                                                            |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Analysis Set                                               | Prior Platinum Chemotherapy (N=247)                        | Treatment- Naive (N=69)                                    | Prior Other Systemic Therapy (N=19)                        | Non- Measurable Disease (N=20)                             | Totalb (N=355)                                             |
| Primary tumor type, n (%)                                  | Primary tumor type, n (%)                                  | Primary tumor type, n (%)                                  | Primary tumor type, n (%)                                  | Primary tumor type, n (%)                                  | Primary tumor type, n (%)                                  |
| NSCLC                                                      | 247 (100.0)                                                | 69 (100.0)                                                 | 19 (100.0)                                                 | 20 (100.0)                                                 | 355 (100.0)                                                |
| Time sinceinitial diagnosis,months                         | Time sinceinitial diagnosis,months                         | Time sinceinitial diagnosis,months                         | Time sinceinitial diagnosis,months                         | Time sinceinitial diagnosis,months                         | Time sinceinitial diagnosis,months                         |
| Median                                                     | 21.90                                                      | 2.00                                                       | 8.30                                                       | 18.90                                                      | 16.30                                                      |
| Range                                                      | 1.2-194.3                                                  | 0.5-21.9                                                   | 2.0-112.5                                                  | 7.4-223.7                                                  | 0.5-223.7                                                  |
| Investigator reported history of metastatic disease, n (%) | Investigator reported history of metastatic disease, n (%) | Investigator reported history of metastatic disease, n (%) | Investigator reported history of metastatic disease, n (%) | Investigator reported history of metastatic disease, n (%) | Investigator reported history of metastatic disease, n (%) |
| Yes                                                        | 240 (97.2)                                                 | 68 (98.6)                                                  | 19 (100.0)                                                 | 20 (100.0)                                                 | 347 (97.7)                                                 |
| No                                                         | 7 (2.8)                                                    | 1 (1.4)                                                    | 0 (0.0)                                                    | 0 (0.0                                                     | 8 (2.3)                                                    |
| Months since metastatic disease                            | Months since metastatic disease                            | Months since metastatic disease                            | Months since metastatic disease                            | Months since metastatic disease                            | Months since metastatic disease                            |
| Median                                                     | 18.15                                                      | 1.60                                                       | 8.30                                                       | 10.80                                                      | 10.90                                                      |
| Range                                                      | 1.0-158.5                                                  | 0-8.1                                                      | 2.0-75.5                                                   | 0.4-91.1                                                   | 0-158.5                                                    |
| At least 1 measuable lesion by investigator, n (%)         | At least 1 measuable lesion by investigator, n (%)         | At least 1 measuable lesion by investigator, n (%)         | At least 1 measuable lesion by investigator, n (%)         | At least 1 measuable lesion by investigator, n (%)         | At least 1 measuable lesion by investigator, n (%)         |
| Yes                                                        | 246 (99.6)                                                 | 69 (100.0)                                                 | 19 (100.0)                                                 | 0                                                          | 334 (94.1)                                                 |
| No                                                         | 1 (0.4)                                                    | 0 (0.0)                                                    | 0 (0.0)                                                    | 20 (100.0)                                                 | 21 (5.9)                                                   |
| Sum of diameters at baseline by investigator, mm           | Sum of diameters at baseline by investigator, mm           | Sum of diameters at baseline by investigator, mm           | Sum of diameters at baseline by investigator, mm           | Sum of diameters at baseline by investigator, mm           | Sum of diameters at baseline by investigator, mm           |
| Median                                                     | 51.130                                                     | 69.500                                                     | 75.000                                                     | NA                                                         | 56.000                                                     |
| Range                                                      | 10.00-297.00                                               | 11.00-191.00                                               | 12.00-249.60                                               | NA                                                         | 10.00-297.00                                               |
| CNS metastases at baseline by investigator, n (%)          | CNS metastases at baseline by investigator, n (%)          | CNS metastases at baseline by investigator, n (%)          | CNS metastases at baseline by investigator, n (%)          | CNS metastases at baseline by investigator, n (%)          | CNS metastases at baseline by investigator, n (%)          |
| Yes                                                        | 77 (31.2)                                                  | 16 (23.2)                                                  | 11 (57.9)                                                  | 2 (10.0)                                                   | 106 (29.9)                                                 |
| No                                                         | 170 (68.8)                                                 | 53 (76.8)                                                  | 8 (42.1)                                                   | 18 (90.0)                                                  | 249 (70.1)                                                 |

- Baseline disease characteristics for The First 105 Patients with Prior Platinm Chemotherapy Analysis Setis summarized in Table 8.9and Table 8.10.

Abbreviations: CNS = central nervous system; N = mumber of patients; n = mumber of patients in specific category: NSCLC =non-small cell hmg cancer; RET = REaranged duuing Transfection.

- b The total colun is calculated from the Prior Platimum Chemotherapy, Treatment-Naive, Prior Other Systemic Therapy, and Non-Measuable Disease Analysis Sets.
- Patient was emrolled in Phase 1.
- RET fusion status for The First 105 Patients with Prior Platinumm Chemotherapy Analysis Set is suummarized in Table 8.10
- h Total columm is calculated from the Prior Platimum Chemotherapy, Treatment-Naive, Prior Other Systemic Iherapy, and Non-Measurable Disease Analysis Sets.
- Other molecular assay type is Nanostring Technology

Table 13: Baseline Disease Characteristics -RET Fusion Status RET Fusion-Positive NSCLC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

|                              |                                     |                        | Supportive Analysis Sets\"           | Supportive Analysis Sets\"      |                |
|------------------------------|-------------------------------------|------------------------|-------------------------------------|--------------------------------|----------------|
| Analysis Set                 | Prior Platinum Chemotherapy (N=247) | Treatnent- Naive (=69) | Prior Other Systemic Therapy (N=19) | Non- Measurable Disease (N=20) | Totalb (N=355) |
| RET fusion parhmer, n(%o)    |                                     |                        |                                     |                                |                |
| KIF5B                        | 153 (61.9)                          | 48 (69.6)              | 14 (73.7)                           | 12 (60.0)                      | 227 (63.9)     |
| CCDC6                        | 53 (21.5)                           | 10 (14.5)              | 3 (15.8)                            | 5 (25.0)                       | 71 (20.0)      |
| NC0A4                        | 5 (2.0)                             | 1 (1.4)                | 1 (5.3)                             | 1 (5.0)                        | 8 (2.3)        |
| Other                        | 16 (6.5)                            | 2 (2.9)                | 1 (5.3)                             | 0 (0.0)                        | 19 (5.4)       |
| Unknowm                      | 22 (8.9)                            | 8 (11.6)               | 0 (0.0)                             | 2 (10.0)                       | 32 (9.0)       |
| Molecular Assay Type, n (%6) |                                     |                        |                                     |                                |                |
| NGS on Tumor                 | 209 (84.6)                          | 42 (60.9)              | 16 (84.2)                           | 17 (85.0)                      | 284 (80.0)     |
| PCR on Tumor                 | 4 (1.6)                             | 1 (1.4)                | 1 (5.3)                             | 0                              | 6 (1.7)        |
| NGS on Plasma/Blood          | 23 (9.3)                            | 21 (30.4)              | 2 (10.5)                            | 3 (15.0)                       | 49 (13.8)      |
| FISH on Tumor                | 10 (4.0)                            | 5 (7.2)                | 0 (0.0)                             | 0 (0.0)                        | 15 (4.2)       |
| Other\"                       | 1 (0.4)                             | 0 (0.0)                | 0 (0.0)                             | 0 (0.0)                        | 1 (0.3)        |

Abbreviations: FISH =Fluorescence in situ hybridization ; N = mumber of patients; n = mumber of patients in specific reaction; RET =REaranged duuing Transfection.

<div style=\"page-break-after: always\"></div>

Table 14: Prior Cancer Therapy RET Fusion-Positive NSCLC Efficacy Analysis Population (Data Cutoff: 15 June 2021)

<!-- image -->

|                                                  |                                                  |                                                  | Supportive Analysis Sets\"                        | Supportive Analysis Sets\"                        |                                                  |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Analysis Set                                     | Prior Platinum Chemotherapy (N = 247)            | Treatment- Naive (IN = 69)                       | Prior Other Systemic Therapy (N = 19)            | Non- Measurable Disease (N =20)                  | Total' (N=355)                                   |
| Received prior systemic therapy, n (96)          | Received prior systemic therapy, n (96)          | Received prior systemic therapy, n (96)          | Received prior systemic therapy, n (96)          | Received prior systemic therapy, n (96)          | Received prior systemic therapy, n (96)          |
| sa1.                                             | 247 (100.0)                                      | NA                                               | 19 (100.0)                                       | 20 (100.0)                                       | 286 (80.6)                                       |
| No                                               | 0 (0.0)                                          | 69 (100.0)                                       | 0 (0.0)                                          | 0 (0.0)                                          | 69 (19.4)                                        |
| Tvpe of prior svstemic therapy', n (96)          | Tvpe of prior svstemic therapy', n (96)          | Tvpe of prior svstemic therapy', n (96)          | Tvpe of prior svstemic therapy', n (96)          | Tvpe of prior svstemic therapy', n (96)          | Tvpe of prior svstemic therapy', n (96)          |
| Chemotherapy                                     | 247 (100.0)                                      | NA                                               | 1 (5.3)                                          | 20 (100.0)                                       | 268 (75.5)                                       |
| Platinm chemotherapy                             | 247 (100.0)                                      | NA                                               | 0                                                | 19 (95.0)                                        | 266 (74.9)                                       |
| Immumotherapy                                    | 145 (58.7)                                       |                                                  | 13 (68.4)                                        | 9 (45.0)                                         | 167 (47.0)                                       |
| Anti-PD-1/PD-L1 therapy                          | 144 (58.3)                                       | NA.                                              | 13 (68.4)                                        | 9 (45.0)                                         | 166 (46.8)                                       |
| Anti C TLA4 山erapy                               | 6 (2.4)                                          | NA.                                              | 2 (10.5)                                         | 0                                                | 8 (2.3)                                          |
| Multikinase inhibitor                            | 85 (34.4)                                        | 0 (0.0)                                          | 8 (42.1)                                         | 5 (25.0)                                         | 98 (27.6)                                        |
| Cabozautinib                                     | 25 (10.1)                                        | NA                                               | 3 (15.8)                                         | 2 (10.0)                                         | 30 (8.5)                                         |
| Vandetanib                                       | 12 (4.9)                                         | NA.                                              | 1 (5.3)                                          | 1 (5.0)                                          | 14 (3.9)                                         |
| Sorafemib                                        | 0 (0.0)                                          | NA.                                              | 0 (0.0)                                          | 0 (0.0)                                          | 0 (0.0)                                          |
| Leuvatinib                                       | 8(3.2)                                           | NA                                               | 1 (5.3)                                          | 1 (5.0)                                          | 10 (2.8)                                         |
| Other MkIs                                       | 61 (24.7)                                        | NA                                               | 4 (21.1)                                         | 2 (10.0)                                         | 67 (18.9)                                        |
| Other\"                                           | 97 (39.3)                                        | 0                                                | 3 (15.8)                                         | 7 (35.0)                                         | 107 (30.1)                                       |
| VEGF/VEGFRinhibitor                              | 79 (32.0)                                        | NA.                                              | 0 (0.0)                                          | 4 (20.0)                                         | 83 (23.4)                                        |
| EGFR. inhibitor                                  | 13 (5.3)                                         | NA.                                              | 1 (5.3)                                          | 1 (5.0)                                          | 15 (4.2)                                         |
| Number of prior systemic regimens, n (96)        | Number of prior systemic regimens, n (96)        | Number of prior systemic regimens, n (96)        | Number of prior systemic regimens, n (96)        | Number of prior systemic regimens, n (96)        | Number of prior systemic regimens, n (96)        |
| 0                                                | 0                                                | 69 (100.0)                                       | 0 (0.0)                                          | 0 (0.0)                                          | (61)69                                           |
| 1                                                | 73 (29.6)                                        | NA                                               | 14 (73.7)                                        | 7 (35.0)                                         | 94 (26.5)                                        |
| 2                                                | 67 (27.1)                                        | NA                                               | 3 (15.8)                                         | 5 (25.0)                                         | 75 (21.1)                                        |
| 23                                               | 107 (43.3)                                       | NA.                                              | 2 (10.5)                                         | 8 (40.0)                                         | 117 (33.0)                                       |
| Number of prior systemic regimens                | Number of prior systemic regimens                | Number of prior systemic regimens                | Number of prior systemic regimens                | Number of prior systemic regimens                | Number of prior systemic regimens                |
| Mediam                                           | 2.0                                              | NA                                               | 1.0                                              | 2.0                                              | 2.0                                              |
| Ramge                                            | 1-15                                             | NA.                                              | 1-5                                              | 1-9                                              | 0-15                                             |
| Best response to last systemic treatment, n (96) | Best response to last systemic treatment, n (96) | Best response to last systemic treatment, n (96) | Best response to last systemic treatment, n (96) | Best response to last systemic treatment, n (96) | Best response to last systemic treatment, n (96) |
| Complete response                                | 2 (0.8)                                          | NA                                               | 0                                                | 0                                                | 2 (0.6)                                          |
| Partial response                                 | 36 (14.6)                                        | NA.                                              | 1 (5.3)                                          | NA.                                              | 37 (10.4)                                        |
| Stable disease                                   | 74 (30.0)                                        | NA                                               | 2 (10.5)                                         | 6 (30.0)                                         | 82 (23.1)                                        |
| Progressive disease                              | 71 (28.7)                                        | NA                                               | 11 (57.9)                                        | 5 (25.0)                                         | 87 (24.5)                                        |
| Not ewaluated                                    | 62 (25.1)                                        | NA.                                              | 5 (26.3)                                         | 9 (45.0)                                         | 76 (21.4)                                        |
| Unknowm\"                                         | 2 (0.8)                                          | 69 (100.0)                                       | 0 (0.0)                                          | 0 (0.0)                                          | 71 (20.0)                                        |
| Prior radiotherapr, n (96)                       | Prior radiotherapr, n (96)                       | Prior radiotherapr, n (96)                       | Prior radiotherapr, n (96)                       | Prior radiotherapr, n (96)                       | Prior radiotherapr, n (96)                       |
|                                                  | 132 (53.4)                                       | 23 (33.3)                                        | 10 (52.6)                                        | 13 (65.0)                                        | 178 (50.1)                                       |
| No                                               | 115 (46.6)                                       | 46 (66.7)                                        | 9 (47.4)                                         | 7 (35.0)                                         | 177 (49.9)                                       |
| Prior cancer related surgery, D (96)             | Prior cancer related surgery, D (96)             | Prior cancer related surgery, D (96)             | Prior cancer related surgery, D (96)             | Prior cancer related surgery, D (96)             | Prior cancer related surgery, D (96)             |
| sa1.                                             | 110 (44.5)                                       | 17 (24.6)                                        | 9 (47.4)                                         | 13 (65.0)                                        | 149 (42.0)                                       |
| No                                               | 137 (55.5)                                       | 52 (75.4)                                        | 10 (52.6)                                        | 7 (35.0)                                         | 206 (58.0)                                       |

<div style=\"page-break-after: always\"></div>

## Dose intensity

Table 15: Selpercatinib Dose Intensity Overall Safety Population and NSCLC Safety Population (Data Cutoff: 15 June 2021)

|                                            | NSCLC Safety Population (N=356)   | Overall Safety Population (N=796)   |
|--------------------------------------------|-----------------------------------|-------------------------------------|
| Time on Treatiment (imonths)               |                                   |                                     |
| Median                                     | 19.09                             | 21.29                               |
| Minimum                                    | 0.1                               | 0.1                                 |
| Maximum                                    | 49.0                              | 49.0                                |
| Relative Dose Intensity (%o)               |                                   |                                     |
| Mean (standard deviation)                  | 83.36 (19.9)                      | 84.64 (19.1)                        |
| Median                                     | 92.71                             | 94.46                               |
| Range                                      | 21.3, 100.1                       | 17.3, 100.1                         |
| Relative Dose Intensity Categories, n (%6) |                                   |                                     |
| 290%                                       | 197 (55.3)                        | 466 (58.5)                          |
| 75 to ≤90%                                 | 62 (17.4)                         | 122 (15.3)                          |
| 50 to ≤75%                                 | 64 (18.0)                         | 146 (18.3)                          |
| 50%                                        | 33 (9.3)                          | 62 (7.8)                            |

Abbreviations: N = number of patients; n = number of patients in specific category; NSCLC = non-small cell lung cancer.

## Dose Modification and Compliance

Table 16: Dose Modifications in NSCLC and Overall Safety Populations (Data Cutoff: 15 June 2021)

|                           | NSCLC Safety Population (I=356)   | Overall Safety Population (I=796)   |
|---------------------------|-----------------------------------|-------------------------------------|
| Dose reduction, n (9o)    |                                   |                                     |
| Any                       | 180 (50.6)                        | 343 (43.1)                          |
| For AE                    | 172 (48.3)                        | 325 (40.8)                          |
| For other reason          | 22 (6.2)                          | 47 (5.9)                            |
| Dose withheld, n (%o)     |                                   |                                     |
| Any                       | 276 (77.5)                        | 580 (72.9)                          |
| For AE                    | 245 (68.8)                        | 510 (64.1)                          |
| Forotherreason            | 103 (28.9)                        | 229 (28.8)                          |
| Doseimcrease,n(%o)        |                                   |                                     |
| Any                       | 102 (28.7)                        | 183 (23.0)                          |
| Intra-patient escalation? | 36 (10.1)                         | 69 (8.7)                            |
| Re-escalationb            | 51 (14.3)                         | 84 (10.6)                           |
| Otherreason               | 27 (7.6)                          | 52 (6.5)                            |

Abbreviations: AE =adverse event; N=mumber of patients; n =number of patients in specific category;NSCLC = non-smallcelllungcancer.

a Startedatalowerdoseduuringdoseescalationthatwassubsequentlyincreased.

b Re-escalation after adosereduction.

## Numbers analysed

At the DCO date, all 355 patients with RET fusion-positive NSCLC from Cohorts 1, 2, and 5 are included in the efficacy analysis as they had achieved at least 6 months of potential follow-up time from the first dose.

The primary efficacy analysis set to support the proposed first-line indication included 69 TreatmentNaïve Patients (previously named SAS1);

<div style=\"page-break-after: always\"></div>

The main supportive analysis sets include:

- Patients  Previously  Treated  with  Platinum-Based  Chemotherapy  (N=247)  (previously  named IAS);
- CNS Response Analysis Set (N=106).

Patients in Cohort 6 (only 1 patient at the DCO), which was introduced in protocol version 8, are not included in the evaluation of efficacy as it is a different population of patients who have received prior treatment with a selective RET inhibitor.

## Outcomes and estimation

## Treatment-Naïve Patients with RET Fusion-Positive NSCLC

Objective Response Rate, Best Overall Response, Duration of Response and Clinical Benefit Rate

Table 17: Objective Response Rate, Best Overall Response, and Clinical Benefit Rate Based on IRC and Investigator Assessment Treatment-Naïve Patients (Data Cutoff Date: 15 June 2021)

|                                      | IRC Assessment (I=69)   | Investigator Assessiment (IN=69)   |
|--------------------------------------|-------------------------|------------------------------------|
| Objective Response Rate\"             |                         |                                    |
| n (96)                               | 58 (84.1)               | 59 (85.5)                          |
| 10 9656                              | (73.3, 91.8)            | 75.0, 92.8                         |
| Best Overall Respomse -no. (%o)      |                         |                                    |
| Complete response (CR)               | 4 (5.8)                 | 1 (1.4)                            |
| Pautial response (PR)                | 54 (78.3)               | 58 (84.1)                          |
| Stable disease (SD)                  | 6 (8.7)                 | 5 (7.2)                            |
| SD-16 weeks*                         | 6 (8.7)                 | 4 (5.8)                            |
| Progressive disease (PD)             | 3 (4.3)                 | 3 (4.3)                            |
| Not evaluable                        | 2 (2.9)                 | 2 (2.9)                            |
| Climical Benefit Rate (CR +PR + SD)\" |                         |                                    |
| n (%)                                | 64 (92.8)               | 63 (91.3)                          |
| 95%6 CTb                             | (83.9, 97.6)            | (82.0, 96.7)                       |
| Duration of Response (months)et      |                         |                                    |
| Mediam (95%。 CI)                     | 20.21 (13.0, NE)        | 20.27 (14.8, NE)                   |
| Censored                             | 32 (55.2)               | 31 (52.5)                          |
| Duration of Follow-Up (months)*      |                         |                                    |
| Mfediam                              | 20.27                   | 23.03                              |
| 25th, 75th percentiles               | 12.9, 26.7              | 15.2, 26.5                         |
| Rate (%o) of Duration of Responsere  |                         |                                    |
| ≥6 months (95% CI)                   | 87.7 (75.9, 93.9)       | 86.2 (74.3, 92.9)                  |
| ≥12 months (95% CI)                  | 66.1 (51.6, 77.3)       | 66.3 (52.4, 77.1)                  |
| ≥24 months (95% C1)                  | 41.6 (25.6, 56.8)       | 41.8 (26.1, 56.7)                  |
| ≥36 months (95% CI)                  | 41.6 (25.6, 56.8)       | 41.8 (26.1, 56.7)                  |

Eligible patients are treated on or before 15 December 2020. Stable disease includes Non-CR/Non-PD.

Abbreviations: CI = confidence interval; CR = complete response; IRC = Independent Review Committee; N = mmber of patients; n = muumber of patients in specific category; NE = not estimable; No. = mmmber; ORR = objective response rate; PR = pautial response; SD = stable disease.

b 95% CI was calculated using Clopper-Peauson method.

ORR. is defined as the proportion of patients with best overall response of confinmed CR. or PR. Response was comfimmed by a repeat assessment ≥ 28 days.

C Indicates SD lasting 2 16 weeks following initiation of selpercatinib umtil the criteria for disease progression was first met.

Climical benefit rate (%o) is defined as the proportion of patients with best overall response of confinmed CR, PR. or SD lasting 16 or more weeks (SD*). Stable disease Was measuued from the date of the first dose selpercatinib Wtil the criteria for disease pro gression was first met.

<div style=\"page-break-after: always\"></div>

Figure 5. Waterfall plot of best change in tumour burden based on IRC assessments -Treatment naïve patients (Data cut-off: 15 June 2021)

<!-- image -->

Eligiblepatientsaredefined aspatients treated on or before15December2020. For eachsubject,thebest percent changefrom baselinein the sum of diametersfor all targetlesions isrepresented by a vertical bar.The dashed lines represent the RECIST vl.1. criteria forresponse (30%decrease) or progressive disease(20%increase).

Abbreviations:IRC=IndependentReview Committee;RECIST=ResponseEvaluation Criteria inSolid Tumors.

Figure 6. Kaplan-Meier Plot of Duration of Response Based on IRC Assessments -Efficacy Eligible Subjects of RET fusion-positive NSCLC with confirmed CR or PR

<!-- image -->

Time to Response and Time to Best Response

<div style=\"page-break-after: always\"></div>

Table 18: Time to Response and Based on IRC and Investigator's Assessments Treatment -Naïve Patients (Data Cutoff Date: 15 June 2021)

| Status                          | IRC Assessiment (IN=69)   | Imvestigator Assessment (IN=69)   |
|---------------------------------|---------------------------|-----------------------------------|
| Time to Response (months)       |                           |                                   |
| Median                          | 1.81                      | 1.81                              |
| 25th, 75th Percentiles          | 1.7.3.4                   | 1.7,1.9                           |
| Minimm, Maximum                 | 0.7, 10.8                 | 0.8,5.6                           |
| Time to Response, n (%)         |                           |                                   |
| 2 months                        | 41 (70.7)                 | 46 (78.0)                         |
| ≥2 to 4 months                  | 15 (25.9)                 | 9 (15.3)                          |
| ≥4 to 6 months                  | 0 (0.0)                   | 4 (6.8)                           |
| ≥6 to 9 months                  | 1 (1.7)                   | 0 (0.0)                           |
| ≥9 months                       | 1 (1.7)                   | 0 (0.0)                           |
| Time to Best Response (monthis) |                           |                                   |
| Median                          | 1.82                      | 1.84                              |
| 25th, 75th percentiles          | 1.7, 3.5                  | 1.7, 1.9                          |
| Min, max                        | 0.7, 24.8                 | 0.8,5.6                           |
| Time to Best Response, n (96)   |                           |                                   |
| ≤2 months                       | 39 (67.2)                 | 45 (76.3)                         |
| ≥2 to 4 months                  | 14 (24.1)                 | 10 (16.9)                         |
| 24 to 6 months                  | 0 (0.0)                   | 4 (6.8)                           |
| ≥6 to 9 monihs                  | 1 (1.7)                   | 0 (0.0)                           |
| ≥9 months                       | 4 (6.9)                   | 0 (0.0)                           |

Abbreviations: IRC = Independent Review Committee; max =maximum, min = minimum; N = number of patients; n = mmmber of patients in specific category.

## Progression-free Survival

| Status                                           | IRC Assessment (N=69)   | Investigator Assessment (N=69)   |
|--------------------------------------------------|-------------------------|----------------------------------|
| Progression Status, n (96)*                      |                         |                                  |
| Disease progression                              | 29 (42.0)               | 34 (49.3)                        |
| Died (no disease progression beforehand)         | 3 (4.3)                 | 2 (2.9)                          |
| Censored                                         | 37 (53.6)               | 33 (47.8)                        |
| Duration of Progression-Free Survival (months)be |                         |                                  |
| Median                                           | 21.95                   | 20.73                            |
| 95% CI for median                                | 13.8, NE                | 13.6, NE                         |
| Min, max                                         | 0.0+, 41.0+             | 0.0+, 41.0+                      |
| Duration of Follow-Up (months)b                  |                         |                                  |
| Median                                           | 21.91                   | 24.67                            |
| 25th, 75th percentiles                           | 13.8, 27.6              | 18.7, 27.6                       |
| Rate (%o) of Progression-Free Suvivalbd          |                         |                                  |
| ≥6 months (95% CI)                               | 86.6 (75.8, 92.8)       | 84.9 (73.8, 91.6)                |
| ≥12 months (95% CI)                              | 70.6 (57.8, 80.2)       | 66.4 (53.5, 76.4)                |
| ≥24 months (95% CI)                              | 41.6 (26.8, 55.8)       | 44.1 (30.8, 56.5)                |
| ≥36 months (95% CI)                              | 38.4 (23.8, 52.9)       | 36.0 (21.9, 50.4)                |

Eligible patients are defined as patients treated on or before 15 December 2020.

- Abbreviations: CI = confidence interval; IRC = Independent Review Committee; N = mmber of patients; n = mmber of patients in specific category; NE = not estimable; NSCLC = non-small cell lumg cancer, RET = REaranged duming Transfection; SD = stable disease.
- a Status as of the patient's last disease assessment on or before 15 Jume 2021.
- b Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.
- C 95% CI was calculated using Brookmeyer and Crowley method.
- d 95% CI was calculated using Greenwood's formula.

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan-Meier plot of progression-free survival based on IRC assessments -Treatment naïve patients (Data cutoff: 15 June 2021)

<!-- image -->

Abbreviations: IRC = Independent Review Committee; PFS = progression-ffee stuvival.

## Overall Survival

Table 19: Overall Survival Treatment-Naïve Patients (Data Cutoff Date: 15 June 2021)

| Status                                  | Treatment-Naive Patients (N=69)   |
|-----------------------------------------|-----------------------------------|
| Survival Status n (96)                  |                                   |
| Dead                                    | 20 (29.0)                         |
| Censored                                | 49 (71.0)                         |
| Duration of Overall Suvival (months) ab |                                   |
| Median                                  | NE                                |
| 95% CI for median                       | 27.9, NE                          |
| Min, max                                | 1.4,41.9+                         |
| Duration of Follow-up (months) *        |                                   |
| Median                                  | 25.20                             |
| 25th, 75th percentiles                  | 17.9,29.4                         |
| Rate (%o) of Overall Survivalb.         |                                   |
| ≥12 months (95% CI)                     | 92.7 (83.3, 96.9)                 |
| ≥24 months (95% Cl)                     | 69.3 (55.2, 79.7)                 |
| ≥36 months (95% CI)                     | 57.1 (35.9, 73.6)                 |

Status as of the last contact on or before 15 Jume 2021.

Abbreviations: CI = confidence interval; max = maximumr; min = minimum; N = mumber of participants im the specified category; NE =not estimable

- a Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.
- b 95% CI was calculated using Greenwood's fommula.

<div style=\"page-break-after: always\"></div>

Figure 8: Kaplan-Meier plot of OS in treatment naïve patients (DCO: 15 June 2021)

<!-- image -->

Patients with RET Fusion-Positive NSCLC Previously Treated with Platinum-Based Chemotherapy

-Objective Response Rate, Best Objective Response Rate, Duration of Response, and Clinical Benefit Rate

<div style=\"page-break-after: always\"></div>

Table 20: Objective Response Rate, Best Objective Response, Duration of Response, and Clinical Benefit Rate Based on IRC and Investigator Assessments (Data Cutoff Date: 15 June 2021)

|                                                | IRC Assessment (N=247)   | Investigator Assessinent (N=247)   |
|------------------------------------------------|--------------------------|------------------------------------|
| Objective Response Rateab                      |                          |                                    |
| n (%)                                          | 151 (61.1)               | 159 (64.4)                         |
| 10 %56                                         | (54.7, 67.2)             | (58.1, 70.3)                       |
| Best Overall Response -n (%6)                  |                          |                                    |
| Complete response (CR)                         | 18 (7.3)                 | 9 (3.6)                            |
| Partial response (PR)                          | 133 (53.8)               | 150 (60.7)                         |
| Stable disease (SD)                            | 81 (32.8)                | 74 (30.0)                          |
| SD -16 weeks                                   | 60 (24.3)                | 55 (22.3)                          |
| Progressive disease (PD)                       | 7 (2.8)                  | 5 (2.0)                            |
| Not evaluable                                  | 8 (3.2)                  | 9 (3.6)                            |
| Clinical Benefit Rate (CR + PR + SD-16 weeks)d |                          |                                    |
| n (%)                                          | 211 (85.4)               | 214 (86.6)                         |
| 95% CI                                         | (80.4, 89.6)             | (81.8, 90.6)                       |
| Duration of Response (months)et                |                          |                                    |
| Mediam (95% CI)                                | 28.58 (20.4, NE)         | 21.22 (18.4, 31.8)                 |
| Censoredn (%)                                  | 92 (60.9)                | 80 (50.3)                          |
| Duration of Follow-Up (months)*                |                          |                                    |
| Median                                         | 21.19                    | 23.20                              |
| 25th, 75th percentiles                         | 16.6, 26.0               | 20.3, 29.5                         |
| Rate (%o) of Duration of Response*e            |                          |                                    |
| ≥6 months (95% CT)                             | 86.9 (80.3, 91.5)        | 89.2 (83.2, 93.1)                  |
| ≥12 months (95% CI)                            | 73.1 (64.9, 79.7)        | 73.4 (65.6, 79.6)                  |
| ≥24 months (95% CI)                            | 55.8 (46.4, 64.2)        | 46.2 (37.3, 54.7)                  |
| 36 months (95% CI)                             | 49.4 (37.5, 60.3)        | 26.3 (12.1, 42.8)                  |

Eligible patients were treated on or before 15 December 2020. Stable disease includes non-CR/non-PD.

- Abbreviafions: CI = confidence interval; CR = complete response; IRC = Independent Review Committee; N = mmber of patients; n = mumber of patients in specific category; NE = not estimable; No. = mumber; NSCLC = non-small cell hmg cancer, ORR = objective response rate; PR = partial response; SD = stable disease.
- ORR is defined as the proportion of patients with best overall response of confirmed CR or PR. Response was confimmed by a repeat assessment ≥ 28 days.
- b 95% CI was calculated using Clopper-Pearson method
- C Indicates SD lasting ≥ 16 weeks following initiation of selpercatimib umtil the criteria for disease progression was first met.
- d Clinical benefit rate (%o) is defined as the proportion of patients with best overall response of confinmed CR, PR, or SD lasting 16 or more weeks (SD-16 weeks). Stable disease was measured from the date of the first dose of selpercatinib tmtil the criteria for disease progression was first met.
- Estimate based on Kaplan-Meier method.
- 95% CI was calculated using Brookmeyer and Crowley method.

<div style=\"page-break-after: always\"></div>

Figure 9. Kaplan-Meier Plot of Duration of Response Based on IRC Assessments -Efficacy Eligible Subjects of RET fusion-positive NSCLC with Confirmed CR of PR

<!-- image -->

Note:

Eligiblepatients are defined

patients on or before

15-DEC-2020.

COHORTS 1-S BUT DISCONTINUED SELECTIVE RET INHIBITOR(S)DUE TO INTOLERANCE'

Phase are

exeluded

Figure 10: Waterfall plot of best change in tumour burden based on IRC assessments Patients previously treated with platinum-based chemotherapy

<!-- image -->

Subjecis (N =226)

For each subject, the best percent change from baseline in the sum of diameters for all target lesions is represented by a vertical bar. The dashed lines represent the RECIST v1.1. criteria for response (30% decrease) or progressive disease (20% increase).

Note: Twenty-one subjects are not included because 16 subjects have non-target lesion only and 5 do not have postbaseline target lesion measulrement.

Abbreviations: IRC = Independent Review Committee; RECIST = Response Evaluation Criteria in Solid Tumors.

enrolledincohort

'COHORT6ELIGIBLEFOR

<div style=\"page-break-after: always\"></div>

- -Time to response and Time to Best Response

Table 21: Time to Response in Patients Previously Treated with Platinum-Based Chemotherapy Based on IRC and Investigator Assessments

| Status                           | IRC Assessment (N=247)   | Investigator Assessment (N=247)   |
|----------------------------------|--------------------------|-----------------------------------|
| Time to Response (months)\"       |                          |                                   |
| Median                           | 1.87                     | 1.84                              |
| 25th, 75th Percentiles           | 1.8, 3.8                 | 1.7, 2.1                          |
| Minimum, Maximum                 | 0.7, 21.9                | 0.7, 35.3                         |
| Time to Response, n (%6)         |                          |                                   |
| 2months                          | 92 (60.9)                | 115 (72.3)                        |
| ≥2 to 4 months                   | 24 (15.9)                | 28 (17.6)                         |
| ≥4 to 6 months                   | 16 (10.6)                | 6 (3.8)                           |
| ≥6 to 9 months                   | 6 (4.0)                  | 3 (1.9)                           |
| ≥9 months                        | 13 (8.6)                 | 7 (4.4)                           |
| Tiime to Best Response (months)b |                          |                                   |
| Median                           | 1.87                     | 1.84                              |
| 25th, 75th percentiles           | 1.8, 5.4                 | 1.7, 3.6                          |
| Min, max                         | 0.7, 32.9                | 0.7, 35.3                         |
| Time to Best Response, n (%6)    |                          |                                   |
| 2 months                         | 85 (56.3)                | 109 (68.6)                        |
| ≥2 to 4 months                   | 25 (16.6)                | 29 (18.2)                         |
| ≥4 to 6 months                   | 16 (10.6)                | 9 (5.7)                           |
| ≥6 to 9 months                   | 7 (4.6)                  | 4 (2.5)                           |
| ≥9 months                        | 18 (11.9)                | 8 (5.0)                           |

Abbreviations: CR = complete response; IRC = Independent Review Committee; max = maximum; min = minimum; PR = partial response.

- Time to response is defined as the mumber of months elapsed between the date of the first dose of selpercatinib amd the first docuumentation of objective response (CR or PR whichever occiured earlier) that was subsequently confimed.
- Time to best response is defined as the mumber of months elapsed between the date of the first dose of selpercatinib and the first documentation of CR (if patient's best response is confinmed CR) or PR (if patient's best response is confinmed PR) that was subsequently confinmed.

<div style=\"page-break-after: always\"></div>

Progression-Free Survival

Table 22: Progression-Free Survival Patients Previously Treated with Platinum-Based Chemotherapy Based on IRC and Investigator Assessments

| Stahus                                           | IRC Assessment (N=247)   | Investigator Assessment (IN=247)   |
|--------------------------------------------------|--------------------------|------------------------------------|
| Progression Status, n (96)*                      |                          |                                    |
| Disease progression                              | 89 (36.0)                | 116 (47.0)                         |
| Died (mo disease progression beforehand)         | 20 (8.1)                 | 16 (6.5)                           |
| Censored                                         | 138 (55.9)               | 115 (46.6)                         |
| Duration of Progression-Free Surrival (months)bc |                          |                                    |
| Median                                           | 24.94                    | 21.75                              |
| 95% CI for median                                | 19.3,NE                  | 16.8.24.9                          |
| Min, max                                         | 0.0+,44.2+               | 0.0+,44.2+                         |
| Duration of Follo-Up (months)b                   |                          |                                    |
| Median                                           | 24.71                    | 24.94                              |
| 25th, 75th percentiles                           | 19.3,28.7                | 22.1,30.4                          |
| Rate (%o) of Progression-free Survivalbd         |                          |                                    |
| ≥6 months (95% CI)                               | 83.7 (78.4, 87.9)        | 82.6 (77.1, 86.9)                  |
| ≥12 months (95% CI)                              | 70.5 (64.1, 76.0)        | 67.0 (60.5, 72.6)                  |
| ≥24 months (95% CI)                              | 51.4 (44.3, 58.1)        | 44.9 (38.1, 51.5)                  |
| ≥36 months (95% CI)                              | 42.6 (33.4, 51.6)        | 30.1 (19.5, 41.4)                  |

Abbreviations: CI = confidence interval; IRC =Independent Review Committee; max =maximum; min minimum; N = mumber of patients; n = mmmber of patients in specific category;, NE =not estimable.

- Status as of the patient's last disease assessment on or before 15 Jume 2021.
- b Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.
- C 95% CI was calculated using Brookmeyer and Crowley method.
- d 95% CI was calculated using Greemwood's formula.

Figure 11. Kaplan-Meier Plot of Progression-Free Survival

<!-- image -->

Note: + = Censored.

Eligible patients are defined as patients treated on or before 15 December 2020.

Abbreviation: IRC = Independent Review Committee; No. = number, PFS = progression-fee suvival.

Overall Survival

<div style=\"page-break-after: always\"></div>

Table 23: Overall Survival Patients Treated with Platinum-Based Chemotherapy

| Status                                 | Patients with RET Fusion-Positive NSCLC Previously Treated with Platinum-based Chemotherapy (N=247)   |
|----------------------------------------|-------------------------------------------------------------------------------------------------------|
| Suvival Status n (%6)*                 |                                                                                                       |
| Dead                                   | 78 (31.6)                                                                                             |
| Censored                               | 169 (68.4)                                                                                            |
| Reason Censored (n, %6)                |                                                                                                       |
| Lost to Follow-up                      | 1 (0.4)                                                                                               |
| OS Follow-up Ongoing                   | 143 (57.9)                                                                                            |
| Withdrawal of Consent                  | 25 (10.1)                                                                                             |
| Duration of Orerall Suvival (months)be |                                                                                                       |
| Median                                 | NE                                                                                                    |
| 95% CI for median                      | 33.5, NE                                                                                              |
| Min max                                | 0.3, 49.0+                                                                                            |
| Duration of Follow-up (months)b        |                                                                                                       |
| Median                                 | 26.41                                                                                                 |
| 25th, 75thpercentiles                  | 22.0, 31.3                                                                                            |
| Rate (%o) of Overall Survivalbd        |                                                                                                       |
| 212 months (95% CI)                    | 87.9 (83.0, 91.4)                                                                                     |
| ≥24 months (95% CI)                    | 68.9 (62.2, 74.7)                                                                                     |
| ≥36 months (95% CI)                    | 58.5 (49.7, 66.3)                                                                                     |

Abbreviations: CI = confidence interval; max = maximum; min = minimum; N = mumber of participants in the specified category; n = muumber of patients in specific category; NE = not estimable; NSCLC = non-small cell lmg cancer; OS = overall suuvival; RET = REaranged duuing Transfection.

- Status as of the last contact on or before 15 Jume 2021.
- b Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.
- C 95% CI was calculated using Brookmeyer and Crowley method.
- d 95% CI was calculated using Greenwood's formula.

Figure 12. Kaplan-Meier plot of overall survival

<!-- image -->

Note:+=Censored. Eligiblepatients aredefined aspatientstreated on or before15December 2020. Abbreviations:No.=mumber;OS=overallsuurvival.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Treatment-Naïve Patients with RET Fusion-Positive NSCLC

Figure 13: Forest plot of objective response rate in special/subgroup populations by demography and baseline characteristics based on IRC assessments in Treatment-naïve patients with RET Fusion positive NSCLC

Subjoct

<!-- image -->

OER

Two-sided 95% exact binomial CI is calculated using the Clopper-Pearson method.

Dashed reference line = 30%6, solid reference line = 84.1% (overall ORR).

Abbreviafions: CI = confidence interval; CNS = central nervous system; ECOG = Eastem Cooperative Oncology Group; FISH = Fluorescence in situ hybridization; IRC = Independent Review Committee; NGS = next generation sequencing: ORR = objective response rate; PCR = polymerase chain reaction; PD-1 = programmed cell death 1 receptor; PD-L1 = programmed cell death receptor ligamd 1; RET = REairanged dhuing Transfection.

<div style=\"page-break-after: always\"></div>

## Patients with RET Fusion-Positive NSCLC Previously Treated with Platinum-Based Chemotherapy

Figure 14: Forest plot of objective response rate in special/subgroup populations by demography and baseline characteristics based on IRC assessments in Patients Previously Treated with Platinum- Based Chemotherapy

Sutbjeet

<!-- image -->

ORR

Two-sided 95% exact binomial CI is calculated using the Clopper-Pearson method.

Dashed reference line = 30%, solid reference line = 61.1% (overall ORR). Abbreviations: CI = confidence interval; CNS = central nervous system; ECOG = Eastem Cooperative Oncology Group; FISH = Fluorescence in situ hybridization; RC = Independent Review Committee; NGS =next generaftion sequencing: ORR = objective response rate; PCR = polymerase chain reaction; PD-1 = programmed cell death 1 receptor; PD-L1 = programmed cell death receptor ligand 1; RET = REaranged duuing Transfection.

## Prior Immunotherapy

Among  the  247  patients  with  RET  fusion-positive  NSCLC  previously  treated  with  platinum  based chemotherapy, 58.7% patients (145/247) also received prior immunotherapy, either sequentially or concurrently with platinum-based chemotherapy.

The immunotherapies received by the patients previously treated with platinum-based therapy were:

- -Anti-PD1/PD-L1 therapy by 144 patients (58.3%), and
- -Anti CTLA4 therapy by 6 patients (2.4%).

<div style=\"page-break-after: always\"></div>

Table 24: BOR, ORR, CBR, DOR, and PFS Based on IRC Assessments by Prior Immunotherapy (Data Cutoff Date: 15 June 2021)

| Response                                          | Prior Platinum-Based Chemotherapy   | Prior Platinum-Based Chemotherapy   |
|---------------------------------------------------|-------------------------------------|-------------------------------------|
|                                                   | With Prior Immunotherapy            | Without Prior Immunotherapy         |
| Objective Response Ratea                          |                                     |                                     |
| n (%)                                             | 91 (62.8)                           | 60 (58.8)                           |
| 0%56                                              | (54.3,70.6)                         | (48.6, 68.5)                        |
| Best Overall Response -no. (%6)                   |                                     |                                     |
| Complete response (CR)                            | 9 (6.2)                             | 9 (8.8)                             |
| Partial response (PR)                             | 82 (56.6)                           | 51 (50.0)                           |
| Stable disease (SD)                               | 42 (29.0)                           | 39 (38.2)                           |
| SDF                                               | 26 (17.9)                           | 34 (33.3)                           |
| Progressive disease (PD)                          | 6 (4.1)                             | 1(1.0)                              |
| Not evaluable                                     | 6 (4.1)                             | 2 (2.0)                             |
| Clinical Benefit Rate (CR + PR + SDb)             |                                     |                                     |
| n (%)                                             | 117 (80.7)                          | 94 (92.2)                           |
| 10 %56                                            | (73.3, 86.8)                        | (85.1, 96.6)                        |
| Patients with Best Response of Confirmed CR or PR | 91                                  | 60                                  |
| Response Status (n, 96)*                          |                                     |                                     |
| Disease Progression                               | 33 (36.3)                           | 19 (31.7)                           |
| Died (No Disease Progression Beforehand)          | 5 (5.5)                             | 2 (3.3)                             |
| Censored                                          | 53 (58.2)                           | 39 (65.0)                           |
| Duration of Response (months)                     |                                     |                                     |
| Median (95% CI for median)                        | 28.58 (14.8, NE)                    | NR. (20.4, NE)                      |
| Min, max                                          | 1.8+, 38.8+                         | 2.7+, 43.3+                         |
| Duration of Follow-up (months)                    |                                     |                                     |
| Median                                            | 20.50                               | 23.03                               |
| 25th, 75th Percentiles                            | 16.4, 26.0                          | 16.6, 28.7                          |
| Duration of Progression-Free Suvival (months)ed   |                                     |                                     |
| Median (95% CI for median)                        | 19.35 (13.9, 27.6)                  | NE (22.1, NE)                       |
| Min max                                           | 0.3, 44.2+                          | 0.0+,44.2+                          |

Abbreviations: BOR = best overall response; CBR = climical benefit rate; CI = confidence interval; DOR = dhuation of response; IRC = Independent Review Committee; max = maximum; min = minimum; N = mmber of patients; n = mumber of patients in specific category; NE = not estimable; ORR = objective response rate; PFS = progression-free suuvival.

- 95% CI was calculated using Clopper-Pearson method.
- Indicates SD lasting ≥ 16 weeks following initiation of selpercatinib umtil the critenia for disease progression was first met.
- Estimate based on Kaplan-Meier method. NE = Not estimable. NR = Not reached. + = Censored observation.
- d 95% CI was calculated using Brookmeyer and Crowley method.
- 95% CI was calculated using Greenwood's fonmula.

<div style=\"page-break-after: always\"></div>

Table 25 Objective Response Rate, Best Overall Response, and Clinical Benefit Rate Based on IRC and Investigator Assessment Supportive Efficacy Analysis Sets

| Status                                | Patients with RET Fusion-Positive NSCLC Previously Treated with Other Systemic Therapy (N=19)   | Patients with RET Fusion-Positive NSCLC Previously Treated with Other Systemic Therapy (N=19)   | Patients with Non-Mfeasurable RET Fusion-Positive NSCLC (N=20)   | Patients with Non-Mfeasurable RET Fusion-Positive NSCLC (N=20)   | First 105 Patients Emrolled with RET Fusion-Positive NSCLC Who Were Previously Treated with Platinum-Based Chemotherapy (N=105)   | First 105 Patients Emrolled with RET Fusion-Positive NSCLC Who Were Previously Treated with Platinum-Based Chemotherapy (N=105)   |
|---------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
|                                       | IRC Assessment                                                                                  | Investigator Assessment                                                                         | IRC Assessment                                                   | Investigator Assessment                                          | IRC Assessment                                                                                                                    | Investigator Assessment                                                                                                           |
| Objective Response Rate'b (CR + PR)   |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| n (%)                                 | 9 (47.4)                                                                                        | 12 (63.2)                                                                                       | 8 (40.0)                                                         | 0 (0.0)                                                          | 65 (61.9)                                                                                                                         | 74 (70.5)                                                                                                                         |
| 95%CI                                 | (24.4, 71.1)                                                                                    | (38.4, 83.7)                                                                                    | (19.1, 63.9)                                                     | (0.0, 16.8)                                                      | (51.9, 71.2)                                                                                                                      | (60.8, 79.0)                                                                                                                      |
| Best Overall Response, n (%)          |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| CR                                    | 0 (0.0)                                                                                         | 0 (0.0)                                                                                         | 3 (15.0)                                                         | 0 (0.0)                                                          | 4 (3.8)                                                                                                                           | 3 (2.9)                                                                                                                           |
| PR.                                   | 9 (47.4)                                                                                        | 12 (63.2)                                                                                       | 5 (25.0)                                                         | 0 (0.0)                                                          | 61 (58.1)                                                                                                                         | 71 (67.6)                                                                                                                         |
| SD                                    | 9 (47.4)                                                                                        | 5 (26.3)                                                                                        | 9 (45.0)                                                         | 20 (100.0)                                                       | 32 (30.5)                                                                                                                         | 24 (22.9)                                                                                                                         |
| SD-16 weeks*                          | 4 (21.1)                                                                                        | 1 (5.3)                                                                                         | 8 (40.0)                                                         | 16 (80.0)                                                        | 24 (22.9)                                                                                                                         | 17 (16.2)                                                                                                                         |
| PD                                    | 1 (5.3)                                                                                         | 2 (10.5)                                                                                        | 0 (0.0)                                                          | 0 (0.0)                                                          | 4 (3.8)                                                                                                                           | 3 (2.9)                                                                                                                           |
| NE                                    | 0 (0.0)                                                                                         | 0 (0.0)                                                                                         | 3 (15.0)                                                         | 0 (0.0)                                                          | 4 (3.8)                                                                                                                           | 4 (3.8)                                                                                                                           |
| Clinical Benefit Rate (CR + PR + SDbd |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| Number of Patients (n, %)             | 13 (68.4)                                                                                       | 13 (68.4)                                                                                       | 16 (80.0)                                                        | 16 (80.0)                                                        | 89 (84.8)                                                                                                                         | 91 (86.7)                                                                                                                         |
| 95% Confidence Interval               | (43.4, 87.4)                                                                                    | (43.4, 87.4)                                                                                    | (56.3,94.3)                                                      | (56.3, 94.3)                                                     | (76.4, 91.0)                                                                                                                      | (78.6, 92.5)                                                                                                                      |
| Duration of Response (months)         |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| Median (95% CI)                       | 15.84 (12.0, NE)                                                                                | 15.08 (7.3, NE)                                                                                 | 22.21 (12.0, NE)                                                 | 0 (0.0)                                                          | 20.86 (14.7, NE)                                                                                                                  | 21.22 (17.7, 35.0)                                                                                                                |
| Censored                              | 5 (55.6)                                                                                        | 5 (41.7)                                                                                        | 5 (62.5)                                                         | 0 (0.0)                                                          | 31 (47.7)                                                                                                                         | 32 (43.2)                                                                                                                         |
| Duation of Follow-Up (months)         |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| Median                                | 28.52                                                                                           | 25.56                                                                                           | 21.16                                                            | 0 (0.0)                                                          | 28.75                                                                                                                             | 30.39                                                                                                                             |
| 25th, 75th percentiles                | 14.7, 28.6                                                                                      | 14.8, 26.7                                                                                      | 17.5, 29.3                                                       | 0 (0.0)                                                          | 24.6,31.3                                                                                                                         | 26.7,34.1                                                                                                                         |
| Rate(%o) of Duration of Response      |                                                                                                 |                                                                                                 |                                                                  |                                                                  |                                                                                                                                   |                                                                                                                                   |
| ≥6 months (95% CI)                    | 100.0 (NE, NE)                                                                                  | 91.7 (53.9, 98.8)                                                                               | 100.0 (NE, NE)                                                   | 0 (0.0)                                                          | 87.7 (76.9, 93.6)                                                                                                                 | 90.4 (81.0, 95.3)                                                                                                                 |
| ≥12 months (95% CI)                   | 100.0 (NE, NE)                                                                                  | 58.3 (27.0, 80.1)                                                                               | 85.7 (33.4, 97.9)                                                | 0 (0.0)                                                          | 72.2 (59.5, 81.5)                                                                                                                 | 75.2 (63.5, 83.6)                                                                                                                 |
| ≥24 months (95% CI)                   | 37.5 (5.6, 71.7)                                                                                | 37.5 (10.9, 64.8).                                                                              | 35.7 (1.4, 78.0)                                                 | 0                                                                | 49.0 (36.1, 60.7)                                                                                                                 | 46.9 (34.7, 58.1)                                                                                                                 |
| 36 months (95% CI)                    | NE (NE, NE)                                                                                     | NE (NE, NE)                                                                                     | NE (NE, NE)                                                      | 0                                                                | 43.4(30.0,56.1)                                                                                                                   | 26.6 (11.8, 44.0)                                                                                                                 |

Eligible patients are treated on or before 15 December 2020. Stable disease includes Non-CR/Non-PD.

Abbreviations: CI = confidence interval; CR = complete response; IRC = Independent Review Committee; N = mumber of patients; n = mumber of patients in specific category; NE = not estimable; NSCLC = non-small cell lumg cancer, ORR = objective response rate; PR = partial response; RET = REairanged duuing Transfection; SD = stable disease.

- ORR is defined as the proportion of patients with best overall response of confirmed CR or PR Response was confirmed by a repeat assessment ≥ 28 days.
- Indicates SD lasting ≥ 16 weeks following initiation of selpercatinib util the criteria for disease progression was first met.
- 95% CI was calculated using Clopper-Pearson method.
- d Clinical benefit rate (%) is defined as the proportion of patients with best overall response of confinmed CR, PR, or SD lasting 16 or more weeks (SD*). Stable disease was measured from the date of the first dose selpercatinib umtil the cniteria for disease progression was first met.
- Estimate based on Kaplan-Meier method.
- 95% CI was calculated using Brookmeyer and Crowley method.
- 95% CI was calculated using Greenwood's fonmula.
- First 105 Patients Emrolled with RET Fusion-Positive NSCLC Who Were Previously Treated with Platimum-Based Chemotherapyis a subset of patients with RET fiusion-positive NSCLC previously treated with platimum-based chemotherapy.

Sources: Table 8.18,Table 8.19, Table 8.21, Table 8.22.

Time to response (TTR) and Time to best response (TBR)

<div style=\"page-break-after: always\"></div>

Table 26: Time to Response Based on IRC and Investigator's Assessments Supportive Efficacy Analysis Sets

|                                | Patients with RET Fusion- Positive NSCLC Previously Treated with Other Systemic Therapy (N=19)   | Patients with RET Fusion- Positive NSCLC Previously Treated with Other Systemic Therapy (N=19)   | Patients with Non-Measurable RET Fusion-Positive NSCLC (N=20)   | Patients with Non-Measurable RET Fusion-Positive NSCLC (N=20)   | First l05 Patients Enrolled with RET Fusion- Positive NSCLC Who Were Previously Treated with Platinum-Based Chemotherapy (N=105)   | First l05 Patients Enrolled with RET Fusion- Positive NSCLC Who Were Previously Treated with Platinum-Based Chemotherapy (N=105)   |
|--------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Status                         | IRC Assessment                                                                                   | Investigator Assessment                                                                          | IRC Assessment                                                  | Investigator Assessment                                         | IRC Assessment                                                                                                                     | Investigator Assessment                                                                                                            |
| Time to Response (months)      | Time to Response (months)                                                                        | Time to Response (months)                                                                        | Time to Response (months)                                       | Time to Response (months)                                       | Time to Response (months)                                                                                                          | Time to Response (months)                                                                                                          |
| Median                         | 1.68                                                                                             | 2.79                                                                                             | 2.73                                                            |                                                                 | 1.87                                                                                                                               | 1.84                                                                                                                               |
| 25th, 75th percentiles         | 1.6, 1.9                                                                                         | 1.7, 3.7                                                                                         | 1.7, 4.6                                                        |                                                                 | 1.8,3.7                                                                                                                            | 1.7,3.5                                                                                                                            |
| Min, max                       | 0.7, 3.7                                                                                         | 1.6, 22.0                                                                                        | 0.9, 14.1                                                       |                                                                 | 0.8, 13.7                                                                                                                          | 0.7, 35.3                                                                                                                          |
| Time to Response, n (%)        | Time to Response, n (%)                                                                          | Time to Response, n (%)                                                                          | Time to Response, n (%)                                         | Time to Response, n (%)                                         | Time to Response, n (%)                                                                                                            | Time to Response, n (%)                                                                                                            |
| 2months                        | 7 (77.8)                                                                                         | 6 (50.0)                                                                                         | 4 (50.0)                                                        |                                                                 | 41 (63.1)                                                                                                                          | 53 (71.6)                                                                                                                          |
| ≥2 to 4 months                 | 2 (22.2)                                                                                         | 4 (33.3)                                                                                         | 2 (25.0)                                                        |                                                                 | 11 (16.9)                                                                                                                          | 15 (20.3)                                                                                                                          |
| ≥4 to 6 months                 | 0 (0.0)                                                                                          | 0 (0.0)                                                                                          | 1 (12.5)                                                        |                                                                 | 6 (9.2)                                                                                                                            | 3 (4.1)                                                                                                                            |
| 6 to 9months                   | 0 (0.0)                                                                                          | 1 (8.3)                                                                                          | 0 (0.0)                                                         |                                                                 | 2 (3.1)                                                                                                                            | 0 (0.0)                                                                                                                            |
| 9 months                       | 0 (0.0)                                                                                          | 1 (8.3)                                                                                          | 1 (12.5)                                                        |                                                                 | 5(7.7)                                                                                                                             | 3 (4.1)                                                                                                                            |
| Time to Best Response (months) | Time to Best Response (months)                                                                   | Time to Best Response (months)                                                                   | Time to Best Response (months)                                  | Time to Best Response (months)                                  | Time to Best Response (months)                                                                                                     | Time to Best Response (months)                                                                                                     |
| Median                         | 1.68                                                                                             | 2.79                                                                                             | 2.73                                                            |                                                                 | 1.87                                                                                                                               | 1.84                                                                                                                               |
| 25th, 75th percentiles         | 1.6, 1.9                                                                                         | 1.7, 3.7                                                                                         | 1.7, 4.6                                                        |                                                                 | 1.8, 3.8                                                                                                                           | 1.7, 3.5                                                                                                                           |
| Min, max                       | 0.7, 3.7                                                                                         | 1.6, 22.0                                                                                        | 0.9, 14.1                                                       |                                                                 | 0.8, 32.9                                                                                                                          | 0.7,35.3                                                                                                                           |
| Time to Best Response, n (%)   | Time to Best Response, n (%)                                                                     | Time to Best Response, n (%)                                                                     | Time to Best Response, n (%)                                    | Time to Best Response, n (%)                                    | Time to Best Response, n (%)                                                                                                       | Time to Best Response, n (%)                                                                                                       |
| 2months                        | 7 (77.8)                                                                                         | 6 (50.0)                                                                                         | 4 (50.0)                                                        |                                                                 | 39 (60.0)                                                                                                                          | 52 (70.3)                                                                                                                          |
| 2 to 4 months                  | 2 (22.2)                                                                                         | 4 (33.3)                                                                                         | 2 (25.0)                                                        |                                                                 | 10 (15.4)                                                                                                                          | 15 (20.3)                                                                                                                          |
| ≥4 to 6 months                 | 0 (0.0)                                                                                          | 0 (0.0)                                                                                          | 1 (12.5)                                                        |                                                                 | 6 (9.2)                                                                                                                            | 3 (4.1)                                                                                                                            |
| 6 to 9 months                  | 0 (0.0)                                                                                          | 1 (8.3)                                                                                          | 0 (0.0)                                                         |                                                                 | 2 (3.1)                                                                                                                            | 0 (0.0)                                                                                                                            |
| 9 months                       | 0 (0.0)                                                                                          | 1 (8.3)                                                                                          | 1 (12.5)                                                        |                                                                 | 8 (12.3)                                                                                                                           | 4 (5.4)                                                                                                                            |

Progression-Free Survival

Table 27: Progression-Free Survival Based on IRC and Investigator Assessments Supportive Efficacy Analysis Sets

|                                                  | PatientsmithRET Fusion-PositiveNSCLC Previously-Treated with Other Systemic Therapy (M=19)   | PatientsmithRET Fusion-PositiveNSCLC Previously-Treated with Other Systemic Therapy (M=19)   | Patients with Non- Mleasurable RET Fusion-Positive NSCLC (I=20))   | Patients with Non- Mleasurable RET Fusion-Positive NSCLC (I=20))   | First lo5 Patients EmrolledwithRET Fusion-PosiliweISCLC Wlho Were Previously Treated with Platimwm- Based Chemotherapy (1=105)   | First lo5 Patients EmrolledwithRET Fusion-PosiliweISCLC Wlho Were Previously Treated with Platimwm- Based Chemotherapy (1=105)   |
|--------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
|                                                  | IR.C Alsses sumem. t                                                                         | Inrestigato Alssessmen t                                                                     | IRC: Aissessumen t                                                 | Inmesbigato T Alssessmmen t                                        | TR.C Aissessmen t                                                                                                                | Investigato T Alssessmen t                                                                                                       |
| Progression Stahus, n (96)                       |                                                                                              |                                                                                              |                                                                    |                                                                    |                                                                                                                                  |                                                                                                                                  |
| Disease progression                              | 8 (42.1)                                                                                     | 10 (52.6)                                                                                    | 6 (30.0)                                                           | 9 (45.0)                                                           | 53 (50.5)                                                                                                                        | 57 (54.3)                                                                                                                        |
| Died (no disease progression beforehamd)         | 2 (10.5)                                                                                     | 4 (21.1)                                                                                     | 4 (20.0)                                                           | 3 (15.0)                                                           | 5 (4.8)                                                                                                                          | 7 (6.7)                                                                                                                          |
| Cemsored                                         | 9 (47.4)                                                                                     | 5 (26.3)                                                                                     | 10 (50.0)                                                          | 8 (40.0)                                                           | 47 (44.8)                                                                                                                        | 41 (39.0)                                                                                                                        |
| Duration of Progression-Free Survival (monthsjub | Duration of Progression-Free Survival (monthsjub                                             | Duration of Progression-Free Survival (monthsjub                                             |                                                                    |                                                                    |                                                                                                                                  |                                                                                                                                  |
| Median                                           | 19.42                                                                                        | 11.53                                                                                        | 18.69                                                              | 18.69                                                              | 19.25                                                                                                                            | 19.52                                                                                                                            |
| 95%6 CI for median                               | 3.5, 30.5                                                                                    | 3.4, 30.5                                                                                    | 9.1, NE                                                            | 7.6, NE                                                            | 13.9, 30.4                                                                                                                       | 16.5, 28.6                                                                                                                       |
| Mfim, max                                        | 1.7+, 30.5                                                                                   | 1.7.30.5                                                                                     | 3.0, 30.1+                                                         | 3.0, 33.1+                                                         | 0.3,44.2+                                                                                                                        | 0.0+,44.2+                                                                                                                       |
| Duration of Follow-Up (months)b                  | Duration of Follow-Up (months)b                                                              | Duration of Follow-Up (months)b                                                              |                                                                    |                                                                    |                                                                                                                                  |                                                                                                                                  |
| Median                                           | 30.26                                                                                        | 30.26                                                                                        | 22.08                                                              | 24.87                                                              | 30.32                                                                                                                            | 33.08                                                                                                                            |
| 25th, 75th percentiles                           | 11.5,30.4                                                                                    | 21.4, 30.4                                                                                   | 16.8, 24.9                                                         | 19.4, 33.1                                                         | 26.4, 35.6                                                                                                                       | 28.7, 35.8                                                                                                                       |
| Raite (9o) of Progression-free Survival*         | Raite (9o) of Progression-free Survival*                                                     | Raite (9o) of Progression-free Survival*                                                     | Raite (9o) of Progression-free Survival*                           | Raite (9o) of Progression-free Survival*                           | Raite (9o) of Progression-free Survival*                                                                                         | Raite (9o) of Progression-free Survival*                                                                                         |
| ≥6 monihs (95%6 C1)                              | 76.5(48.8, 90.4)                                                                             | 63.2 (37.9, 80.4)                                                                            | 79.1 (53.2. 91.6)                                                  | 80.0 (55.1, 92.0)                                                  | 81.1 (71.9, 87.5)                                                                                                                | 82.1 (73.1, 88.3)                                                                                                                |
| ≥12 months (95% CI)                              | 76.5 (48.8, 90.4)                                                                            | 47.4 (24.4, 67.3)                                                                            | 67.8 (41.7. 84.1)                                                  | 69.3 (44.0, 84.9)                                                  | 65.7 (55.5, 74.2)                                                                                                                | 68.1 (58.0, 76.2)                                                                                                                |
| ≥24momths(95%6 CI)                               | 30.6 (8.0, 57.4)                                                                             | 30.1 (11.5, 51.3)                                                                            | 49.4 (24.8. 70.1)                                                  | 37.3 (14.6, 60.4)                                                  | 44.2 (34.0, 53.8)                                                                                                                | 41.8 (31.9, 51.4)                                                                                                                |
| ≥36 months (95%6 CI)                             | 0.0 NE, NE)                                                                                  | 0.0 ONE, NE)                                                                                 | NE (NE, NE)                                                        | NE (NE, NE)                                                        | 37.5 (27.0, 47.91                                                                                                                | 29.2 (18.0, 41.4)                                                                                                                |

Note: Status as of the patient's last disease assessment on or before 15 Jhume 2o21.

Abbreviations: CI = confidence interval; IRC =Imdependent Rleview Comwmittee; max : nm minimum; N= mumber of patients; n = mumber of patients in specific category;: NE = not estimable; NSCLC = mon-small cell hmg cancer, RET = REaranged dwing Tramsfection. Souurces:Table S.25,Table S.26.aEstimate basedon Kaplam-

Mfeier method. NE = Not estimable. + = Censored obsenation.

959. CI was caleulated using Greemwood's fommmla.

b 95%6 CI was calculated using Brookmeyer amd Crowdey method.

<div style=\"page-break-after: always\"></div>

## Overall Survival

Table 28: Overall Survival Supportive Efficacy Analysis Sets

| Status                                  | Patients with RET Fusion-Positive NSCLC Previously Treated with Other Systemie Therapy (N=19)   | Patients with Non-Mfeasurable RET Fusion-Positive NSCLC (N=20)   | First 105 Patients Enrolled with RET Fusion-Positive NSCLC Who Were Previously Treated with Platinum-Based Chemotherapy (N=105)   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Survival Status (n,%)*                  |                                                                                                 |                                                                  |                                                                                                                                   |
| Dead                                    | 7 (36.8)                                                                                        | 6 (30.0)                                                         | 38 (36.2)                                                                                                                         |
| Censored                                | 12 (63.2)                                                                                       | 14 ( 70.0)                                                       | 67 (63.8)                                                                                                                         |
| Reason Censored (n, %)                  |                                                                                                 |                                                                  |                                                                                                                                   |
| Loss to Follow-up                       | 1 (5.3)                                                                                         | 0 (0.0)                                                          | 0 (0.0)                                                                                                                           |
| OS Follow-up Ongoing                    | 10 (52.6)                                                                                       | 11 (55.0)                                                        | 50 (47.6)                                                                                                                         |
| Withdrawal of Consent                   | 1 (5.3)                                                                                         | 3 (15.0)                                                         | 17 (16.2)                                                                                                                         |
| Duration of Overall Survival (months)be | Duration of Overall Survival (months)be                                                         |                                                                  |                                                                                                                                   |
| Median                                  | 30.52                                                                                           | NE                                                               | NE                                                                                                                                |
| 95% CI for median                       | 11.0, NE                                                                                        | 21.1, NE                                                         | 33.5, NE                                                                                                                          |
| Min, max                                | 2.3, 32.6+                                                                                      | 3.0, 35.2+                                                       | 0.3, 49.0+                                                                                                                        |
| Duration of Follow-up (months)b         | Duration of Follow-up (months)b                                                                 |                                                                  |                                                                                                                                   |
| Median                                  | 26.18                                                                                           | 22.77                                                            | 33.05                                                                                                                             |
| 25th, 75th percentiles                  | 19.1, 31.6                                                                                      | 19.1, 27.4                                                       | 30.3, 37.1                                                                                                                        |
| Rate (%) of Overall Survivalbd          | Rate (%) of Overall Survivalbd                                                                  | Rate (%) of Overall Survivalbd                                   | Rate (%) of Overall Survivalbd                                                                                                    |
| ≥12 months (95% CI)                     | 72.7 (46.3, 87.6)                                                                               | 84.7 (59.7, 94.8)                                                | 88.2 (80.2,93.2)                                                                                                                  |
| ≥24 months (95% CI)                     | 72.7 (46.3, 87.6)                                                                               | 71.9 (44.3, 87.5)                                                | 70.5 (60.4, 78.5)                                                                                                                 |
| ≥36 months (95% CI)                     | NE (NE, NE                                                                                      | NE (NE, NE                                                       | 59.2 (48.1, 68.7)                                                                                                                 |

Abbreviations: CI = confidence interval; max = maximum; min = minimum; N = mumber of paticipants in the specifed category; n = number of patients in specifie category; NE =not estimable; NSCLC = non-small cell lumg cancer; RET = REaranged duing Transfection.

Stahus as of the last contact on or before 15-JUN-2021.

Estimate based on Kaplan-Meier method. NE = Not estimable. + = Censored observation.

CNS Response in the CNS Response Analysis Set Measurable CNS disease

<div style=\"page-break-after: always\"></div>

Table 29: CNS ORR and CNS DOR by IRC Assessments in RET Fusion-Positive NSCLC Patients with Measurable CNS Lesions- CNS Response Analysis Set

|                                             | NSCLC with Prior RT                          | NSCLC with Prior RT                          | NSCLC with Prior RT           | No Prior Brain RT   | AIINSCLC          |
|---------------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------|---------------------|-------------------|
|                                             | Brain RT ≤2 Months Prior to First Dose (N=3) | Brain RT >1 Months Prior to First Dose (N=7) | AlINSCLC with Prior RT (N=10) | (N=16)              | (9t=ND)           |
| CNS Objective Response Rate* (CR + PR)      |                                              |                                              |                               |                     |                   |
| Number of Patients with CR + PR (n, %)      | 3 (100.0)                                    | 5 (71.4)                                     | 8 (80.0)                      | 14 (87.5)           | 22 (84.6)         |
| qI0 %56                                     | (29.2, 100.0)                                | (29.0, 96.3)                                 | (44.4, 97.5)                  | (61.7, 98.4)        | (65.1, 95.6)      |
| CNS Best Overall Response, n (%)            |                                              |                                              |                               |                     |                   |
| Complete response                           | 1 (33.3)                                     | 1 (14.3)                                     | 2 (20.0)                      | 5 (31.3)            | 7 (26.9)          |
| Partial response                            | 2 (66.7)                                     | 4 (57.1)                                     | 6 (60.0)                      | 9 (56.3)            | 15 (57.7)         |
| Stable disease                              | 0 (0.0)                                      | 2 (28.6)                                     | 2 (20.0)                      | 2 (12.5)            | 4 (15.4)          |
| SD                                          | 0 (0.0)                                      | 2 (28.6)                                     | 2 (20.0)                      | 0 (0.0)             | 2(7.7)            |
| Progressive disease                         | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                       | 0 (0.0)             | 0 (0.0)           |
| Not evaluable                               | 0 (0.0)                                      | 0 (0.0)                                      | (0°0) 0                       | 0 (0.0)             | 0 (0.0)           |
| Undefined                                   | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                       | 0 (0.0)             | 0 (0.0)           |
| CNS Clinical Benefit Rate                   |                                              |                                              |                               |                     |                   |
| Number ofPatients with CR + PR + SD (n, %)  | 3 (100.0)                                    | 7 (100.0)                                    | 10 (100.0)                    | 14 (87.5)           | 24 (92.3)         |
| qI %56                                      | (29.2,100.0)                                 | (59.0, 100.0)                                | (69.2, 100.0)                 | (61.7, 98.4)        | (74.9, 99.1)      |
| CNS Duration of Response (months)e          |                                              |                                              |                               |                     |                   |
| No. ofpatients censored, n (%)              | 1 (33.3)                                     | 2 (40.0)                                     | 3 (37.5)                      | 3 (21.4)            | 6 (27.3)          |
| Median (95% CI)                             | 8.28 (5.1, 8.3)                              | 12.12 (3.7, NE)                              | 8.28 (3.7, NE)                | 9.36 (6.7, 15.3)    | 9.36 (7.4, 15.3)  |
| Minimum, Maximum                            | 5.1, 8.3                                     | 3.7, 25.8+                                   | 3.7, 25.8+                    | 2.8, 35.0+          | 2.8, 35.0+        |
| CNS Duration of Response Follow-up (months) |                                              |                                              |                               |                     |                   |
| Median                                      | NR                                           | 24.84                                        | 23.89                         | 26.68               | 25.79             |
| 25, 75 Percentiles                          | 7.4, NE                                      | 23.9, 25.8                                   | 23.9, 25.8                    | 26.7, 35.0          | 23.9, 26.7        |
| CNS Rate (%) of Duration of Response\"!      |                                              |                                              |                               |                     |                   |
| ≥6 months (95% CI)                          | 66.7 (5.4, 94.5)                             | 80.0 (20.4, 96.9)                            | 75.0 (31.5, 93.1)             | 85.7 (53.9, 96.2)   | 81.8 (58.5, 92.8) |
| ≥12 months (95% CI)                         | 0.0 (NE, NE)                                 | 60.0 (12.6, 88.2)                            | 45.0 (10.8, 75.1)             | 31.2 (9.7, 55.9)    | 36.1 (16.4, 56.4) |
| ≥24 months (95% CI)                         | 0.0 (NE, NE)                                 | 40.0 (5.2, 75.3)                             | 30.0 (4.4, 62.8)              | 15.6 (2.5, 39.1)    | 20.6 (6.5, 40.2)  |
| ≥36 months (95% CI)                         | 0.0 (NE, NE)                                 | NE (NE, NE)                                  | NE (NE, NE)                   | NE (NE, NE)         | NE (NE, NE)       |

Note: + = censored observation.

Note: Partial response is not applicable for non-measuable patients. Stable disease includes non-CR/non-PD.

Abbreviations: CI = confidence interval; CNS = cenhal nervous system; CR = complete response; DOR = dhuation of response; IRC = Independent Review Committee; N = mumber of patients; n = number of patients in specific category; NE = not estimable; No. = number; NR = not reported; NSCLC = non-small

- CNS ORR is defined as the proportion of patients with best overall response of CR or PR. Response was confirmed by a repeat assessment no less than 28 days.

cell lumg cancer; ORR = objective response rate; PR = patial response; RT = radiation therapy.

- 95% CI was caleulated using Clopper-Pearson method.
- Indicates SD lasting ≥ 16 weeks following initiation of selpercatinib until the criteria for disease progression was first met.
- d Estimate based on Kaplan-Meier method. NE = Not estimable. NR = Not reached. + = Censored observation.
- 95% CI was caleulated using Brookmeyer and Crowley method.
- 95% CI was caleulated using Greenwood's formula.

<div style=\"page-break-after: always\"></div>

Figure 15. Waterfall plot of best change in CNS tumour burden by prior therapy based on IRC assessments in patients with measurable CNS disease-CNS response analysis set

<!-- image -->

*SRS*imcludes all patients reported to receive SRT, SBRT, GKS, and/or SRS. *TWBRT* inchudes all patients reported to receive radiation of any kind to the *whole brain including conventional exteimal beam, IMRT, and 3DCRT.

For each subject, the best percent chamge firombaseline in the sum of diawmeters for all target lesions is represented by a vertieal bar. The dashed lines represent the RECIST vl.1. critenia for response (3oy6 decrease) or progressive dlisease (2096 imcnease).

Abbreviations: CNS = cenhal nerrous system; DCRT = defimitive chemoradiotherapy: EGFR. = epidenmal growth factor receptor; GKS = gamma knife swgery: IMRT = imtensity modlated radiotherapy; MKI = multikinase inhibitor; RECIST = Response Evahuation Cniteria in Solid Tumors; SBRT = stereotactic body radiotherapy, SRS = stereotactic iadioswgery: SRT = stereotactic tadiotherapy: VEGF = Wascmlar endothelial growth factor: VEGFR. = Tascular endothelial growth factor receptor; WBRT = mhole brain radiotherapy.

Non-measurable CNS disease

The CNS ORR in the 80 patients with RET fusion-positive NSCLC and non-measurable CNS metastasis at baseline was 37.5% (95% CI: 26.9, 49.0), by IRC. The CNS CBR was 75.0% (95% CI: 64.1, 84.0) by IRC.

The median CNS DOR by IRC for patients with CNS non-measurable disease was not yet reached (95% CI: 22.1, NE) at a median follow-up time of 20.70 months.

## CNS Response in Treatment-Naïve Patients with RET Fusion-Positive NSCLC

Measurable CNS Disease

<div style=\"page-break-after: always\"></div>

Table 30. CNS ORR and CNS DOR by IRC Assessments -RET Fusion-Positive TreatmentNaïve Patients with Measurable CNS Lesions CNS Response Analysis Set

|                                             | NSCLC with Prior RT                          | NSCLC with Prior RT                          | NSCLC with Prior RT                         | No Prior Brain RT                           | AlINSCLC (N=5)                              |
|---------------------------------------------|----------------------------------------------|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                             | Brain RT ≤2 Months Prior to First Dose (N=2) | Brain RT >2 Months Prior to First Dose (N=0) | AIINSCLC with Prior RT (N=2)                | (N=3)                                       |                                             |
| CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)       | CNS Objective Response Rate* (CR + PR)       | CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)      |
| Number of Patients with CR + PR (n, %)      | 2 (100.0)                                    | NA                                           | 2 (100.0)                                   | 2 (66.7)                                    | 4 (80.0)                                    |
| 95% CIb                                     | (15.8, 100.0)                                | NA                                           | (15.8, 100.0)                               | (9.4, 99.2)                                 | (28.4, 99.5)                                |
| CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)             | CNS Best Overall Response, n (%)             | CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)            |
| Complete response                           | 1 (50.0)                                     | NA                                           | 1 (50.0)                                    | 0 (0.0)                                     | 1 (20.0)                                    |
| Partial response                            | 1 (50.0)                                     | NA                                           | 1 (50.0)                                    | 2 (66.7)                                    | 3 (60.0)                                    |
| Stable disease                              | 0                                            | NA                                           | 0 (0.0)                                     | 1 (33.3)                                    | 1 (20.0)                                    |
| SDe                                         | 0                                            | NA                                           | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Progressive disease                         | 0                                            | NA                                           | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Not evaluable                               | 0                                            | NA                                           | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Undefined                                   | 0                                            | NA                                           | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                    | CNS Clinical Benefit Rate                    | CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                   |
| Number of Patients with CR +PR + SD (n, %)  | 2 (100.0)                                    | NA                                           | 2 (100.0)                                   | 2 (66.7)                                    | 4 (80.0)                                    |
| 95% CIb                                     | (15.8, 100.0)                                | NA                                           | (15.8, 100.0)                               | (9.4, 99.2)                                 | (28.4, 99.5)                                |
| CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle         | CNS Duration of Response (months)dle         | CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle        |
| No. of patients censored, n (%)             | 1 (50.0)                                     | NA                                           | 1 (50.0)                                    | 0                                           | 1 (25.0)                                    |
| Median (95% CI)                             | NR (5.1, NE)                                 | NA                                           | NR (5.1, NE)                                | 12.19 (9.0, 15.3)                           | 9.03 (5.1, 15.3)                            |
| Minimum, Maximum                            | 5.1, 7.4+                                    | NA                                           | 5.1, 7.4+                                   | 9.0, 15.3                                   | 5.1, 15.3                                   |
| CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months)  | CNS Duration of Response Follow-up (months)  | CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months) |
| Median                                      | 7.39                                         | NA                                           | 7.39                                        | NR.                                         | NR.                                         |
| 25\", 75 Percentiles                         | 7.4, 7.4                                     | NA                                           | 7.4, 7.4                                    | NE, NE                                      | 7.4, NE                                     |
| CNS Rate (%) of Duration of Response        | CNS Rate (%) of Duration of Response         | CNS Rate (%) of Duration of Response         | CNS Rate (%) of Duration of Response        | CNS Rate (%) of Duration of Response        | CNS Rate (%) of Duration of Response        |
| 6 months (95% CI)                           | 50.0 (0.6, 91.0)                             | NA                                           | 50.0 (0.6, 91.0)                            | 100.0 (NE, NE)                              | 75.0 (12.8, 96.1)                           |
| ≥12 months (95% CI)                         | NE (NE, NE)                                  | NA                                           | NE (NE, NE)                                 | 50.0 (0.6, 91.0)                            | 37.5 (1.1, 80.8)                            |
| ≥24 months (95% CI)                         | 0.0 (NE, NE)                                 | NA                                           | NE (NE, NE)                                 | NE (NE, NE)                                 | NE (NE, NE)                                 |
| ≥36 months (95% CI)                         | 0.0 (NE, NE)                                 | NA                                           | NE (NE, NE)                                 | NE (NE, NE)                                 | NE (NE, NE)                                 |

Note: += censored observation.

Note: Partial response is not applieable for non-measwable patients. Stable disease includes non-CR/PD.

Abbreviations: CI = confidence interval; CNS = cental nervous system; CR = complete response; DOR = duation of response; IRC = Independent Review Committee; N = number of patients; n =mumber of patients in specific category; NE = not estimable; No. = number; NR = not reported; NSCLC = non-small cell lumg cancer; ORR = objective response rate; PR = partial response; RET = REaranged duing Transfection; RT = radiation therapy.

- 95% CI was caleulated using Clopper-Pearson method.
- CNS ORR is defined as the proportion of patfients with best overall response of CR or PR. Response was confiumed by a repeat assessment no less than 28 days.
- Indicates SD lasting ≥ 16 weeks following initiation of selpereatinib until the criteria for disease progression was first met.
- Estimate based on Kaplan-Meier method NE = Not estimable. NR = Not reached. + = Censored observation.
- 95% CI was caleulated using Brookmeyer and Crowley method.
- 95% CI was caleulated using Greenwood's formula.

<div style=\"page-break-after: always\"></div>

Figure 16. Waterfall plot of best change in CNS tumour Burden by Prior therapy based on IRC assessments in treatment-naïve patients-CNS response analysis set

<!-- image -->

(9 = Nl-spo9 kqng

Note: The dashed lines represent the RECIST vl.1. criteria for response (30% decrease) or progressive disease (20% imcrease).

Abbreviations: CNS = cenhal nervous system; IR.C =Independent Review Comwittee; N=mumber of patienis; RECIST =Response Evaluation Crnitenia in Solid Tumors; SRS = stereotactic radiosuwgery: WBRT =whole brain radiotherapy.

## Non-Measurable CNS Disease

The CNS ORR in the 11 patients with RET fusion-positive treatment-naïve and CNS metastasis with nonmeasurable CNS disease at baseline was 27.3% (95% CI: 6.0, 61.0) by IRC.

The  median  CNS  DOR  for  treatment-naïve  patients  with  CNS  non-measurable  disease  was  not  yet reached (95% CI: NE, NE) at a median follow-up time of 21.0 months.

Median duration of observed PFS in patients with RET fusion-positive treatment-naïve NSCLC and nonmeasurable CNS metastasis (N=11) was not estimable (95% CI: 3.7, NE) with a median duration of follow-up of 21.9 months.

## CNS Response in Patients with RET Fusion-Positive NSCLC Previously Treated with PlatinumBased Chemotherapy

Measurable CNS Disease

<div style=\"page-break-after: always\"></div>

Table 31. CNS ORR and CNS DOR by IRC Assessments RET Fusion-Positive NSCLC Previously Treated with Platinum-Based Chemotherapy Patients with Measurable CNS Lesions-CNS Response Analysis Set

|                                             | NSCLC with Prior RT                         | NSCLC with Prior RT                           | NSCLC with Prior RT                         | No Prior Brain RT                           | AIINSCLC                                    |
|---------------------------------------------|---------------------------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                             | Brain RT2 Months Prior to First Dose (N=1)  | Brain RT >2 Mlonths Prior to First Dose (N=6) | AIINSCLC with Prior RT (N=7)                | (N=9)                                       | (N=16)                                      |
| CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)        | CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)      | CNS Objective Response Rate* (CR + PR)      |
| Number of Patients with CR + PR (n, %)      | 1 (100.0)                                   | 4 (66.7)                                      | 5 (71.4)                                    | 9 (100.0)                                   | 14 (87.5)                                   |
| qIO %56                                     | (2.5, 100.0)                                | (22.3, 95.7)                                  | (29.0, 96.3)                                | (66.4, 100.0)                               | (61.7, 98.4)                                |
| CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)              | CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)            | CNS Best Overall Response, n (%)            |
| Complete response                           | 0 (0.0)                                     | 1 (16.7)                                      | 1 (14.3)                                    | 4(44.4)                                     | 5 (31.3)                                    |
| Partial response                            | 1 (100.0)                                   | 3 (50.0)                                      | 4 (57.1)                                    | 5 (55.6)                                    | 9 (56.3)                                    |
| Stable disease                              | 0 (0.0)                                     | 2 (33.3)                                      | 2 (28.6)                                    | 0 (0.0)                                     | 2 (12.5)                                    |
| SD:                                         | 0 (0.0)                                     | 2 (33.3)                                      | 2 (28.6)                                    | 0 (0.0)                                     | 2 (12.5)                                    |
| Progressive disease                         | 0 (0.0)                                     | 0 (0.0)                                       | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Not evaluable                               | 0 (0.0)                                     | 0 (0.0)                                       | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Undefined                                   | 0 (0.0)                                     | 0 (0.0)                                       | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                     | CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                   | CNS Clinical Benefit Rate                   |
| Number of Patients with CR + PR + SD (n, %) | 1 (100.0)                                   | 6 (100.0)                                     | 7 (100.0)                                   | 9 (100.0)                                   | 16 (100.0)                                  |
| qID %56                                     | (2.5, 100.0)                                | (54.1, 100.0)                                 | (59.0, 100.0)                               | (66.4, 100.0)                               | (79.4, 100.0)                               |
| CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle          | CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle        | CNS Duration of Response (months)dle        |
| No. ofpatients censored, n (%)              | 0 (0.0)                                     | 2 (50.0)                                      | 2 (40.0)                                    | 3 (33.3)                                    | 5 ( 35.7)                                   |
| Median (95% CI)                             | 8.28 (NE, NE)                               | NR (7.4, NE)                                  | 12.12 (7.4, NE)                             | 10.05 (5.4, NE)                             | 10.05 (7.4, NE)                             |
| Minimu, Maximum                             | 8.3, 8.3                                    | 7.4, 25.8+                                    | 7.4, 25.8+                                  | 5.4, 35.0+                                  | 5.4, 35.0+                                  |
| CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months)   | CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months) | CNS Duration of Response Follow-up (months) |
| Median                                      | NR.                                         | 24.84                                         | 24.84                                       | 26.68                                       | 25.79                                       |
| 25, 75 Percentiles                          | NE, NE                                      | 23.9, 25.8                                    | 23.9, 25.8                                  | 26.7, 35.0                                  | 23.9, 26.7                                  |
| CNS Rate (%) of Duration of Response\"       | CNS Rate (%) of Duration of Response\"       | CNS Rate (%) of Duration of Response\"         | CNS Rate (%) of Duration of Response\"       | CNS Rate (%) of Duration of Response\"       | CNS Rate (%) of Duration of Response\"       |
| 6 months (95% CI)                           | 100.0 (NE, NE)                              | 100.0 (NE, NE)                                | 100.0 (NE, NE)                              | 88.9 (43.3, 98.4)                           | 92.9 (59.1, 99.0)                           |
| ≥12 months (95% CI)                         | 0.0 (NE, NE)                                | 75.0 (12.8, 96.1)                             | 60.0 (12.6,88.2)                            | 25.4 (3.8, 56.4)                            | 38.7 (14.2, 63.0)                           |
| ≥24 months (95% CI)                         | 0.0 (NE, NE)                                | 50.0 (5.8, 84.5)                              | 40.0 (5.2, 75.3)                            | 25.4 (3.8, 56.4)                            | 31.0 (9.6, 55.6)                            |
| ≥36 months (95% CI)                         | 0.0 (NE, NE)                                | NE (NE, NE)                                   | NE (NE, NE)                                 | NE (NE, NE)                                 | NE (NE, NE)                                 |

Note: += censored observation.

Note: Patial response is not applicable for non-measuable patients Stable disease includes non-CR/PD.

Abbreviations: CI = confidence interval; CNS = cenhal nervous system; CR = complete response; DOR = duation of response; IRC = Independent Review

Committee; N = number of patients; n =mumber of patients in specific category; NE = not estimable; NR = not reported; NSCLC = non-small cell lumg cancer; ORR = objective response rate; PR = partial response; RT = radiation therapy.

- 95% CI was caleulated using Clopper-Pearson method.
- CNS ORR is defined as the proportion of patients with best overall response of CR or PR Response was confiumed by a repeat assessment no less than 28 days.
- Indicates SD lasting ≥ 16 weeks following initiation of selpercatinib umtil the criteria for disease progression was first met.
- Estimate based on Kaplan-Meier method. NE = Not estimable. NR = Not reached. + = Censored observation.
- 95% CI was caleulated using Brookmeyer and Crowley method.
- 95% CI was caleulated using Greenwood's fomula.

<div style=\"page-break-after: always\"></div>

Figure 17. Waterfall plot of best change in CNS tumour burden by prior therapy based on IRC assessments in RET fusion-positive NSCLC patients previously treated with platinumbased chemotherapy - CNS response analysis set

<!-- image -->

Eligible patiemts aue defined as patientsheated on or before 15December 2020.

*SRS* imcludes all patients reported to receive SRT, SBRT, GKS amd/or SRS. *WBRT\" inchudes all patients reported to receive iadliation of amyy kind to the *whole brain', including comwentional extemal beam, IvRT amd 3DC RT. For each subject, the best percent change from baseline in the sum of diaweters for all tauget CNS lesions is represented by a vertical bar. The dashed lines represent the RECIST vl.1. critenia for response (30y6 decrease) or progressiwe disease (2og6 increase).

Abbreviations: CNS = cenhal menwous system; DCRT = defimitive chemoiadiotherapy: EGFR. = epidenmal growth factor receptor; GkS = gauma kmife sw gery: IMRtT = imtensity modmlated iadliotherapy; MkI = mmltilkinase imhibitor; RECIST = Response Evaluation Chiteria im Solid Tumois; RET =REatanged duing Tramsfection: SBRT = stereotactic body radiotherapys SRLS = stereotactic tadliosuwgery; SRT = stereotactic Iadiotherapy: VEGF = Wascular emdothelialgrowth factor; WEGFR.= wascnlar emdoiheliallgrowth factor receptor; TWBRT = wholebraim Iadiotherapy.

Non-Measurable CNS Disease

The CNS ORR in the 61 patients with RET fusion-positive NSCLC previously treated with platinum therapy and CNS metastasis with non-measurable CNS disease at baseline was 39.3% (95% CI: 27.1, 52.7), by IRC.

The median CNS DOR for patients with CNS measurable disease was not yet reached (95% CI: 12.1, NE) at a median follow-up time of 20.3 months.

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 32. Summary of Efficacy for trial LIBRETTO-001

Title:  A  Phase  1/2  Study  of  Oral  LOXO-292  in  Patients  with  Advanced  Solid  Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer and Other Tumours with RET Activation (LIBRETTO-001)

| Study identifier          | LOXO-RET-17001; LIBRETTO-001                                                   | LOXO-RET-17001; LIBRETTO-001                                                   | LOXO-RET-17001; LIBRETTO-001                                                                                                                   |
|---------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Phase 1/2, multicentre, open-label                                             | Phase 1/2, multicentre, open-label                                             | Phase 1/2, multicentre, open-label                                                                                                             |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | ongoing not applicable not applicable                                                                                                          |
| Hypothesis                | Superiority                                                                    | Superiority                                                                    | Superiority                                                                                                                                    |
| Treatments groups         | Selpercatinib                                                                  | Selpercatinib                                                                  | Oral 10-, 20- or 80- mg capsules or 20 mg/mL suspension, QD or BID Dose escalation: 20 mg QD to 240 mg BID. Phase 2: 160mg BID                 |
| Endpoints and definitions | Primary endpoint                                                               | Objective response rate (ORR) by IRC                                           | Proportion of patients with best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST, 1.1. |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                      | Duration of Response (DOR) by IRC                                       | The number of months from the start date of PR or CR, and subsequently confirmed, to the date of disease progression or death.                     |
|-------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                                      | Progression Free Survival (PFS) by IRC                                  | The number of months elapsed between the date of the first dose of selpercatinib and the earliest date of documented disease progression or death. |
|                                                 | Secondary endpoint                                                      | Overall Survival (OS)                                                   | The number of months elapsed between the date of the first dose of selpercatinib and the date of death.                                            |
| Database lock                                   | Not provided, DCO: 15 June 2021                                         | Not provided, DCO: 15 June 2021                                         | Not provided, DCO: 15 June 2021                                                                                                                    |
| Results and Analysis                            | Results and Analysis                                                    | Results and Analysis                                                    | Results and Analysis                                                                                                                               |
| Analysis description                            | Primary Analysis                                                        | Primary Analysis                                                        | Primary Analysis                                                                                                                                   |
| Analysis population and time point description  | RET Fusion-Positive NSCLC Patients- Treatment-Naïve DCO: 15 June 2021   | RET Fusion-Positive NSCLC Patients- Treatment-Naïve DCO: 15 June 2021   | RET Fusion-Positive NSCLC Patients- Treatment-Naïve DCO: 15 June 2021                                                                              |
| Descriptive statistics and variability          |                                                                         |                                                                         |                                                                                                                                                    |
| estimate                                        | Treatment group                                                         | Treatment group                                                         | Selpercatinib                                                                                                                                      |
| estimate                                        | Number of patients 69 ORR % (95% CI) by IRC                             | Number of patients 69 ORR % (95% CI) by IRC                             | 58 (84.1) (73.3, 91.8)                                                                                                                             |
| estimate                                        | DOR median, months (95% CI)                                             | DOR median, months (95% CI)                                             | 20.21 (13.0, NE)                                                                                                                                   |
| estimate                                        | PFS median, months (95% CI) 21.95 (13.8,                                | PFS median, months (95% CI) 21.95 (13.8,                                | NE)                                                                                                                                                |
| estimate                                        | OS landmark rates (%) (95% CI) 92.7 at 69.3 at                          | OS landmark rates (%) (95% CI) 92.7 at 69.3 at                          | 12 months (83.3, 96.9) 24 months (55.2, 79.7) 57.1 at 36 months (35.9, 73.6)                                                                       |
| Analysis population and time point description  | RET-Fusion Positive NSCLC-Prior Platinum Chemotherapy DCO: 15 June 2021 | RET-Fusion Positive NSCLC-Prior Platinum Chemotherapy DCO: 15 June 2021 | RET-Fusion Positive NSCLC-Prior Platinum Chemotherapy DCO: 15 June 2021                                                                            |
| Descriptive statistics and estimate variability |                                                                         |                                                                         |                                                                                                                                                    |
|                                                 | Treatment group                                                         | Treatment group                                                         | Selpercatinib                                                                                                                                      |
|                                                 | Number of patients 247                                                  | Number of patients 247                                                  | 151 (61.1)                                                                                                                                         |
|                                                 | ORR %(95% CI) DOR median, months (95% CI) 28.58 (20.4,                  | ORR %(95% CI) DOR median, months (95% CI) 28.58 (20.4,                  | (54.7, 67.2)                                                                                                                                       |
|                                                 | PFS median, months (95% 24.94                                           | CI)                                                                     | (19.3, NE)                                                                                                                                         |
|                                                 | OS landmark rates (%) (95% CI) 87.9 68.9                                | OS landmark rates (%) (95% CI) 87.9 68.9                                | at 12 months (83.0, 91.4) at 24 months (62.2, 74.7) 58.5 at 36 months (49.7, 66.3)                                                                 |
| Effect estimate per comparison Notes            | Not applicable, single arm trial                                        | Not applicable, single arm trial                                        | Not applicable, single arm trial                                                                                                                   |
| Effect estimate per comparison Notes            | CI = confidence interval; NE = not estimable                            | CI = confidence interval; NE = not estimable                            | CI = confidence interval; NE = not estimable                                                                                                       |

## Clinical studies in special populations

No data from clinical studies in special populations was submitted in this application.

<div style=\"page-break-after: always\"></div>

In the table below, the number of elderly patients included in the LIBRETTO-001 trial is presented.

|                                                                        | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older number number)   | subjects /total   |
|------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------|-------------------|
| LIBRETTO-001 trial RET Fusion-Positive NSCLC Patients- Treatment-Naïve | 24/69 (34.8%)                                     | 4/69 (5.8%)                                       | 3/69 (4.3%)                     |                   |

## 2.4.3. Discussion on clinical efficacy

The  MAH  is  seeking  by  this  application  an  extension  of  indication  of  selpercatinib  for  the  first  line treatment of advanced RET fusion-positive NSCLC. Selpercatinib has a conditional approval for previously treated advanced RET fusion-positive NSCLC (immunotherapy and/or platinum based chemotherapy). In addition, a CMA was granted to thyroid cancer patients following prior treatment with sorafenib and/or lenvatinib  and  advanced  RET  mutant  medullary  thyroid  cancer  (MTC)  following  prior  treatment  with cabozantinib and/or vandetanib. In order to fulfil this CMA, clinical data are to be provided as a SOB from two separate ongoing phase 3 studies within a specified timeframe (Annex II of the SmPC); J2GMC-JZJC  (LIBRETTO-431)  in  treatment-naive  RET-fusion  non-squamous  NSCLC  and  J2G-MC-JZJB (LIBRETTO-531) in previously untreated RET-mutant MTC.

The provided efficacy data in support of the currently intended indication 'advanced RET fusion positive NSCLC' is based on results from the ongoing study LOXO -RET-17001 (LIBRETTO-001) as of the cut-off date of 21 June 2021. This was an open-label, multicentre, Phase 1/2 study which consisted on a dose escalation  phase  (Phase  1)  to  determine  the  MTD  and  RP2D  of  selpercatinib  followed  by  a  Phase  2 expansion with diverse RET-altered cancer cohorts (6 cohorts), among them NSCLC (1L/2L), MTC, and other tumours.

The Phase 1 portion of the study has been completed. The Phase 2 portion is ongoing and continuing to enroll patients with advanced solid tumours. The study was however closed for enrollment of patients with RET fusion-positive NSCLC in May 2020.

## Design and conduct of clinical study

LIBRETTO-001 is non-randomized and non-blinded single arm study. The absence of a control arm is an important limitation and a source of bias for a confirmatory study. Overall, inclusion and exclusion criteria are considered acceptable. Amendments made on eligibility criteria since the initial submission of the CMA (DCO of June 2019) are not expected to have a substantial impact on study population or efficacy data. A new cohort, cohort 6, was introduced by amendment protocol (version 9) to include patients who discontinued another selective RET inhibitor because of intolerance. Efficacy data from patients with NSCLC in this cohort is not yet available and this was adequately reflected in the therapeutic indication.

The RP2D of selpercatinib (160 mg BID) was selected in Phase 1 and has been used as the starting dose for patients in the Phase 2 of the study. Patients continued selpercatinib dosing in 28-day cycles until PD, unacceptable toxicity, or other reason for treatment discontinuation. Patients with PD could continue selpercatinib if, in the opinion of the investigator, they deriving clinical benefit from continuing study treatment.

The primary efficacy endpoint was ORR based on RECIST v1.1. Given the uncontrolled design of the clinical trial, ORR could be an acceptable primary endpoint. PFS, OS and DOR were assessed as secondary endpoints. CNS ORR and DOR were also included as secondary endpoints. It is important to consider

<div style=\"page-break-after: always\"></div>

that even if results in term of ORR are outstanding, interpretation of benefit in term of survival endpoints is difficult and uncertain in uncontrolled setting.

Some non-substantial modifications are made to the SAP as outlined in the SAP addendum 1 dated 14 June 2021. There is no change to efficacy analysis sets defined in the original version of the SAP. FDA censoring rules were used for DoR and PFS.

Up to DCO of 15 June 2021, 921 patients were screened. Of these, 123 patients have failed screening (13.4%), with main reason not satisfying all inclusion  and exclusion criteria. 796 patients had been enrolled in the Phase 1 and Phase 2 cohorts and were treated with at least 1 dose of selpercatinib. Of these,  356  patients  had  RET  fusion-positive  NSCLC.  All  these  patients  fulfilled  the  efficacy  dataset requirement to allow for appropriate response assessment (at least 6 months of a potential follow-up time). One patient from cohort 6 received prior treatment with a selective RET inhibitor and therefore is not included in the efficacy analysis. Of the 355 patients with RET fusion-positive NSCLC, 69 patients were treatment-naïve and 247 patients were previously treated with platinum based chemotherapy. Of note,  this  corresponds  to  enrolment  of  21  additional  treatment-naïve  patients  and  29  additional previously treated patients from 30 March 2020 to 15 June 2021.

Of the 355 patients with RET fusion-positive NSCLC, 165 (46.5%) patients were still on treatment. Of the 69 treatment-naïve patients, 46.4% of patients were still on treatment and the main reason for treatment discontinuation was disease progression (37.7%) followed by AEs (8.7%). Of the 247 patients who  were  previously  treated,  47.4%  of  patients  were  still  on  treatment  and  the  main  reason  for treatment discontinuation was disease progression (29.6%) followed by AEs (9.3%).

The MAH provides information on study conduct from Protocol version 8.0 up to Protocol version 9.0 (03 June 2020). Some of the changes introduced with Protocol v8 are the addition of the new cohort 6 to allow the inclusion of patients previously treated with another RET-selective inhibitor with around 50 patients planned to be enrolled. Moreover, with protocol v9 the number of patients to be enrolled in Cohort 1 is increased to 250 participants and Cohort 5 up to approximately 200 in order to accommodate enrollment demand of patients with RET fusion-positive solid tumours other than NSCLC and to allow for the characterization of AEs that may occur with low frequency.

Regarding protocol deviations, 25.8% of NSCLC patients had at least one major protocol deviation.

Baseline demographics and disease characteristics for patients previously treated with platinum based chemotherapy remain consistent with those provided at the DCO of June 2019.

Treatment-Naïve Patients had a median age of 63 years (range: 23-92), being 10% 75 years or older. 62.3% of patients were female, 69.6% were White and 18.8% Asian. The majority of patients had an ECOG PS of 0 (36.2%) or 1 (58%) and had never smoked (69.6%) or were former smokers (27.5%). History  of  metastatic  disease  was  present  in  98.6%  and  23.2% of  patients  had  CNS  metastases  at baseline. The median time from initial diagnosis and diagnosis of metastatic disease were 2.0 and 1.6 months, respectively. 98.6% had metastases and 1.4% had advanced disease at enrollment as reported by the Investigator.

The most common fusion partners were KIF5B (70%) and CCDC6 (14.5%). Moreover, there were 8 patients (11.6%) in which fusion partner was unknown. In the majority of cases, the RET alteration was determined by NGS, 60.9% on tumour and 30.4% on plasma/blood.

## Efficacy data and additional analyses

The evidence supporting of the claimed indication in first line NSCLC came from the 69 treatment naïve patients which could be considered limited to generate evidence. Supportive evidence came mostly from

<div style=\"page-break-after: always\"></div>

the 247 patients previously treated (Platinum-Based Chemotherapy) and the 26 evaluable patients who had CNS measurable disease by IRC.

## Treatment-naïve advanced NSCLC

As of the cut-off date of 21 June 2021, the ORR among 69 treatment-naïve patients was 84.1% (95% CI: 73.3, 91.8) by IRC and 85.5% (95% CI: 75.0, 92.8) by Investigator (Inv). Concordance between the IRC and Investigator assessments is 89.9% (95% CI: 80.2, 95.8).

The  median  DOR  by  IRC  was  20.2  months  (95%  CI:  13.0,  NE)  with  39.7%  of  patients  continuing treatment or PD free at median follow-up of 21.2 months. The mDOR by inv was 20.27 months (14.8; NE). Kaplan-Meier estimates of the rate of duration of response at 12 months was 66.1% (95% CI: 51.6, 77.3) and at 24 months was 41.6% (95% CI: 25.6, 56.8). A stable median cannot yet be estimated.

The median TTR by IRC was 1.81 months, with most patients demonstrating an initial and best response at the first post-baseline radiographic assessment.

Median duration of observed PFS by IRC was 21.95 months (95% CI: 13.8, NE) with 53.6% of the patients remaining progression free with a median follow-up of 21.91 months. mPFS by inv is 20.73 months (13.6, NE). PFS data is not yet considered mature. KM estimates of the rate of PFS by IRC at 12 months or more was 70.6% (95% CI: 57.8, 80.2), and at 24 months was 41.6% (95% CI: 26.8, 55.8).

Sensitivity analyses for PFS and DOR where patients who received a subsequent anti-cancer therapy are imputed as event were provided and results were consistent with the main analyses.

Median duration of observed OS was not estimable with 71.0% patients remaining alive at a median follow-up of 25.2 months. The rate of OS at 24 months was 69.3%, and at 36 months was 57.1%.

Analysis  by  subgrou ps  in  the  treatment  naïve  patient's  population  did  not  reveal  any  remarkable difference to main analysis. Overall, ORR were mostly in line with the main analysis.

## Prior-platinum treated advanced NSCLC

The ORR in the 247 patients previously treated with platinum-based chemotherapy (previously named IAS)  was  of  61.1%  (95%  CI:  54.7,  67.2)  by  IRC  and  64.4%  (95%  CI:  58.1,  70.3)  by  Inv  with  a concordance rate of 74.9% (69.0, 80.2). There were 133 PRs (53.8%) and 18 CRs (7.3%).

The median TTR by IRC was 1.87 months. Estimated mPFS by IRC was 24.94 months (95% CI: 19.3, NE) with a median follow-up of 24.71 months. mPFS by inv was 21.75 months (95% CI: 16.8, 24.9). Due to the number of patients who were progression free (55.9%), the PFS data is not yet mature. KM estimates of the rate of PFS by IRC at 12 months was 70.5% (95% CI: 64.1, 76.0) and at 24 months was 51.4% (95% CI: 44.3, 58.1).

The  median  DOR  by  IRC  was  28.6  months  (95%  CI:  20.4,  NE)  with  49.0%  of  patients  continuing treatment or PD free at median follow-up of 21.2 months. The mDOR by inv was slightly lower (21.22 months (95% CI: 18.4, 31.8).  This could be explained by the fact that the data are still not mature, with censoring rates of 50.3% (investigator assessed) and 60.9% (IRC-assessed).

Median duration of OS was not estimable with 57.9% of the patients remaining alive and continuing OS follow-up at a median follow-up time of 26.4 months. The rate of OS at 24 months was 68.9%, and at 36 months was 58.5%.

Overall results were consistent with those of the primary analysis that led to the initial CMA.

ORR remained consistent across the pre-specified subgroups except for subgroups of the RET fusion partner genes where the ORR for patients with CCDC6-RET (81.1%; 95% CI, 68.0, 90.6) was higher compared to those with KIF5B-RET fusion (55.6%; 95% CI, 47.3, 63.6). Response appears to be lower

<div style=\"page-break-after: always\"></div>

in those patients with non-KIF5B/non-CCDC6 fusion (47.6%) although the number of patients is low (n=21).  Although  these  results  cannot  be  readily  attributed  to  a  specific  covariate(s)  or  identified mechanistic differences in the underlying biology, the ORRs observed in the NSCLC population with KIF5B (55.6%; n=153), CCDC6 (81.1%; n=53), and non-KIF5B/CCDC6 (47.6%; n=21) exceed those observed with standard chemotherapy (8.8% to 23%) or monotherapy immune checkpoint inhibitors (13.7% to 33.1%). The confirmatory Phase 3 study, LIBRETTO-431, will provide an opportunity to obtain more data on the efficacy of selpercatinib with different fusion partners, data on the predictive and prognostic value of different fusion partners, and inform whether this result is potentially attributable to underlying biology or is unique to the LIBRETTO-001 dataset.

The ORR benefit of selpercatinib for the intended population was observed regardless of line of treatment. But, higher ORR in the treatment-naïve population (81%) were observed and this subpopulation has a lower K-M estimates of median PFS (21.95 months) and mDOR (20.2 months) compared to the priorplatinum subpopulation (24.94 months and 28.6 months, respectively). The MAH clarified that this is likely a result of the random statistical variability that comes from comparing point estimates in a small dataset that is not yet mature.

## CNS responses

CNS metastasis are common in lung cancer patients. Of the 355 patients with NSCLC, 106 patients had CNS metastasis at baseline by Inv, of whom 26 had CNS measurable disease by IRC. ORR in the 26 patients with measurable CNS metastasis was 84.6% (95% CI: 65.1, 95.6), including 7 CRs (27%) and 15 PRs (58%) with a median duration of response of 9.36 months (95% CI: 7.4, 15.3). Median PFS by IRC for these patients (N=26) was 11.01 months (95% CI: 9.2, 17.1).

ORR was much lower in the total 80 patients with non-measurable CNS metastasis at baseline with ORR of 37.5% (95% CI: 26.9, 49.0), by IRC. Per RECIST 1.1, in a non-measurable population, only patients achieving a CR are considered to be responders. The median CNS DOR by IRC for these patients was not yet reached (95% CI: 22.1, NE) at a median follow-up time of 20.70 months.

Responses were observed both in patients previously treated with platinum based chemotherapy as well as treatment-naïve patients.

## Other supportive analyses

In patients with RET fusion-positive NSCLC previously treated with other systemic therapy (N=19), ORR by IRC was 47.4% (95% CI: 24.4, 71.1), the mDOR was 15.84 months with median duration of followup of 28.52 months. mPFS by IRC was 19.42 months (95% CI: 3.5, 30.5) with a median follow up of 30.26 months.

Among Patients with non-measurable RET fusion-positive NSCLC by inv (N=20), 8 patients were deemed to have measurable disease by the IRC. The ORR by IRC was 40.0% (95% CI: 19.1, 63.9). mDOR by IRC was 22.21 with median duration of follow-up of 21.16 months. mPFS by IRC was 18.69 months (95% CI: 9.1, NE) with a median follow-up of 22.08 months.

In the first enrolled 105 previously treated patients, who have the longest potential follow-up time, ORR by IRC was 61.9% (95% CI: 51.9, 71.2). mDOR was 20.86 months with median duration of follow-up of 28.75 months. mPFS by IRC was 19.25 (95% CI: 13.9, 30.4) with a median follow up of 30.32 months.

## 2.4.4. Conclusions on the clinical efficacy

The updated efficacy results from the ongoing phase 1/2 study LIBRETTO-001 in previously treated NSCLC are consistent with those provided in the original submission. For treatment naïve patients, the obtained ORR of 84% is considered clinically meaningful. Responses seem durable and K-M estimates

<div style=\"page-break-after: always\"></div>

for median PFS and OS allow to anticipate lasting benefits from treatment. Selpercatinib has shown activity in patients with CNS disease regardless of line of therapy.

Although, other approved front-line therapies with established benefit exist, efficacy with selpercatinib is considered of sufficient magnitude and across multiple lines of therapy. Since efficacy results are based on a single clinical trial with a low number of treatment-naïve subjects (n=69), data corresponding to a longer follow-up are still required as well as efficacy results from the ongoing phase 3 study LIBRETTO431 (the SOB study related to the CMA).

## 2.5. Clinical safety

## Introduction

Safety data are available from a total of 796 patients in the LIBRETTO 001 study which is still ongoing. All patients in the ITT population received at least one dose of selpercatinib as of the data cutoff date of 15 June 2021.

Table 33. Description of Safety Analysis Sets (Data Cutoff Date: 15 June 2021)

| Safety Analysis                                                             | Analysis Set Description                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Overall Safety Population (N=796)                                           | All patients who received at least 1 dose of selpercatinib, including: RET fusion-positive NSCLC RET fusion-positive thyroid cancer RET-mutant MTC RET-altered other cancers, and Other cancers without a RET alterationa |
| Treatment-Naive SafetyPopulation (N=69)                                     | All treatment-naive patients with RET fusion-positive NSCLC who received at least 1 dose of selpercatinib. This is a subset of the Overall Safety Population.                                                             |
| NSCLC Safety Population (n=356)                                             | All patients with documented RET fusion-positive NSCLC who received at least 1 dose of selpercatinib. This is a subset of the Overall Safety Population.                                                                  |
| PreviouslyTreated withPlatinum-Based Chemotherapy Safety Population (N=248) | All patients with RET fusion-positive NSCLC previously treated with platinum-based chemotherapy who received at least 1 dose of selpercatinib. This is a subset of the OverallSafetyPopulation                            |

Abbreviations: MTC = medullary thyroid cancer; N = number of patients; NSCLC = non-small cell lung cancer; PK = pharmacokinetic; RET = rearranged during transfection.

Note that during Phase 1, a RET gene alteration was not required for enrolment until adequate PK exposure was achieved.

## Patient exposure

Through 15 June 2021, a total of 796 patients have been treated with selpercatinib at doses ranging from 20 mg QD to 240 mg BID, most patients (96% ) received at least 1 dose of the selpercatinib recommended dose (Phase 2 dose) of 160 mg BID.

Five hundred thirty-nine (539) patients (68%) were still on study, of which 462 patients (58%) were still receiving selpercatinib and 77 patients (10%) were in follow-up, but off treatment.

<div style=\"page-break-after: always\"></div>

The most common reason for treatment discontinuation in the Overall Safety Population was disease progression (23%), followed by AE (8%).

In the NSCLC Safety Population, 95.8% patients received at least 1 dose of selpercatinib 160 mg BID and 87.4% patients had a selpercatinib starting dose of 160 mg.

Table 34. Treatment and study disposition (NSCLC Safety Population)

| Status                                                 | Integrated (N=248)   | SAS1 (N= 69)   | RET Fusion-positive NSCLC (N=356)   |
|--------------------------------------------------------|----------------------|----------------|-------------------------------------|
| Treatment Status （n，&）                                 |                      |                |                                     |
| Discontinued                                           | 130 (52.4)           | 37( 53.6)      | 190 ( 53.4)                         |
| Continuing                                             | 118 ( 47.6)          | 32 (46.4)      | 166 ( 46.6)                         |
| Reason Treatment Discontinued (n,&)                    |                      |                |                                     |
| Progressive Disease                                    | 73(29.4)             | 26 (37.7)      | 115 ( 32.3)                         |
| Adverse Event                                          | 23 ( 9.3)            | 6 8.7)         | 32 （ 9.0)                           |
| Intercurrent Illness Compromising Ability              | 1 0.4)               | 0 0.0)         | 1 0.3)                              |
| to Fulfill Protocol Requirements                       |                      |                |                                     |
| Requirement for Alternative Treatment per Investigator | 2 0.8)               | 0 0.0)         | 2 0.6)                              |
| Withdrawal of Consent                                  | 14 5.6)              | 3 4.3)         | 17 4.8)                             |
| Death                                                  | 8 3.2)               | 2 2.9)         | 14 3.9)                             |
| Other                                                  | 9 3.6)               | 0 0.0)         | 9 2.5)                              |
| Study Status (n,&)                                     |                      |                |                                     |
| Discontinued                                           | 104 ( 41.9)          | 25 (36.2)      | 147 ( 41.3)                         |
| Continuing                                             | 144 ( 58.1)          | 44 (63.8)      | 209 ( 58.7)                         |
| Reason Study Discontinued （n,&)                        |                      |                |                                     |
| Withdrawal of Consent                                  | 25 ( 10.1)           | 5 (7.2)        | 34 (9.6)                            |
| Lost to Follow-Up                                      | 1 (0.4)              | 0 (0.0)        | 2 (0.6)                             |
| Death                                                  | 78 ( 31.5)           | 20 (29.0)      | 111 ( 31.2)                         |

The  median  time  on  treatment  was  21.29  and  19.09  months,  respectively,  for  the  Overall  Safety Population and NSCLC Safety Population.

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 77.5% in the NSCLC Safety Population) primarily attributed to adverse events (AEs) (64.1% in the Overall Safety Population and 68.8% in the NSCLC Safety Population).

## Adverse events

A summary of all-causality and treatment-related AEs registered by data-cutoff is shown in below table

Table 35. Summary of Safety Trends- Overall Safety Population

| DataCut-OffDate                                   | 16 December2019   | 30March 2020   | 15 Jume 2021   |
|---------------------------------------------------|-------------------|----------------|----------------|
| Patients with                                     | N=702             | N=746          | N=796          |
| any TEAE, n (%)                                   | 695 (99.0)        | 740 (99.2)     | 795 (99.9)     |
| Related to selpercatinib                          | 640 (91.2)        | 690 (92.5)     | 756 (95.0)     |
| Grade ≥3 TEAEs, n (%)                             | 415 (59.1)        | 445 (59.7)     | 572 (71.9)     |
| Related to selpercatinib                          | 206 (29.3)        | 239 (32.0)     | 307 (38.6)     |
| TEAEs leading to treatment discontinuation, n (%) | 37 (5.3)          | 45 (6.0)       | 64 (8.0)       |
| Related to selpercatinib                          | 14 (2.0)          | 16 (2.1)       | 25 (3.1)       |
| TESAEs, n (%)                                     | 234 (33.3)        | 262 (35.1)     | 353 (44.3)     |
| Related to selpercatinib                          | 54 (7.7)          | 62 (8.3)       | 87 (10.9)      |
| fatal TEAEs, n (%)                                | 21 (3.0)          | 25 (3.4)       | 45 (5.7)       |
| Related to selpercatinib                          | 0                 | 0              | 1 (0.1)        |

<div style=\"page-break-after: always\"></div>

Table 36. Adverse Drug Reactions in LIBRETTO-001-Overall Safety Population

| System Organ Class                     | Event                          | Selpercatinib (N=796)   | Selpercatinib (N=796)   | Selpercatinib (N=796)   |
|----------------------------------------|--------------------------------|-------------------------|-------------------------|-------------------------|
| System Organ Class                     | Event                          | Any Grades Toxicity (%) | Grade 3 Toxicity (%)    | Grade 4 Toxicity (%)    |
| Immune system disordersa               | Hypersensitivityb              | 5.9                     | 1.9                     | 0                       |
| Metabolism and nutrition disorders     | Decreased appetite             | 18.8                    | 0.4                     | 0                       |
| Neivous system disorders               | Headacheb                      | 27.6                    | 1.4                     | 0                       |
| Neivous system disorders               | Dizzinessb                     | 19.1                    | 0.3                     | 0                       |
| Cardiac disorders                      | ElectrocardiogramQT prolongedb | 21.1                    | 4.8                     | 0                       |
| Vascular disorders                     | Hypertensionb                  | 41.0                    | 19.6                    | 0.1                     |
| Gastrointestinal disorders             | Abdominal painb                | 33.7                    | 2.5                     | 0                       |
| Gastrointestinal disorders             | Diarrhoeab                     | 47.0                    | 5.0                     | 0                       |
| Gastrointestinal disorders             | Nausea                         | 31.2                    | 1.1                     | 0                       |
| Gastrointestinal disorders             | Vomiting                       | 22.4                    | 1.8                     | 0                       |
| Gastrointestinal disorders             | Constipation                   | 32.8                    | 0.8                     | 0                       |
| Gastrointestinal disorders             | Dry Mouthb                     | 43.2                    | 0                       | 0                       |
| Skin and subcutaneous tissue disorders | Rashb                          | 32.8                    | 0.6                     | 0                       |
| General disorders and conditions       | Pyrexia                        | 17.0                    | 0.1                     | 0                       |
| administration site                    | Fatigueb                       | 45.9                    | 3.1                     | 0                       |
| administration site                    | Oedemab                        | 48.5                    | 0.8                     | 0                       |
| Investigations                         | AST increasedb                 | 36.7                    | 7.9                     | 0.9                     |
| Investigations                         | ALT increasedb                 | 35.7                    | 10.7                    | 0.8                     |
| Investigations                         | Thrombocytopeniab              | 15.5                    | 2.0                     | 1.0                     |
| Investigations                         | Lymphopenia                    | 13.9                    | 4.4                     | 0.8                     |
| Investigations                         | Hypomagnesaemia                | 12.6                    | 0.3                     | 0                       |
| Investigations                         | Creatinine increasedb,c        | 28.5                    | 1.4                     | 0.5                     |
| Blood and lymphatic system             | Haemorrhaged                   | 22.0                    | 2.1                     | 0.5                     |

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients.

Investigators were instructed to report hypersensitivity reactions, characterised by a maculopapular rash often preceded by a fever with associated arthralgias/myalgias during the patient's first cycle of treatment (typically between Days 7 through 21).

b Composite terms are italicized.

C Toxicity grade assignment based on CTCAE (v5.0)

d See description of selected adverse reactions for further characterisation.

Toxicity grade assignment based on CTCAE (v4.03).

<div style=\"page-break-after: always\"></div>

Table 37. Laboratory Adverse Drug Reactions in LIBRETTO-001- Overall Safety Population

| System Organ    |                           | Selpercatinib (N=796)   | Selpercatinib (N=796)   | Selpercatinib (N=796)   | Selpercatinib (N=796)   |
|-----------------|---------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Class           | Event                     | Na                      | Any Grades Toxicity (%) | Grade 3 Toxicity (%)    | Grade 4 Toxicity (%)    |
| Investigationsa | AST increased             | 791                     | 58.9                    | 9.7                     | 0.9                     |
|                 | ALT increased             | 791                     | 55.5                    | 10.7                    | 1.0                     |
|                 | Platelets decreased       | 791                     | 37.4                    | 1.9                     | 1.3                     |
|                 | Lymphocyte count decrease | 765                     | 51.8                    | 17.6                    | 1.8                     |
|                 | Magnesium decreased       | 787                     | 32.9                    | 0.4                     | 0.3                     |
|                 | Creatinine increasedb     | 791                     | 47.3                    | 1.5                     | 0.9                     |

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients.

- Based on laboratory assessments. Percentage is calculated based on the number of patients with baseline assessment in the corresponding safety analysis set (N) and at least one postbaseline assessment as the denominator (N'), which was 765 for Lymphocyte count decrease, 787 for Magnesium decreased and 791 for the other PTs.

bToxicity grade assignment based on CTCAE (v5.0)

Toxicity grade assignment based on CTCAE (v4.03).

<div style=\"page-break-after: always\"></div>

Table 38. Summary of Treatment-Emergent Adverse Events-Overall Safety Population and NSCLC Safety Population

| Term                                              | Treatment-Naive Patients (N=69)   | Patients Previously Treated with Platinum-Based Chemotherapy (N=248)   | NSCLC Safety Population (N=356)   | Overall Safety Population (N=796)   |
|---------------------------------------------------|-----------------------------------|------------------------------------------------------------------------|-----------------------------------|-------------------------------------|
| Any TEAEs, n (%)                                  | 69 (100.0)                        | 248 (100.0)                                                            | 356 (100.0)                       | 795 (99.9)                          |
| Related to selpercatinib                          | 67 (97.1)                         | 235 (94.8)                                                             | 341 (95.8)                        | 756 (95.0)                          |
| Grade ≥3 TEAEs, n (%)                             | 50 (72.5)                         | 182 (73.4)                                                             | 263 (73.9)                        | 572 (71.9)                          |
| Related to selpercatinib                          | 25 (36.2)                         | 107 (43.1)                                                             | 143 (40.2)                        | 307 (38.6)                          |
| TEAEs leading to treatment discontinuation, n (%) | 7 (10.1)                          | 24 (9.7)                                                               | 34 (9.6)                          | 64 (8.0)                            |
| Related to selpercatinib                          | 3 (4.3)                           | 8 (3.2)                                                                | 11 (3.1)                          | 25 (3.1)                            |
| TESAE, n (%)                                      | 26 (37.7)                         | 123 (49.6)                                                             | 173 (48.6)                        | 353 (44.3)                          |
| Related to selpercatinib                          | 8 (11.6)                          | 38 (15.3)                                                              | 52 (14.6)                         | 87 (10.9)                           |
| Fatal TEAEs, n (%)                                | 4 (5.8)                           | 14 (5.6)                                                               | 24 (6.7)                          | 45 (5.7)                            |
| Related toselpercatinib                           | 0                                 | 0                                                                      | 0                                 | 1 (0.1)                             |

Percentage is calculated based on the number of patients in the column heading as the denominator.

Treatment-emergent Adverse Events (TEAEs) are defined as adverse events that start on or after the first administration of selpercatinib.

Related events are those judged by the Investigator as related to selpercatinib.

Severity grade assignment based on CTCAE (v4.03): Grade 3 (severe), Grade 4 (life-threatening/debilitating). Grade 5 (fatal).

The  most  frequent  TEAEs  occurring  in  30%  or  more  in  the  Overall  Safety  Population  were edema , diarrhea , fatigue , dry  mouth , hypertension , aspartate  aminotransferase ( AST)  increased , alanine aminotransferase ( ALT) increased , constipation , rash , abdominal pain , and nausea.

The most frequent TEAEs of any grade occurring 30% or more in the NSCLC Safety Population were edema , diarrhea , fatigue , dry mouth , hypertension , AST increased , ALT increased , nausea, and rash.

The most common Grade ≥ 3 TEAEs in both the Overall and NSCLC Safety Populations were hypertension followed by ALT increased and AST increased. There were no Grade 5 (fatal) events noted for these 3 TEAEs in either of the populations.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in &gt;2% of patients in both the Overall and NSCLC Safety Populations were pneumonia, pleural effusion, abdominal pain, dyspnea, and hyponatremia.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious AEs

## Table 39. Serious Treatment-emergent Adverse Events and Related to Study Drug

| Preferred Term                             | Integrated (N=248) n (%)   | SAS1 (N= 69) n (8)   | RET Fusion-positive NSCLC (N=356) n (%)   |
|--------------------------------------------|----------------------------|----------------------|-------------------------------------------|
| Patients with TESAEs Related to Study Drug | 38 (15.3)                  | 8 ( 11.6)            | 52 (14.6)                                 |
| Drug hypersensitivity                      | 3.2)                       | 1.4)                 | 10 2.8)                                   |
| Alanine aminotransferase increased         | 4 1.6)                     | 1.4)                 | 6 1.7)                                    |
| Aspartate aminotransferase increased       | 4 1.6)                     | 1 1.4)               | 6 1.7)                                    |
| Hypersensitivity                           | 1 0.4)                     | 1 1.4)               | 4 1.1)                                    |
| Hypertension                               | 3 1.2)                     | 0 0.0)               | 3 0.8)                                    |
| Pleural effusion                           | 2 0.8)                     | 1.4)                 | 4 1.1)                                    |
| Ascites                                    | 3 1.2)                     | 0 0.0)               | 3 0.8)                                    |
| Dehydration                                | 0.0)                       | 0 0.0)               | 2 0.6)                                    |
| Diarrhoea                                  | 1 0.4)                     | 0 0.0)               | 2 0.6)                                    |
| Pericardial effusion                       | 2 0.8)                     | 0 0.0)               | 0.6)                                      |
| Chylothorax                                | 2 0.8)                     | 0 0.0)               | 0.6)                                      |
| Constipation                               | 1 0.4)                     | 1 1.4)               | 0.6)                                      |
| Drug-induced liver injury                  | 1 0.4)                     | 0 0.0)               | 0.3)                                      |
| Fatigue                                    | 1 0.4)                     | 0 0.0)               | 0.3)                                      |
| Haemorrhage intracranial                   | 1 0.4)                     | 0 0.0)               | 0.3)                                      |
| Nausea                                     | 0.0)                       | 1.4)                 | 0.3)                                      |
| Thrombocytopenia                           | 1 0.4)                     | 0.0)                 | 0.3)                                      |
| Cardiac failure                            | 1( 0.4)                    | 0.0)                 | 0.3)                                      |
| Colitis                                    | 0.4)                       | 0 0.0)               | 0.3)                                      |
| Drug eruption                              | 0.4)                       | 0 0.0)               | 1 0.3)                                    |
| Dysphagia                                  | 0.4)                       | 0 0.0)               | 1 0.3)                                    |
| Electrocardiogram T wave inversion         | 0 0.0)                     | 1 1.4)               | 0.3)                                      |
| Focalsegmentalglomerulosclerosis           | 0.4)                       | 0 0.0)               | 1 0.3)                                    |
| Hypothyroidism                             | 0.4)                       | 0 0.0)               | 1 0.3)                                    |
| Ischaemic stroke                           | 0.4)                       | 0 0.0)               | 0.3)                                      |
| Liver function test increased              | 0.4)                       | 0 0.0)               | 0.3)                                      |
| Mental disorder                            | 0.4)                       | 0 0.0)               | 0.3)                                      |
| Retroperitoneal haematoma                  | 0.0)                       | 1.4)                 | 0.3)                                      |

Percentage is calculated based on the number of patients in the column heading as the denominator.

Treatment-emergent Adverse Events (TEAEs) are defined as adverse events that start on or after the first administration of Loxo-292. Patients are counted once within each preferred term.

Adverse events are sorted in descending frequency based on the overall count in the overall safety analysis set.

## Deaths

Table 40. List of Patients with Grade 5 Adverse Events (NSCLC Safety Population)

|                                 | Integrated (N=248) n (8)   | SAS1 (N= 69) n (名)   | RET Fusion-positive NSCLC (N=356) n   |
|---------------------------------|----------------------------|----------------------|---------------------------------------|
| Within 28 Days of Last Dose     | 19 (7.7)                   | 5 (7.2)              | 33 (9.3)                              |
| Disease Progression             | 11 (4.4)                   | 2 (2.9)              | 15 (4.2)                              |
| Adverse Event                   | 8(3.2)                     | 3(4.3)               | 17 (4.8)                              |
| Other                           | 0(0.0)                     | 0(0.0)               | 1 (0.3)                               |
| More than28 Days afterLast Dose | 59(23.8)                   | 15 (21.7)            | 78 ( 21.9)                            |
| Disease Progression             | 43 (17.3)                  | 12 ( 17.4)           | 58 (16.3)                             |
| Adverse Event                   | 5 (2.0)                    | 1 (1.4)              | 6(1.7)                                |
| Other                           | 11 (4.4)                   | 2 (2.9)              | 14 (3.9)                              |

One patienthad a grade 5 treatment-emergent adverse event with fatal outcome in the adverse event form, but primary death reason was disease progression

<div style=\"page-break-after: always\"></div>

Table 41. Death events occurring within 28 days from the last dose of selpercatinib (NSCLC Safety Population)

| Preferred Term                         | Integrated (N=248) n (%)   | SAS1 (N= 69) n (%)   | RET Fusion-positive NSCLC (N=356) n (%)   |
|----------------------------------------|----------------------------|----------------------|-------------------------------------------|
| Patients with TEAEs with Outcome Fatal | 14 ( 5.6)                  | 5.8)                 | 24 ( 6.7)                                 |
| Respiratory failure                    | 3 1.2)                     | 1.4)                 | 6 1.7)                                    |
| Sepsis                                 | 2 0.8)                     | 0 0.0)               | 2 0.6)                                    |
| Cardiac arrest                         | 2 0.8)                     | 0 0.0)               | 4 1.1)                                    |
| Acute respiratory failure              | 1 0.4)                     | 0 0.0)               | 1 0.3)                                    |
| Pneumonia                              | 1 0.4)                     | 0 0.0)               | 2 0.6)                                    |
| Cardio-respiratory arrest              | 0 0.0)                     | 1 1.4)               | 1 0.3)                                    |
| Cerebral haemorrhage                   | 2 0.8)                     | 0 0.0)               | 2 0.6)                                    |
| Dyspnoea                               | 0 0.0)                     | 1.4)                 | 1 0.3)                                    |
| Corona virus infection                 | 1 0.4)                     | 0 0.0)               | 1 0.3)                                    |
| Hypoxia                                | 1 0.4)                     | 0 0.0)               | 1 0.3)                                    |
| Multiple organ dysfunction syndrome    | 1 0.4)                     | 0 0.0)               | 1 0.3)                                    |
| Somnolence                             | 0 0.0)                     | 1 1.4)               | 1 0.3)                                    |
| Sudden death                           | 0 0.0)                     | 0 0.0)               | 0.3)                                      |

## Adverse Events of Special Interest

Table 42. Adverse Events of Special Interests Reported in LIBRETTO-001 as of the 15 June 2021 Data Cut-Off Overall Safety Population and Treatment-Naïve Patients

| AESI                                                       | Overall Safety Population (N=796)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Treatment-NaivePatients(N=69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Liver injury AST/ALT increaseda                            | TEAEs of AST increased in 36.7% and ALT increased in 35.7%; reported as related to selpercatinib: AST increased 28.8% and ALT increased 28.5% Most were Grade 1 or 2 Grade 3 AST increased in 7.9% and ALT increased 10.7% Grade 4 AST increased in 0.9% and ALT increased in 0.8% No Grade 5 events TESAEs: AST increased in 1.5%and ALTincreased in 1.5%; reported as related to selpercatinib: AST increased in 1.1% and ALT increased in 1.1% Median time tofirst onset of AST and ALT increased was 6.0 and 5.8weeks Dose withheld in 10.7% (AST increased) and 11.8% (ALT increased). Dose reduction in 7.2% (AST increased) and 7.8% (ALT increased) Permanent discontinuations in only 0.5% (AST increased) and 0.6% (ALT increased)                                                                                         | TEAEs of AST increased in 46.4% and ALT increased 42.0%; reported as related to selpercatinib: AST increased in 37.7% and ALT increased in 34.8% Most were of Grade 1 or 2 Grade 3 AST increased in 7.2% and ALT increased: in 14.5% No Grade 4or 5 events TESAEs: AST increased in 1.4% and ALT increased in 1.4%; reported as related to selpercatinib: AST increased in 1.4%andALTincreasedin1.4% Median time tofirst onsetofbothAST and ALTincreased was 4.1 weeks Dose withheld in 15.9% (AST increased) and 17.4% (ALT increased). Dose reduction in 10.1% (AST increased) and 14.5% (ALT increased) Permanentdiscontinuationin1.4% |
| Liver injury Drug related hepatic disorders based on SMQsb | 58.0% of patients reported a TEAE from this SMQ; reported as related to selpercatinib in 43.0% TEAEs in ≥10% of patients were AST increased, ALT increased, blood ALP increased, ascites, hypoalbuminaemia, and blood bilirubin increased Most were Grade 1 and 2 Grade 3 or 4 TEAEs: 15.7% and 2.0%, respectively No Grade 5 events TESAEs: 3%; reported as related to selpercatinib in 2.3% Median time to first onset was 4.3 weeks Dose withheld in 18.2% and dose reduction in 13.2% Permanent discontinuation in 1% HepatocellularIniurybasedonHy'sLaw An analysis toidentifypotential cases of liverinjurywith impairment of liver function using the criteria for Hy's law was performed.  4 NSCLC patients (none were treatment-naive patients), potentially met the laboratory criteria for Hy's Law (ALT or AST ≥3 x ULN, | 58.0% of patients reported a TEAE from this SMQ: reported as related to selpercatinib in 43.5% TEAEs in ≥10% of patients were AST increased, ALT increased, blood bilirubin increased, hypoalbuminaemia, and blood ALP increased Most were Grade 1 or 2 Grade 3: 20.3% No Grade 4 or Grade 5 events TESAEs: 1.4%; all reported as related to selpercatinib Median time to first onset was 4.1 weeks Dose withheld in 24.6% and dose reduction in 17.4% Permanent discontinuations in 1.4%                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | and a concurrent increase in TBL > 2 x ULN and ALP < 2 x ULN) In all 4 cases other factors were present that may have led to the elevatedlaboratory findings (history of liver metastasis and/or diagnosis of new liver lesions around the time of the event 3 patients; initiation of nitrofurantoin (a known hepatoxic agent) 1 patient). Therefore, none of the cases met the criteria for Hy's law.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypertensionc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Any-grade hypertension in 41.0%; reported as related to selpercatinib in 28.1% Grade 3: 19.6%; Grade 4: 0.1% No Grade 5 events TESAEs: 0.9%; reported as related to selpercatinib in 0.6% Median time to first onset: 4.1 weeks Dose withheld in 6.3% and dose reduction in 1.3% Permanent discontinuation due to hypertension in 0.1% In addition to the analysis using the composite term for hypertension an analysis using the MedDRA SMQ (narrow scope) for hypertension was conducted. Based on this review the incidence of events of any grade Was 41.1%. The increase was due to reports of the TEAEs essential hypertension and secondary hypertension. No significant new information was identified from the additional analysis.                                                                                                                                  | Any-grade hypertension in 44.9%; reported as related to selpercatinib in 26.1% Grade 3: 20.3% No Grade 4 or Grade 5 events No TESAEs Median time to first onset: 6.3weeks Dose withheld in 7.2% and dose reduction in 1.4% No permanent discontinuation due to hypertension No additional TEAEs were identified in the Treatment-Naive Patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypersensitivityd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Any-grade hypersensitivity in 5.9%; reported as related to selpercatinib in 4.4% Most were Grade 1 or 2 Grade 3: 1.9% No Grade 4 or Grade 5 events. The median time to first onset: 1.9 weeks TESAEs: 2.0%; all related to selpercatinib Dose withheld in 4.0% and dose reduction in 3.9% Permanent discontinuation due to hypersensitivity in 0.4% In addition to the analysis using the composite term for hypersensitivity an analysisusing a broader list of MedDRAPTsdpotentially associated with hypersensitivity was conducted. Based on this review the incidence of any grade events was 6.5%. The increase was due to reports of the TEAEs drug eruption. No additional reports were identified in the Treatment-Naive Patients. No significant new                                                                                                                  | Any-grade hypersensitivity in 7.2%; reported as related to selpercatinib in 5.8%Error! Reference source not found. Most events were Grade 1 or 2 Grade 3: 4.3% No Grade 4 or Grade 5 events The median time to first onset: 1.4 weeks TESAEs 2.9% patients; all related to selpercatinib Dose withheld in 4.3% and dose reduction in 4.3% Permanent discontinuation due to hypersensitivity in 1.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Electrocardiogram QT Interval Prolongatione                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | information was identified from the additional analysis. Any-grade electrocardiogram QT prolonged in 21.1%; reported as related to selpercatinib in 16.3% Most events were Grade 1 or Grade 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Electrocardiogram QT prolonged in 20.3%; reported as related to selpercatinib in 14.5% Most events were Grade 1 or Grade 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Abbreviations: ALP = aspartate aminotransferase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query. Analysis of*AST/ALT increased’ was based on composite AE terms (PTs of'AST increased' are 'Aspartate aminotransferase increased' and 'Aspartate aminotransferase abnormal'; PT terms for'ALT increased' are 'Alanine aminotransferase increased' and 'Alanine aminotransferase abnormal).  Analysis of events related to liver injury was performed based on drug-related hepatic disorders - comprehensive search [SMQ]. Interim CSR Table 8.150 provides the PT terms for *liver injuy\".  Analysis of events related to hypertension was performed based on SMQ of hypertension (narrow scope PTs). PTs for composite term hypertension were | Abbreviations: ALP = aspartate aminotransferase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query. Analysis of*AST/ALT increased’ was based on composite AE terms (PTs of'AST increased' are 'Aspartate aminotransferase increased' and 'Aspartate aminotransferase abnormal'; PT terms for'ALT increased' are 'Alanine aminotransferase increased' and 'Alanine aminotransferase abnormal).  Analysis of events related to liver injury was performed based on drug-related hepatic disorders - comprehensive search [SMQ]. Interim CSR Table 8.150 provides the PT terms for *liver injuy\".  Analysis of events related to hypertension was performed based on SMQ of hypertension (narrow scope PTs). PTs for composite term hypertension were | Abbreviations: ALP = aspartate aminotransferase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query. Analysis of*AST/ALT increased’ was based on composite AE terms (PTs of'AST increased' are 'Aspartate aminotransferase increased' and 'Aspartate aminotransferase abnormal'; PT terms for'ALT increased' are 'Alanine aminotransferase increased' and 'Alanine aminotransferase abnormal).  Analysis of events related to liver injury was performed based on drug-related hepatic disorders - comprehensive search [SMQ]. Interim CSR Table 8.150 provides the PT terms for *liver injuy\".  Analysis of events related to hypertension was performed based on SMQ of hypertension (narrow scope PTs). PTs for composite term hypertension were |

- PTs for composite term Electrocardiogram QT prolonged were ECG QT prolonged and ECG QT interval abnormal.

► AST and ALT increases were reported in 36.7% and 37.6% of patients in the Overall Safety Population and 41.9% and 41.3% of patients in the NSCLC Safety Population, respectively. Majority were of Grade 1 or 2.

► The incidence of any-grade hypertension was 41% and 20% were Grade ≥3 in the Overall Safety Population.  Patients  with  a  documented  history  of  hypertension  displayed  a  higher  incidence  of treatment-emergent Grade 3 hypertension than patients without (28% versus 14%, respectively).

<div style=\"page-break-after: always\"></div>

► Electrocardiogram QT prolonged was reported as a TEAE in similar proportion of the patients in both the Overall (20.8%) and NSCLC (21.1%) Safety Populations. Most patients had TEAEs of Grade 1 or 2 in severity in both the Overall Safety (16.3%) and NSCLC safety (14.9%) population.

► The overall incidence of any-grade hypersensitivity was 5.9% in the Overall Safety Population. A total of 15 patients (1.9%) in the Overall Safety and 12 patients (3.4%) in the NSCLC Safety Population had Grade 3 hypersensitivity.

<div style=\"page-break-after: always\"></div>

## Other Adverse Events

Table 43. Other Adverse Events Reported in LIBRETTO-001 as of the 15 June 2021 Data Cut

| Other adverse events reported in LIBRETTO-0ol based on the Overall Safety Population (N=796)   | Other adverse events reported in LIBRETTO-0ol based on the Overall Safety Population (N=796)                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hyponatraemia (Selected terms from hyponatraemia SMQ)a                                         | Any-grade hyponatraemia in 14.1%; related to selpercatinib in 3.1% Grade 3 or 4 events: 8.0% No Grade 5 events TESAEs: 2.3%; none related to selpercatinib Dose withheld in 2.3% and dose reduction in 0.4% No permanent discontinuation due to hyponatraemia                                                                                                                                                                                                                                                                          |
| Acute Kidney Injury (Acute Kidney Injury SMQ)                                                  | Any-grade acute kidney injury (SMQ) in 32.8%; related to selpercatinib in 18.2%. Of note this includes events of creatinine increased, which is a recognised ADR for selpercatinib Grade 3 or 4 events: 2.6% No Grade 5 events TESAEs: 1.3%; none related to selpercatimib The most frequently reported events (≥5%) were: Blood creatinine increased (any-grade 25.6%; Grade ≥3 0.8%) Proteinuria (any-grade 6.7%; Grade ≥3 0.6% Acute kidney injury (any-grade 5.2%; Grade ≥3 1.5%) Dose withheld in 4.5% and dose reduction in 2.6% |
| Dysphagia (MedDRA PTs: dysphagia, malignant dysphagia and radiation dysphagia)                 | Any-grade dysphagia in 7.3%; related to selpercatinib in 1.0% Grade 3 events: 0.9% No Grade 4 or 5 events TESAEs: 1.1%; related to selpercatinib in 0.1% Dose withheld in 1.0% and dose reduction in 0.1% Permanent discontinuation due to dysphagia: 0.3%                                                                                                                                                                                                                                                                             |
| Pulmonary Disorders (Respiratory, Thoracic and Mediastinal Disorders SOC)                      | Any-grade pulmonary disorders in 60.2%; related to selpercatinib in 18.3% Grade 3 or Grade 4 events: 8.9% Grade 5 events 2.0% TESAEs: 9.2%; related to selpercatinib in 1.0% The most frequently reported events (≥10%) were: Dyspnoea (any-grade 18.8%; Grade ≥3 3.1%) Cough (any-grade 19.2%; Grade ≥3 0.0%) Pleural effusion (any-grade 12.1%; Grade ≥3 2.6%)                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Other adverse events reported in LIBRE TTO-00l based on the Overall Safety Population (N=796)                                                                                                                                                                                                                                                       | Other adverse events reported in LIBRE TTO-00l based on the Overall Safety Population (N=796)                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                     | Dysphonia (any-grade 10.7%; Grade ≥3 0.1%) Dose withheld in 7.5% and dose reduction in 2.8% Permanent discontinuation due to pulmonary disorders: 1.1%                                                                                                                                                                                                                                                                                                                                     |
| Sepsis (Sepsis SMQ)                                                                                                                                                                                                                                                                                                                                 | Any-grade Sepsis (SMQ) in 3.0%; related to selpercatinib in 0.1% Grade 3 or 4 events: 2.1% Grade 5 events: 0.9% TESAEs: 2.5%; None related to selpercatinib Dose withheld in 1.6% and no dose reductions Permanent discontinuation due to sepsis: 0.8%                                                                                                                                                                                                                                     |
| Haemorrhages (haemorrhage laboratory terms [narrow scope] SMQ, and haemorrhage terms [excluding laboratory terms] SMQ)b                                                                                                                                                                                                                             | Any-grade haemorrhages in 22.0%; related to selpercatinib in 4.1% Grade 3 or 4 events: 2.6% Grade 5 events: 0.5% TESAEs: 2.8%; related to selpercatinib in 0.4% The most frequently reported events (≥2%) were: Epistaxis (any-grade 6.0%; Grade ≥3 0%) D Haematuria (any-grade 3.6%; Grade ≥3 0%) Haemoptysis (any-grade 2.4%; Grade ≥3 0.3%) Contusion (any-grade 2.4%; Grade ≥3 0.1%) 口 Dose withheld in 3.0% and dose reductions in 0.3% Permanent discontinuation due to sepsis: 0.4% |
| Abbreviations: ADR = adverse drug reaction; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event. Blood sodium abnormal, blood sodium decreased, hyponatraemia, hyponatraemic coma, hyponatraemic | Abbreviations: ADR = adverse drug reaction; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event. Blood sodium abnormal, blood sodium decreased, hyponatraemia, hyponatraemic coma, hyponatraemic                                                                                                                                        |

## Laboratory findings

The highest incidence of any grade treatment-emergent abnormality across hematology parameters was reported for decreased lymphocyte count (51.8% and 56.3%) and decreased white blood cell count (48.7% and 55.1%) in both the Overall Safety Population and the NSCLC Safety Population, respectively.

The highest incidence of treatment-emergent serum abnormality was reported for AST increased (58.9% and 66.2%) and ALT increased (55.5% and 63.9%) in both the Overall Safety Population and the NSCLC Safety  Population,  respectively.  The  most  commonly  reported  abnormalities  (increase  or  decrease) across serum chemistry parameters were primarily Grade 1.

## Safety in special populations

There were no significant differences in the incidence of TEAEs among the age, sex, and race subgroups in the Overall Safety and NSCLC Safety Populations.

## Safety related to drug-drug interactions and other interactions

Please refer to the Pharmacokinetics section.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

The most frequently reported TEAEs leading to doses being withheld in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were ALT increase, AST increased, diarrhoea, and hypertension.

The most frequently reported TEAEs leading to a dose reduction in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were ALT increase and AST increase the increase and AST increase

The most frequently reported TEAEs leading to permanent discontinuation of selpercatinib in 4 or more patients in the Overall Safety Population were ALT increased, fatigue, AST increase, and sepsis. All other AEs  occurred  in  less  than  4  patients.  In  Treatment-Naïve  Patients no  events  leading  to  permanent discontinuation of selpercatinib were reported in more than 1 patient.

## Post marketing experience

As of April 2021, Selpercatinib was approved in 34 countries including those in the EU, the US and Switzerland for treatment of patients with RET fusion-positive NSCLC, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. Specific patient populations and dosing guidance vary by country. Cumulatively, up to the 30 April 2021, an estimated 590 patients were exposed to selpercatinib worldwide. The data reported from the post marketing setting, is generally consistent with the known safety  profile  of  selpercatinib.  Most  events  were  reported  as  non-serious  and  the  most  frequently reported events were recognised ADRs for selpercatinib or clinically expected in the target indication. Overall, no new significant safety information has been identified from post marketing sources. The periodic safety update report/periodic benefit-risk evaluation report with a data lock of 08 May 2021 confirmed and supported the previously established favourable benefit-risk profile for selpercatinib in the currently approved indications.

## 2.5.1. Discussion on clinical safety

Safety was evaluated in patients in the Overall Safety Population (N=796) and in the NSCLC Safety Population (N=356) who received at least 1 dose of selpercatinib as of the data cutoff date of 15 June 2021.

In terms of exposure, the median time on treatment was 21.29 and 19.09 months, respectively, for the Overall Safety Population and NSCLC Safety Population. In the Treatment-Naïve Population (n=69), the median treatment duration is 18.5 months (range: 0.4 to 41.2 months) and 70% of patients were on treatment for at least 12 months.

The median relative dose intensity was similar for the Overall Safety Population (94.1%) and the NSCLC Safety Population (92.7%).

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 77.5% in the NSCLC Safety Population) primarily attributed to adverse events (AEs) (64.1% in the Overall Safety Population and 68.8% in the NSCLC Safety Population).

The types and incidence rates of AEs leading to doses being withheld, dose reductions, and treatment discontinuation were consistent between the Overall Safety Population and Treatment-Naïve Patients.

The most frequent TEAEs occurring in 30% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were oedema, diarrhoea, fatigue, dry mouth, hypertension, AST increased, ALT increased, constipation, rash, abdominal pain, and nausea.

<div style=\"page-break-after: always\"></div>

The most frequent Grade ≥ 3 TEAEs reported in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were hypertension, followed by ALT increased and AST increased, hyponatraemia.

The most frequent TESAEs reported in 2% or more patients both in the Overall Safety Population and Treatment-Naïve Patients were pleural effusion, dyspnoea, and hyponatraemia.

Fatal TEAEs were reported in 21 patients at the initial MAA compared with 45 patients at the 15 June 2021 data cut-off. In Treatment-Naïve Patients, a fatal (Grade 5) TEAE was experienced by a total of 4 patients (6%), including 1 patient who died more than 28 days after the last dose of selpercatinib. None in the NSCLC Safety Population were reported by the investigator as treatment-related.

The adverse events of special interest (AESIs) analyzed did not change compared to those reported previously.

The safety profile observed in the data from the 15 June 2021 cut-off remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile is consistent between the Treatment-Naïve Patients and the Overall Safety Population.

## 2.5.2. Conclusions on clinical safety

The overall  safety  profile  of  selpercatinib  in  Treatment-Naïve  Patients  is  consistent  with  that  of  the Overall  Safety  Population.  The  updated  results  provided  in  this  analysis  show  the  safety  profile  of selpercatinib is consistent with that reported previously, even with longer duration of treatment.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.3 is acceptable.

The CHMP endorsed the Risk Management Plan version 1.3 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                                                         |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                                               |
| Important potential risks    | Liver injury Cardiac arrhythmia due to QT prolongation Reproductive and developmental toxicities Growth Plate Abnormalities in Paediatric Patients |
| Missing information          | Exposure and safety in patients with severe hepatic impairment Exposure and safety in patients with cardiac impairment                             |

<div style=\"page-break-after: always\"></div>

No changes to the list of safety concerns were made as a result of the data submitted for this new indication.

## Pharmacovigilance plan

There are no additional pharmacovigilance activities in place for this product. Routine pharmacovigilance remains sufficient to investigate the risks of selpercatinib.

## Risk minimisation measures

## Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety Concern                            | Risk Minimisation Measures                                                                                           | Pharmacovigilance Activities                                                                                                                                                              |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Liver injury                              | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. Additional risk minimisation measures: Not Applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Studies: None                               |
| Cardiac arrhythmia due to QT prolongation | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. Additional risk minimisation measures: Not Applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Studies: None                               |
| Reproductive and developmental toxicity   | Routine risk minimisation measures: SmPC Section 4.6 Additional risk minimisation measures: Not Applicable           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Pregnancy and Breastfeeding follow-up forms Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                 | Risk Minimisation Measures                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                            |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Growth plate abnormalities in paediatric patients              | Routine risk minimisation measures: SmPC Section 4.2 and 5.3 Additional risk minimisation measures: Not Applicable                                                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None        |
| Exposure and safety in patients with severe hepatic impairment | Routine risk minimisation measures: A clinical pharmacology study assessing the effect of hepatic impairment on the pharmacokinetics of selpercatinib is completed. SmPC is updated based on the safety and pharmacokinetics data. Additional risk minimisation measures: Not Applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study: None |
| Exposure and safety in patients with cardiac impairment        | Routine risk minimisation measures: None Additional risk minimisation measures: Not Applicable                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study: None |

Routine minimisation measures remain sufficient to mitiagate the risks of selpercatinib.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.5, 4.8 and 5.1 of the SmPC have been updated.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The proposed revisions do not significantly affect the overall readability. It is not considered necessary to conduct consultation with target patient groups further to that performed for the initial MAA.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The  MAH  is  seeking  an  extension  of  indication  of  selpercatinib  (RETSEVMO)  currently  authorised  in patients with RET fusion-positive NSCLC previously treated with platinum-based chemotherapy to include the first-line setting.

The agreed indication is: as monotherapy for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.

## 3.1.2. Available therapies and unmet medical need

Although patients with RET fusion-positive NSCLC have an identifiable driver alteration, until recently, they received the same standard-of-care treatment as patients with NSCLC who do not have a driver alteration, as there were no RET-targeted approved therapies. Standard first-line systemic treatment is platinum doublet-based cytotoxic chemotherapy and/or a checkpoint inhibitor. Available options include pembrolizumab, atezolizumab, bevacizumab, and pemetrexed, all in combination with platinum-based chemotherapy regimens. Pembrolizumab monotherapy is only an option for patients with significant PDL1 expression.

In the second line setting, the preferred treatment strategy is systemic immune checkpoints inhibitors, as nivolumab, pembrolizumab or atezolizumab, or other systemic therapy as docetaxel, pemetrexed or ramucirumab with docetaxel, nintedanib with docetaxel, among others.

As of November 2021, pralsetinib (GAVRETO) a selective RET inhibitor, has received conditional approval in patients with advanced RET fusion-positive NSCLC.

## 3.1.3. Main clinical studies

Clinical safety and efficacy of selpercatinib in treatment-naive patients with RET fusion-positive NSCLC are based on analyses of interim data from LIBRETTO-001 (LOXO-RET-17001).

LIBRETTO-001 is a global, multi-cohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. The Phase 2 portion evaluates efficacy in cohorts based on tumour type, type of RET alteration, and prior treatment. The primary objective was to determine ORR by IRC assessment according to RECIST 1.1, or Response Assessment in Neuro-Oncology (RANO) criteria. DOR, PFS and OS were secondary endpoints.

## 3.2. Favourable effects

## Treatment-naïve

At data cut-off 15 June 2021, 69 treatment-naïve patients were efficacy evaluable and the ORR (IRC assessment) was 84.1% (95% CI: 73.3, 91.8).  Four (4) patients exhibited a confirmed CR and 54 patients experienced PR. ORR according to investigator assessment was in line with the IRC assessment (ORR 85.5% [95% CI: 75; 92.8]).

<div style=\"page-break-after: always\"></div>

The median TTR was 1.81 months and, in 66% of responders, DOR was more than 12 months. Median DoR was 20.21 (13.0-NE), with a median duration of follow-up of 20.27 months. However, a stable median cannot yet be estimated.

The median PFS (IRC) was 22.0 months (95% CI: 13.8, NE+), with 29/69 (42%) events observed and median follow-up of 21.9 months. Median OS was not reached at the time of the DCO (29% of events observed). The OS rate was 92.7% at 12 months, 69.3% at 24 months, and 57.1% at 36 months. Efficacy of selpercatinib seems consistent across most important subgroups.

## 3.3. Uncertainties and limitations about favourable effects

The uncertainties and limitations are mainly related to the uncontrolled nature of the pivotal trial which hampers the interpretation of the time-to-event endpoints (PFS, OS).

Even though updated efficacy data have been provided for NSCLC patients regardless of line therapy, the median OS continued to be not estimable. The KM estimates from time-to-event endpoints (PFS, OS) seem promising, but they remain immature.

These limitations will be addressed post authorisation with the submission of updated data and longer follow-up from the LIBRETTO-001 study and the conduct of LIBRETTO-431, a randomised phase III trial in patients with locally advanced or metastatic, RET-fusion-positive non-squamous NSCLC.

## 3.4. Unfavourable effects

Safety data are available from a total of 796 patients in the LIBRETTO-001 study.

Safety was evaluated in patients in the Overall Safety Population (N=796) and in the NSCLC Safety Population (N=356) who received at least 1 dose of selpercatinib as of the data cutoff date of 15 June 2021.

In terms of exposure, the median time on treatment was 21.29 and 19.09 months, respectively, for the Overall Safety Population and NSCLC Safety Population. In the Treatment-Naïve Population (n=69), the median treatment duration is 18.5 months (range: 0.4 to 41.2 months) and 70% of patients were on treatment for at least 12 months.

The median relative dose intensity was similar for the Overall Safety Population (94.1%) and the NSCLC Safety Population (92.7%).

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 77.5% in the NSCLC Safety Population) primarily attributed to adverse events (AEs) (64.1% in the Overall Safety Population and 68.8% in the NSCLC Safety Population).

The types and incidence rates of AEs leading to doses being withheld, dose reductions, and treatment discontinuation were consistent between the Overall Safety Population and Treatment-Naïve Patients.

The most frequent TEAEs occurring in 30% or more patients in both the Overall Safety Population and Treatment-Naïve Patients were oedema, diarrhoea, fatigue, dry mouth, hypertension, AST increased, ALT increased, constipation, rash, abdominal pain, and nausea.

The most frequent Grade ≥ 3 TEAEs reported in 5% or more patients in both the Overall Safety Population and  Treatment-Naïve  Patients  were  hypertension,  followed  by  ALT  increased  and  AST  increased, hyponatraemia.

<div style=\"page-break-after: always\"></div>

The most frequent TESAEs reported in 2% or more patients both in the Overall Safety Population and Treatment-Naïve Patients were pleural effusion, dyspnoea, and hyponatraemia.

Fatal TEAEs were reported in 21 patients at the initial MAA compared with 45 patients at the 15 June 2021 data cut-off. In Treatment-Naïve Patients, a fatal (Grade 5) TEAE was experienced by a total of 4 patients (6%), including 1 patient who died more than 28 days after the last dose of selpercatinib. None in the NSCLC Safety Population were reported by the investigator as treatment-related.

## 3.5. Uncertainties and limitations about unfavourable effects

The uncontrolled design of LIBRETTO-001 study and the limited median exposure (11.7 months) do not allow  to  clearly  disentangle  signs/symptoms  of  the  underlying  malignancy  and  selpercatinib-related adverse events (AEs), limiting precise evaluation of selpercatinib's safety profile. Data on long-term safety is also lacking. Long-term follow-up from the LIBRETTO-001 and the randomised phase 3 study LIBRETTO-431, to be submitted post approval, will address these uncertainties.

## 3.6. Effects Table

Table 44. Effects Table for Retsevmo in advanced RET-fusion positive NSCLC (data cut-off: 15 June 2021).

| Effect                                                   | Short description                                        | Short description               | Unit                            | Treatment                                                                                    | Control                         | Uncertainties / Strength of evidence   | References                      |
|----------------------------------------------------------|----------------------------------------------------------|---------------------------------|---------------------------------|----------------------------------------------------------------------------------------------|---------------------------------|----------------------------------------|---------------------------------|
| Favourable Effects                                       | Favourable Effects                                       | Favourable Effects              | Favourable Effects              | Favourable Effects                                                                           | Favourable Effects              | Favourable Effects                     | Favourable Effects              |
| Treatment-Naïve Patients (n=69)                          | Treatment-Naïve Patients (n=69)                          | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69)                                                              | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69)        | Treatment-Naïve Patients (n=69) |
| ORR                                                      | rate                                                     | rate                            | % (95% CI)                      | 58 (84.1) (73.3, 91.8)                                                                       | NA                              | uncontrolled data                      |                                 |
| DOR                                                      | median                                                   | median                          | Months (95% CI)                 | 20.21 (13.0, NE)                                                                             | NA                              | Immature and uncontrolled data         |                                 |
| PFS                                                      | median                                                   | median                          | Months (95% CI)                 | 21.95 (13.8, NE)                                                                             | NA                              | Immature and uncontrolled data         |                                 |
| OS                                                       | median                                                   | median                          | Months (95% CI)                 | 92.7 at 12 months (83.3, 96.9) 69.3 at 24 months (55.2, 79.7) 57.1 at 36 months (35.9, 73.6) | NA                              | Immature and uncontrolled data         |                                 |
| Unfavourable Effects                                     | Unfavourable Effects                                     | Unfavourable Effects            | Unfavourable Effects            | Unfavourable Effects                                                                         | Unfavourable Effects            | Unfavourable Effects                   | Unfavourable Effects            |
| Treatment-Naïve Patients (n=69)                          | Treatment-Naïve Patients (n=69)                          | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69)                                                              | Treatment-Naïve Patients (n=69) | Treatment-Naïve Patients (n=69)        | Treatment-Naïve Patients (n=69) |
| Any TEAEs                                                | Any TEAEs                                                | rate                            | n (%)                           | 69 (100.0)                                                                                   | NA                              | uncontrolled data                      |                                 |
| Related to selpercatinib                                 | Related to selpercatinib                                 |                                 |                                 | 67 (97.1)                                                                                    |                                 |                                        |                                 |
| Grade ≥3 TEAEs                                           | Grade ≥3 TEAEs                                           | rate                            | n (%)                           | 50 (72.5)                                                                                    | NA                              | uncontrolled data                      |                                 |
| Related to                                               | Related to                                               |                                 |                                 | 25 (36.2)                                                                                    |                                 |                                        |                                 |
| selpercatinib TEAEs leading to treatment discontinuation | selpercatinib TEAEs leading to treatment discontinuation | rate                            | n (%)                           | 7 (10.1)                                                                                     | NA                              | uncontrolled data                      |                                 |
| Related selpercatinib                                    | Related selpercatinib                                    | to                              |                                 | 3 (4.3)                                                                                      |                                 |                                        |                                 |
| TESAE                                                    | TESAE                                                    | rate                            | n (%)                           | 26 (37.7)                                                                                    | NA                              | uncontrolled data                      |                                 |
| Related to selpercatinib                                 | Related to selpercatinib                                 |                                 |                                 | 8 (11.6)                                                                                     |                                 |                                        |                                 |
| Fatal TEAEs                                              | Fatal TEAEs                                              | rate                            | n (%)                           | 4 (5.8)                                                                                      | NA                              | uncontrolled data                      |                                 |
| Related                                                  | Related                                                  | to                              |                                 | 0                                                                                            |                                 |                                        |                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: ORR: Objective Response Rate, DOR: Duration of Response, PFS: Progression Free Survival, OS: Overall Survival

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Data  supporting  this  application  are  based  on  one  single-arm  trial  (LIBRETTO-001),  which  make interpretation of time to event endpoints and any potential long-term benefit challenging. Nevertheless, this approach is acceptable in the context of a CMA for a product intended for a rare population with an unmet medical need as long as the effect observed in ORR is outstanding and durable.

For  treatment  naïve  patients,  clinical  data  from  a  larger  and  more  mature  dataset  of  patients  are available  (median  follow-up  time  of  20  months).  The  obtained  ORR  of  84%  is  considered  clinically meaningful. Available results suggest that these responses are durable (mDOR 20 months) and K-M estimates for median PFS and OS allow to anticipate lasting benefits from treatment. Of note, the ORR benefit for the intended population was observed with selpercatinib regardless of line of treatment, with higher ORR in the treatment-naïve population.

Although, other approved front-line therapies with established benefit exist (platinum based doublets/immune  checkpoint  inhibitor),  efficacy  with  selpercatinib  is  considered  compelling  and  of sufficient  magnitude.  Indirect  comparisons  of  available  results  (KM  estimates  of  PFS  and  OS)  with selpercatinib against those reported with chemoimmunotherapy in 'all -comer' NSCLC patients in studies IMpower130, IMpower150 and KEYNOTE-189 seem promising and give some support to the benefit of targeted treatment in the first line. In addition, clinically meaningful intracranial responses are observed with  selpercatinib  in  patients  with  CNS  metastases,  which  represents  a  significant  advantage  over standard chemotherapy approaches.

In November 2021, another RET inhibitor Gavreto (pralsetinib) was granted a conditional approval in the target population which outlines the advantage of targeted RET treatment: the single-arm ARROW trial showed an ORR of 64% and mDOR of 22.3 months in 233 patients with advanced RET fusion-positive NSCLC. ORR among treatment naïve patients was 72.0% (60.4%, 81.8%).

The safety profile observed in the updated data from the 15 June 2021 cut-off remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile is consistent between the Treatment-Naïve Patients and the Overall Safety Population.

## 3.7.2. Balance of benefits and risks

The provided results from LIBRETTO-001 have shown efficacy in term of confirmed response for the treatment of this rare subtype of NSCLC. Responses seem durable and independent of treatment line. However, given the remaining uncertainties mostly related to the uncontrolled design of the pivotal study with the low number of treatment-naïve subjects (n=69), comparative data from the phase 3 study (J2G-MC-JZJC, LIBRETTO-431) together with further follow-up data from the pivotal trial LIBRETTO-001 are required as confirmatory evidence (SOBs).

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

As comprehensive data on the product are also not available in the first-line treatment of RET fusionpositive NSCLC, a conditional marketing authorisation was requested by the applicant for this extension of  indication.  The  product  falls  within  the  scope  of  Article  14-a  of  Regulation  (EC)  No  726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a life-threatening disease.

Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation:

- The benefit-risk balance is positive, as discussed above.
- It  is  likely  that  the  applicant  will  be  able  to  provide  comprehensive  data.  The  applicant  will provide confirmatory data from the ongoing LIBRETTO-431 study, an open-label randomised phase 3 study comparing selpercatinib to a standard-of-care regimen with platinum-based pemetrexed therapy with  or  without  pembrolizumab  for  treatment-naïve  patients  with  RET  fusion-positive  nonsquamous NSCLC. This study is currently recruiting and the submission of the final clinical study report (CSR) is expected by 31 December 2024. As of 26 October 2021, the study is approximately 70% enrolled, with approximately 28% of patients coming from EU countries. Enrolment is projected to be completed in the first  half  of  2022  Results of the LIBRETTO-431 study are intended to provide a comprehensive data package and potentially convert the conditional MA into a full MA.
- Unmet  medical  need  will  be  addressed,  as  selpercatinib  is  considered  to  provide  a  major therapeutic advantage over existing therapies based on a differential safety profile, the convenience of oral  administration,  and  the  provision  of  a  treatment  with  a  novel  mechanism  of  action  of  such  a magnitude that allows to expect that selpercatinib would be at least similarly active to first line available chemotherapy, immunotherapy or immunochemotherapy options.
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Given the positive benefit/risk and the unmet medical need in the applied indications as described above, this is considered fulfilled.

## 3.8. Conclusions

The overall B/R of Selpercatinib in advanced RET fusion-positive NSCLC patients regardless of line of therapy is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the first-line treatment of RET fusion-positive NSCLC for Retsevmo

<div style=\"page-break-after: always\"></div>

based on results from study LIBRETTO-001, an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours; as a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. In addition, section 5.1 of the SmPC is revised to reflect updated efficacy data in previously treated RET-fusion positive NSCLC based on a data cut-off of 15 June 2021. The Package Leaflet is updated in accordance. Version 1.3 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion ' Retsevmo-H-C-005357-II-0011 '

## Attachments

1. SmPC, Labelling, Package Leaflet (changes highlighted) as adopted by the CHMP on 22 April 2022

## Appendix

Not applicable